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ABSTRACT 
 
Despite the scientific, technological and surgical improvements of the past 50 years organ 
dysfunction following elective paediatric cardiac surgery utilising cardiopulmonary bypass 
continues to account for increased complications, often leading to a protracted course in 
hospital with a longer stay in intensive care and the potential for irreversible organ damage 
long term. Furthermore, paediatric cardiac surgeons are routinely undertaking more 
complex operations with a shift from palliation to early correction. This has resulted in 
younger children being subjected to longer periods on the bypass machine with increased 
effects on vital organs.  
 
This thesis describes two clinical studies designed to further assess and characterise peri-
operative cardiac, renal and pulmonary function in children undergoing elective cardiac 
repair at a tertiary referral centre in Scotland, UK. In the first instance a prospective, 
observational study was undertaken in forty-five children to examine the use of tissue 
Doppler imaging in the assessment of peri-operative cardiac function, its relationship to 
myocardial injury and clinical outcome. Tissue Doppler parameters were obtained using a 
Vivid 7 ultrasound scanner with a 7-MHz probe pre-operatively, on admission to paediatric 
intensive care and on day one. Myocardial injury was assessed using Troponin-I on the 
first post-operative day by a commercially available chemiluminescent immunoassay. 
 
In twenty children within this group peri-operative renal function was also investigated 
using standard estimates of glomerular filtration rate, namely creatinine clearance 
measured by the kinetic Jaffe method during the first and second twelve hour post-
operative periods, in comparison to serum creatinine and the novel biomarker cystatin C. 
Routine plasma retained pre-operatively and on days 0, 1, 2 and 3 post-operatively was 
used to measure serum cystatin C and creatinine using a particle-enhanced nephelometric 
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immunoassay and the Roche Creatinine Plus enzymatic assay respectively. The association 
between cystatin C and recorded perfusion parameters including bypass duration, pump 
flow, haematocrit, oxygen delivery and Troponin-I was investigated. 
 
Peri-operative pulmonary function was evaluated through a phase IV, randomised, double-
blind, placebo controlled trial. In total, twenty four children were randomised to receive 
oral sildenafil or equivalent volume placebo four times the day before surgery. Blood 
samples were collected peri-operatively to measure serum cyclic guanosine 
monophosphate with a commercially available competitive enzyme immunoassay. 
Haemodynamic data and echocardiography were acquired at two and twenty four hours 
post-operatively including pulmonary vascular resistance index and bi-ventricular 
contractility. Post-operative oxygenation was also determined at the same time by oxygen 
delivery and oxygenation index. 
 
In Chapter 2, peri-operative cardiac function as assessed by tissue Doppler imaging was 
examined. The results of this study demonstrated that pre-operatively, bi-ventricular 
systolic function in the study group was reduced compared with normal controls, 
displaying a significant step-wise decrease with increasing complexity of lesion. This 
picture persisted post-operatively predominantly in the right ventricle and was significantly 
associated with the extent of myocardial injury. Impaired peri-operative left ventricular 
function correlated with clinical outcomes. 
 
In Chapter 3, peri-operative renal function as assessed by cystatin C and its association 
with parameters of perfusion was examined. The results of this study demonstrated that in 
comparison to serum creatinine, cystatin C had a superior correlation with glomerular 
filtration rate in the early post-operative period. An elevated level of this biomarker was 
End Organ Effects of Paediatric Cardiopulmonary Bypass         Page 3 of 192 
 
Tony Vassalos  2010 
significantly associated with bypass duration, minimum pump flow and post-operative 
myocardial injury. Haematocrit was not directly linked to renal dysfunction in this study 
although evidence of a critical dysoxic threshold within the kidney was suggested 
indirectly through oxygen delivery calculations. 
 
In Chapter 4, peri-operative pulmonary function and vascular reactivity in association with 
the pre-operative administration of oral sildenafil (0.5mg/kg, six hourly) was examined. 
The results of this trial demonstrated that compared to placebo, pre-operative sildenafil 
resulted in modest elevations of serum cyclic guanosine monophosphate, limited effects on 
pulmonary vascular resistance index, significant reductions in peri-operative bi-ventricular 
contractility, significant reductions in post-operative oxygen delivery and a trend for 
increasing ventilatory support. 
 
In summary, the current thesis has demonstrated that in children undergoing corrective 
cardiac surgery peri-operative bi-ventricular function can be accurately assessed by tissue 
Doppler imaging which to date has had limited use in this patient group. With regards to 
renal function, cystatin C was shown to be a better estimate of glomerular filtration rate 
and a more sensitive marker of early renal dysfunction in children after surgery. 
Furthermore, cystatin C identified a transient post-operative renal impairment, the 
magnitude of which was associated with duration of bypass, pump flow and myocardial 
injury. In relation to pulmonary function, this research identified that pre-operative 
administration of oral sildenafil to children undergoing cardiac surgery produced limited 
effects on pulmonary vascular resistance but was associated with reduced ventricular 
contractility and post-operative oxygenation raising significant concerns over its routine 
clinical use.  
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CHAPTER 1: INTRODUCTION 
 
“A physician at the bedside of a child dying of an intracardiac malformation as recently as 
1952 could only pray for a recovery! Today with the heart-lung machine, correction is 
routine. To bypass the heart, one needs a basic understanding of physiology of the 
circulation, a method of preventing the blood from clotting, a mechanism to pump blood, 
and finally, a method to ventilate the blood.” 
Lillehei (1993) 
 
1.1 The history of cardiopulmonary bypass 
Cardiopulmonary bypass (CPB) is the process by which a patient is sustained by diverting 
the circulation through synthetic devices designed to replace the heart and lungs. Over the 
past 50 years it has evolved from an extremely hazardous procedure into a safe, systematic 
process that is practiced daily in thousands of centres worldwide. The developmental 
advances in CPB can be broadly divided chronologically into: (1) a conceptual period, pre-
1950 (2) a technological period, 1950-1970 and (3) a refinement period, 1970 to present. 
 
1.1.1 Conceptual period (Pre- 1950) 
The goal of CPB has always been to deliver nutritive solutions to the body, namely 
oxygen, with sufficient drive as to maintain physiological homeostasis. As early as 1812 
Julien-Jean Cesar le Gallois demonstrated that blood flow through a circuit located outside 
the body (extracorporeal circulation) was feasible and put forward the original idea for 
resuscitating decapitated heads through the use of blood transfusions. 1 Brown-Sequard in 
1858 arterialised desaturated blood by whipping it and then perfused the head of a dog 
with moderate success. 2 In 1869 Ludwig and Schmidt produced the first report on 
artificial oxygenation when they enriched blood with oxygen by shaking it with gas in a 
balloon. 3 They additionally highlighted the importance of anti-coagulation in enabling 
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flow during extracorporeal circulation.  The earliest uses of ‘bubble’ and ‘film’ oxygenator 
devices that combined blood with oxygen were respectively reported in 1882 by von 
Schroeder and by von Frey and Gruber in 1885. 4, 5 In 1915, Hooker reported a type of film 
oxygenator that utilised a rotating disc assembly within an inverted bell jar. Hooker’s 
device became the forerunner for the disc oxygenator later developed to be used in many 
of the early perfusions in humans in the 1950s. 6 
 
Other key medical developments occurring alongside advances in blood-gas exchange 
systems that strongly influenced progress towards extracorporeal flow came in 1916 when 
Jay McLean, a medical student working in the laboratory of W. H. Howell at the Johns 
Hopkins University at Baltimore, discovered ‘heparin’ and its anticoagulating properties. 7 
Some 20yrs later Chargaff and Olson discovered ‘protamine’ and its antagonistic actions to 
heparin while exploring a means of extending heparin’s anticoagulating effects. 8 
 
In an attempt to mimic the normal circulation, Dale and Schuster in 1928 created a valved 
pumping device that delivered a pulsatile wave. This prototype became the predominant 
device used for extracorporeal perfusions. 9 In 1934, DeBakey modified the twin roller 
pump previously described for blood transfusions to create a roller pump that worked on 
the principle of occluding collapsible tubing along a rigid metal plate. This pump became 
the standard by which all positive displacement pumps used today for extracorporeal 
circulation have been modelled. 10 
 
The culmination of these developments came in 1937 when Dr John H Gibbon, Jr. reported 
the first successful total CPB of an animal (cat) with the use of heparin, a Dale-Schuster-
type pump and vertical rotating cylinder oxygenator. 11 
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1.1.2 Technological period (1950 – 1970) 
Despite Gibbon’s success the ability of blood-gas exchange devices to replace the entire 
human circulation was not achieved for some 15 years. On April 5 1951, Dennis and 
colleagues performed the first total CPB in a 6-year-old patient with an atrial septal 
defect.12 Although their heart-lung machine functioned well, the patient could not be 
separated from CPB and died on the table. After World War II Gibbon and his wife Mary, 
whom many considered to be the first cardiac perfusionist, continued to refine their work 
on CPB and on May 6 1953 at the Thomas Jefferson Hospital in Philadelphia successfully 
closed an atrial septal defect in an 18 year old college girl. The time on the heart-lung 
machine was 26 minutes. 13 Unfortunately, Gibbon was unable to repeat this success and 
with the death of his next 4 patients gave up his pursuit of open heart surgery with the 
heart-lung machine. Other surgeons however utilised techniques that Gibbon had 
developed to successfully treat children with congenital heart disease. It is for this reason 
that Gibbon is considered by most as the ‘father of cardiopulmonary bypass’. 13, 14 
 
Kirklin et al. at the Mayo Clinic in Rochester Minnesota further developed Gibbon’s 
oxygenator into the Mayo-Gibbon pump-oxygenator apparatus which became 
commercially available and led to a pioneering series of successful human intra-cardiac 
operations in March 1955. 15, 16 Around the same time, Kay and Cross and their colleagues 
in 1956 modified the previously described Bjork oxygenator for clinical use. 17, 18 Despite 
satisfactory results from both devices worldwide, by the mid to late 1950s numerous 
problems associated with the film-type blood-gas exchange systems were being reported. 
Their complex, bulky, non-disposable nature, the large quantity of blood and saline 
required to prime the machine and their inefficient gas exchange led to their eventual 
removal from clinical practice. 19, 20 
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In 1950, Clark and colleagues expanded on von Schroeder’s concept and demonstrated that 
oxygen bubbled through a sintered-glass placed directly into a column of venous blood, 
created foam whereby gas exchange occurred. 21 In 1956 Dewall and Lillehei devised a 
bubble oxygenator that was simple and made from readily available hospital equipment. 22 
In the same year Rygg and Kyvsgaard devised an oxygenator that combined the same three 
basic components (bubbling chamber, settling chamber and arterial reservoir) into a single 
disposable polyethylene bag. 23 Bubble-type blood-gas exchange systems were inherently 
simpler, highly efficient, disposable, required smaller (potentially blood free) priming 
volumes and were easier to assemble. 19 As a result, within a short time of being introduced 
bubble oxygenators were commercially available and became a major driving force behind 
the expansion of CPB and open-heart surgery. Despite their success, concerns emerged 
regarding the increasing rates of blood haemolysis, coagulation disorders, activation of 
white blood cells, acidosis and progressive organ failure seen when CPB lasted more than 
four hours. 19 This was thought to be due to the direct contact of blood with air surfaces 
and the plastic and metal components of the pump oxygenator circuit. 19, 24 These 
disadvantages were initially accepted and counteracted by the relatively short duration of 
open-heart surgery and through the use of profound hypothermia. By cooling the body, 
with the aid of a heat-exchanger, to a core temperature of 10-12oC CPB could be turned off 
for up to one hour while prolonged intra-cardiac surgery was performed. 25, 26 
 
Meanwhile, attention turned to the idea of a protective membrane existing between the 
blood and air to reduce trauma inherent with direct-contact oxygenators (bubble and film). 
Kolff and Berk in 1944, whilst developing an artificial kidney, observed that blood passing 
through the cellophane membrane of their haemodialysis machine became oxygenated by 
the aerated dialysates through the process of passive diffusion. 27 Although their device 
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was incapable of exchanging gas other than at very low flows, Kloff and Berks’ finding 
sparked the search for a suitable inert material that could best mimic the endogenous 
alveolar capillary membrane. 27 In 1957, Clowes and colleagues were the first to report the 
clinical use of a ‘membrane’ oxygenator. The surface area of the teflon membrane they 
used however was excessive (25m2) and led to blood protein denaturation and 
coagulopathies. 28 In 1963, Kolobow and Bowman designed a silicone membrane 
oxygenator whose biocompatibility was especially attractive for long-term CPB. The first 
practical membrane oxygenators appeared in the mid to late 1960s as the Bramson lung 
and Lande-Edwards oxygenators. 29, 30 Despite their theoretical advantage membrane 
oxygenators were not widely utilised during the 1960s and 70s mainly due to their higher 
production costs and the lack of clinical evidence that proved their superiority to direct-
contact oxygenators. They remained less efficient, cumbersome and more prone to plasma 
leakages and thrombotic occlusions than their direct-contact counterparts. 19 
 
1.1.3 Refinement period (1970 – present) 
1.1.3.1 Oxygenators 
Research in the design of membrane oxygenators continued and refinements to the 
geometrical arrangement of the gas exchange compartment occurred. The importance of 
reducing blood film thickness and disrupting laminar flow characteristics within the 
oxygenator to optimise gas exchange became apparent. 19 Various design modifications 
including screens, spacers and sheets were utilised to promote ‘secondary flow’ which 
improved gas exchange and resulted in a 10-fold reduction in the membrane surface area 
required for clinical perfusion. 19, 31 With the use of secondary flows in membrane 
oxygenators, the membrane itself, once again became the limiting factor to gas exchange. 
Modern membrane gas exchangers are almost exclusively constructed of microporous 
polypropylene arranged as a bundle of hollow fibre capillaries. 32-34 Bodell and colleagues 
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first put the conceptual use of tubular capillary fibres for gas exchange forward in 1963. 35 
The concomitant use of secondary flow and hollow-fibre technologies resulted in the 
highly efficient gas exchange devices used clinically during the early 1980s. 19, 32-34 By the 
late 1980s a variant of the above design termed inverse-flow or ‘blood outside’ design 
where blood flowed in the external chamber originally designed for gas, while gas flowed 
within the hollow fibres predominated. This new configuration resulted in a much larger 
gas exchange area, lower shear forces of blood and an overall improvement in gas 
exchange performance such that membrane areas were 2 to 2.5 times smaller than the 
conventional design. 32-34 These combined advantages of high gas exchange efficiency, low 
blood trauma, compactness, simplicity and low cost meant that microporous membrane 
devices began to replace efficient bubble oxygenators in the cardiac operating theatres in 
the 1980s. 32-34 Today such devices have surface areas of 2 to 3m2 and are used exclusively 
in 95% of centres; transferring up to 400ml of oxygen while removing more than 300mls 
of carbon dioxide in a single pass. 32-34, 36 
 
The success of hollow fibre oxygenators has led to the innovative concept of 
‘intracorporeal oxygenation’ termed the intravascular oxygenator or IVOX. 37 In IVOX a 
bundle of silicone coated hollow fibres is inserted into the inferior vena cava of a patient 
and oxygen is pumped through. 37, 38 Secondary flow occurs as blood migrates through the 
fibres on its way back to the heart. Further enhancements where a balloon pump is 
incorporated within these fibres to optimise secondary flow has been suggested and termed 
‘intravascular membrane oxygenator’ or IMO. 37-38 At present IVOX / IMO devices can 
only offer partial respiratory support and have failed to gain widespread acceptance due to 
a lack of clinical benefit. 37-39 
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1.1.3.2 Reservoirs 
Venous blood reservoirs form an essential component of the paediatric bypass circuit in 
providing a safety chamber to sequester excess blood during CPB. Two types of reservoirs 
have traditionally been used relating to open (hard shell) and closed (collapsible bag) 
systems. 32, 34, 36, 40 Open systems which vent air to the atmosphere usually incorporate a 
cardiotomy reservoir, defoaming compartment and are made of rigid plastic. Although 
offering a low inlet resistance and passive removal of venous air the direct blood-air 
interface results in a greater inflammatory response as well as the possibility of air being 
pumped into the patient if the reservoir becomes completely empty. 41 The soft-shell, 
collapsible, closed system on the other hand requires a separate cardiotomy reservoir and 
active removal of any air entrained into the venous system during CPB. 36, 40 However, 
despite the inherent safety of the closed system the ease of use of the open system together 
with the option of vacuum assisted venous drainage has prevailed in 88% of centres in 
North America. 32 
 
1.1.3.3 Pumps 
Since the advent of CPB by Gibbon in the 1950s simplistic, low cost, positive 
displacement roller pumps have predominantly performed the role of the artificial heart. In 
the 1970s however a team of engineers collaborated in the design of a new blood pump 
that relied on centrifugal forces. 32, 42 In the absence of any occlusive mechanism 
centrifugal pumps offered a theoretical reduction in the blood trauma normally seen with 
roller pumps. Despite this theoretical advantage centrifugal pumps have not yet gained 
favour in the majority of paediatric cardiac centres in Europe and Asia and usage is 
somewhat confined to the United States where they are used exclusively in 2-14% of 
centres. 32, 33 
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1.1.3.4 CPB circuit modification 
The process of CPB necessitates the exposure of blood to the artificial surfaces of the 
tubing, oxygenator, reservoirs and filters in addition to other non-physiological conditions 
which are all implicated in blood activation ultimately expressed as a systemic 
inflammatory response. 32, 36, 40, 43 In relation to body surface area, compared to adults, the 
surface area of the CPB circuit used in infants is substantially higher and is directly related 
to the magnitude of inflammatory response. 44 As a result numerous attempts have been 
made to improve the biocompatibility of the circuit through the application of biologically 
active or inert substances onto the surfaces and reduction in circuit size. Heparin-bonded 
CPB circuits have been available for clinical use since the late 1980s and extensive studies 
have demonstrated consistent reductions in plasma levels of complement fragment C3a, 
TNF-α, IL-6, IL-8, E- and P-selectins leading to improved clinical outcomes. 45-47 Despite 
this it has taken some 20 years for the use of modified circuits to become routine and they 
currently represent 74% of circuits used in paediatric centres across North America. 32 
 
1.2 The management of perfusion during cardiopulmonary bypass 
Despite the technological advances of the past 50 years there is still no generally accepted 
definition of optimal perfusion during CPB. This is even more difficult when one considers 
variations in the period of survival monitored and the extent to which organ dysfunction is 
investigated. As a result there is considerable variation in how CPB is conducted between 
centres to optimise the fundamental balance between oxygen supply and demand, limit 
activation of inflammatory cascades, maintain vital organ function and ensure a safe, rapid 
and long-lasting recovery. 32-34, 36, 40 Furthermore, important anatomical and physiological 
differences exist between infants and adults which have to be considered in the setting of 
CPB of the paediatric patient. 
End Organ Effects of Paediatric Cardiopulmonary Bypass         Page 22 of 192 
 
Tony Vassalos  2010 
 
1.2.1 Paediatric anatomical and physiological considerations 
In contrast to adults, infants have a high body surface area to weight ratio which when 
combined with their immature thermal auto-regulation makes them particularly vulnerable 
to rapid fluctuations in body temperature. 36 Temperature regulation and the speed with 
which it occurs is an important consideration of perfusion and has been linked to post-
operative organ dysfunction. 48-52  
 
Compared to adults the immature heart has a smaller percentage of contractile proteins, a 
lower oxidative capacity, decreased sympathetic innervation, altered calcium handling and 
decreased compliance. 36, 53 As a result children have a relatively fixed stroke volume 
making their heart rate and rhythm the main determinants of cardiac output. 53 
Additionally, the myocardium of the newborn has an increased glucose dependence when 
compared with the adult with episodes of hypoglycaemia potentiating heart failure. 54 
Native differences are further complicated in the context of congenital heart disease (CHD) 
where a broad spectrum of cyanotic and acyanotic lesions exists, each with specific 
pathophysiological changes that can result in hypoxia, heart failure, altered pulmonary 
blood flow and low cardiac output. 33, 36 
 
Children with CHD in contrast to adults often have pre-existing abnormalities in 
respiratory mechanics prior to surgery. Lesion specific alterations to pulmonary blood 
flow, pulmonary hypertension and volume / pressure loading of the heart are associated 
with decreased lung compliance, atelectasis, pulmonary oedema, increased airway 
resistance and pulmonary endothelial dysfunction related increases in pulmonary vascular 
resistance manifest as episodes of pulmonary hypertension post-operatively. 55-57 Exposure 
to CPB exacerbates pulmonary endothelial dysfunction and is associated post-operatively 
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with an acute lung injury, the severity of which is directly related to the duration on 
bypass. 55-58 
 
Renal function in neonates and infants is associated with differences in electrolyte 
transport, decreased medullary concentrating ability, impaired tubular function, impaired 
excretion of free water and a lower glomerular filtration rate than adults even when 
corrected for body surface area. 59-61 Despite these differences, however, most children 
undergo CPB without developing post-operative renal failure.  That being said children 
exposed to a period of CPB have a much greater fluid retention post-operatively compared 
to adults which if not adequately diuresed can result in prolonged ventilatory support. 36 
The investigation of renal function in children is complicated by the superimposition of 
renal dysfunction on a background on continuing renal development. Moreover, the 
changing muscle mass of the infant influences circulating creatinine levels with resultant 
inaccuracies in the measurement of creatinine clearance. 62, 63 
 
Many factors are known to affect cerebral blood flow during CPB including temperature, 
cerebral metabolic rate, arterial carbon dioxide partial pressure, pump flow and perfusion 
pressure. 64 Retrospective studies have identified decreasing age as an incremental risk 
factor in the development of post-operative neuropsychological dysfunction. 51, 65 In 
particular it has been shown that during periods of deep hypothermia, sometimes used 
during repair of CHD, cerebral autoregulation and cerebral flow / metabolism coupling are 
lost with cerebral blood flow becoming dependent on perfusion pressure. 36, 51, 64  
 
The coagulation system in newborns is deficient with reduced levels of factors XII, XI, 
vitamin K-dependent factors and coagulation inhibitors (antithrombin III, protein C and 
protein S) commonly seen. 66 This is even more so in children with cyanotic congenital 
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heart disease who are known to have platelet dysfunction in addition to decreased levels of 
factors II, V, VII, VIII, and IX. 67 
 
1.2.2 Physiological cardiopulmonary bypass variables 
Modalities used during CPB in adults to a moderate degree are often used in children to a 
much greater extent resulting in an increased physiological insult which is often 
remarkably well tolerated. Marked temperature changes (deep hypothermia with or without 
circulatory arrest), profound haemodilution (2-3 times blood volume), large foreign surface 
area exposure, low perfusion pressures, wide variations in pump flow rates, wide-ranging 
pH management and altered glucose regulation are commonplace during paediatric 
perfusion. 36, 40 
 
1.2.2.1 Perfusion pressure and flow 
The fundamental aim of CPB is to maintain tissue perfusion of all vital organs whilst 
cardiac and pulmonary function is suspended. The optimal mean arterial pressure during 
CPB that would guarantee satisfactory tissue perfusion is not currently known. As a 
consequence the lower limit used varies widely in the adult population from 50 to 
80mmHg and is essentially based on data relating to cerebral autoregulation. 68 In children 
lower perfusion pressures are normally seen ranging from 20 to 50mmHg in association 
with a greater degree of hypothermia. 36 It is generally accepted that at normothermia in 
children a pump flow rate of 100ml/kg/min or 2.2-2.5L/min/m2 together with a mixed 
venous saturation >75% and arterial oxygen saturation >30mmHg are suggestive of 
adequate perfusion. 40 However, as with mean arterial pressure the minimal safe flow rate 
during CPB has not yet been established. 
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1.2.2.2 Hypothermia 
A degree of hypothermia is used during CPB in virtually all cases of corrective paediatric 
heart surgery to provide organ protection, particularly the brain, by reducing metabolic rate 
and oxygen requirements during periods of altered flow. 34, 40, 69 Cerebral metabolic rate 
drops exponentially as temperature is reduced with minimal adverse effects on 
psychomotor testing seen with circulatory arrest times of up to 41 minutes at 18oC. 52, 70 
Typically the degree of hypothermia used varies directly with the complexity of the repair 
and ranges from mild (32 -35oC), through moderate (25-32oC) to deep (15-20oC) 
hypothermia with or without circulatory arrest. However in recent years, with improving 
surgical and perfusion techniques, the use of deep hypothermia with circulatory arrest 
during corrective paediatric heart surgery has become more selective with some groups 
favouring low-flow CPB. 33, 52, 70 
 
1.2.2.3 pH management 
Arterial blood gas management may be more important in children due to the higher levels 
of hypothermia used during cardiac surgical repair. Cooling increases CO2 solubility and 
results in a lower arterial CO2 partial pressure and associated mild alkalosis (0.015pH 
units/oC). 71 Cerebral blood flow is directly affected by arterial CO2 partial pressure and 
becomes pressure-dependent at high levels through a loss of autoregulation. 40 This is 
thought to be an age-dependent process with children <1yr of age demonstrating a blunted 
response to elevated CO2 levels. 36, 72 During periods of hypothermia acid-base balance is 
currently managed by 2 main strategies. The majority of centres use ‘alpha-stat strategy’ 
whereby CO2 is not added to the circuit and pH is therefore not corrected to temperature. 33 
Others in contrast use the ‘pH-stat strategy’ in which CO2 is added to the system to 
maintain a constant pH over varying temperatures. In both adult and paediatric populations 
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recent reviews have been unable to show any clear benefit on clinical outcomes with either 
strategy leading to the use of a combined technique in some centres. 33, 36, 72-74  
 
1.2.2.4 Haemodilution 
The concept of haemodilution was popularised in the 1950s in the belief that it would 
reduce blood and blood product usage in addition to optimising micro-circulation through 
reduced blood viscosity. 34, 75, 76 Compared to adults the relative priming volume of the 
bypass circuit in children is significantly greater than their blood volume and often results 
in a 3 fold haemodilution. 36, 75, 77 The priming fluid used in children can therefore directly 
impact on fluid and electrolyte balance with glucose containing solutions generally 
avoided. 40 Furthermore, paediatric patients have an impaired ability to excrete the excess 
fluid load which tends to accumulate extravascularly in the tissues. 40, 59-61, 75 In time 
several issues emerged related to haemodilution namely reduced perfusion pressure, 
increased cerebral blood flow, renal dysfunction and decreased oxygen delivery all of 
which contributed to the increased morbidity and mortality seen with decreasing 
haematocrit and stimulated the debate as to the optimal pre-CPB haematocrit level. 34, 75-77 
A large contribution to this area in infants was provided by the Boston group who 
investigated the effects of haematocrit in children undergoing cardiac surgery on post-
operative psychomotor development through a succession of randomised clinical trials and 
advocated a haematocrit level of at least 25% before, during and after CPB. 75, 76 
 
1.2.2.5 Myocardial protection 
The cornerstone of myocardial protection in paediatric CPB is hypothermia particularly in 
children with cyanotic CHD and increased non-coronary collateral flow to the heart 
resulting in cardioplegia washout and rewarming of the myocardium. 36 Hypothermia also 
generates a cushion for reducing pump flows which ultimately decreases collateral 
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circulation in such patients. The optimum electrolyte composition of cardioplegia for 
paediatric patients is not currently known but potassium, calcium, magnesium, sodium and 
buffers are thought to preserve myocardial function. 36 Although variations in electrolyte 
composition exist, blood cardioplegia is currently used by the majority of cardiac centres 
with a mean temperature of 8oC and a haematocrit of 15%. 33 
 
1.2.3 The inflammatory response to cardiopulmonary bypass 
The process of CPB is a non-physiological form of circulation that elicits a profound 
inflammatory response within the body through the activation of plasma protein systems 
(coagulation, contact, fibrinolytic, complement) involved in cellular immunity and 
protection. 78-81 This reaction is further enhanced by the activation of blood cells during 
CPB including platelets, neutrophils, monocytes, endothelial cells and lymphocytes 
culminating in the release of powerful vasoactive substances. 79-81 Clinically this systemic 
inflammatory response syndrome (SIRS) manifests within the first 24 hrs post-operatively 
as tissue oedema, thromboembolism, coagulopathy and temporary organ dysfunction 
particularly in the heart, lungs, brain and kidneys. 79, 80 The severity of SIRS ranges from 
being almost undetectable (mild pyrexia, leucocytosis, tachycardia) to the development of 
multiple organ dysfunction syndrome (MODS) requiring intensive supportive therapy. 80, 82 
Furthermore, these sequelae of CPB can occur in the face of an apparently effective and 
complete cardiac repair with satisfactory haemodynamic performance. 81 Children through 
their immature organ systems, higher metabolic demands, greater haemodilution and 
comparatively larger CPB circuits appear to be more susceptible and therefore at risk of 
injury. 83 
 
Several non-biological variables are known to affect the magnitude of this response 
including myocardial ischaemia and reperfusion times, temperature and the biomaterials in 
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contact with blood. 79 Mediators released during CPB include pro-inflammatory cytokines 
TNF-α, interleukins (IL-1, IL-2, IL-4, IL-6, IL-8 and IL-10), complement (C3a, C5a, C5b-
9) and endotoxin whose mechanisms of action are thought to involve neutrophil activation 
and nitric oxide induction. 78-84 The management of the SIRS response to CPB is a difficult 
problem, due to the complex interplay of inflammatory cascades, but includes 
haemofiltration, adenosine, steroids, aprotinin, leukocyte depletion and heparin-bonded 
circuits. 78-84 As a result it is unlikely that a single therapy will successfully inhibit the 
inflammatory response to CPB and current efforts are mainly centred on symptomatically 
treating the multi-organ system dysfunction produced.  
 
1.2.3.1 Ultrafiltration 
Haemodilution, immature renal function and endothelial dysfunction relating to CPB are 
all implicated in the accumulation of extravascular fluid and associated end-organ injury 
commonly seen in children following cardiac surgery. Ultrafiltration of venous blood to 
reduce fluid overload, increase haematocrit and remove inflammatory mediators was first 
introduced as a concept in 1976 by Romanoli et al. 85 Since then the technique has been 
developed to be used before CPB during priming, intermittently and continuously during 
CPB and modified ultrafiltration post CPB to remove patient fluid and haemoconcentrate. 
86 Multiple studies have demonstrated the effectiveness of modified ultrafiltration in 
increasing haematocrit, improving haemodynamics, reducing tissue oedema, removing 
inflammatory markers and optimising end organ function following paediatric CPB. 32, 36, 
40, 87, 88 It is therefore not surprising that currently 98% of centres are routinely using 
ultrafiltration as a whole with 75% utilising the modified approach. 32  
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1.3 Safety 
If one examines heart-lung bypass machines at their advent in the early 1950s and compare 
their safety features to those of modern day devices it is evident that there have been 
limited advances in safety and overall automation of the process of extracorporeal 
circulation. Original designs were complex (often custom built) containing several safety 
features such as oxygenator blood level sensors, level floats and pressure sensors with 
elaborate feedback mechanisms. 89 As the process of extracorporeal circulation moved 
from the lab to clinical practice an increasing need emerged for simpler, cheaper machines 
as seen during the 1970s and early 80s when many CPB circuits were only composed of an 
oxygenator / heat exchanger, roller pump and tubing. 89 
 
However, as the risk of air and particulate embolism became more apparent added 
attention was given to monitoring anti-coagulation and safety devices such as blood level 
sensors, bubble detectors and filters were added. In time newer designs have incorporated 
feedback loops, from these safety devices, that automatically shut off roller pumps if any 
air is detected within the circuit. 89 This is of particular importance in children with CHD 
where intra-cardiac surgery and intra- and extra-cardiac shunts are a common occurrence. 
36 Arterial line filters (20-40µm) in addition to significantly reducing both gaseous and 
particulate emboli have been shown to improve post-operative neurological function in 
adults and should be a feature of all circuits. 32, 34, 36, 40, 90  
 
Further developments with in-line sensing systems enable perfusionists to continuously 
measure arterial and venous pH, PO2, PCO2, mixed venous saturation, haemoglobin / 
haematocrit and temperature. 34, 36 With the evolution of computers within the theatre 
environment data acquisition, storage and analysis became readily available. However, the 
ultimate jump to a fully automated system has to date not been met with much success. In 
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recent years, pump control systems that utilise microcomputers and proportional-integral 
control algorithms to maintain constant intravascular volumes have been developed for 
CPB and applied on 15 children undergoing cardiac surgery. 91 
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1.5 Aims of the thesis 
The objective of this research was to utilise novel investigations and treatment strategies to 
assess and further characterise peri-operative cardiac, renal and pulmonary function in 
children undergoing, present-day standard, elective cardiac surgery utilising 
cardiopulmonary bypass in the hope that this would ultimately increase clinical knowledge 
and improve outcomes. In this regard two clinical studies were undertaken: 
 
1) A prospective observational study to assess cardiac and renal function by exploring: 
- characteristic changes in peri-operative tissue Doppler imaging parameters, their 
relationship to myocardial injury and clinical outcome 
- the use of cystatin C as a means of quantifying renal performance early after cardiac 
surgery and its association with perfusion parameters and peri-operative myocardial 
injury 
 
2) A randomised, double-bind, placebo-controlled trial that: 
- investigated the use of pre-operative oral sildenafil on haemodynamics, contractility, 
oxygenation and serum cyclic guanosine monophosphate levels in children at risk of 
acute post-operative pulmonary hypertension.  
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CHAPTER 2: CARDIAC FUNCTION 
 
2.1 Abstract 
 
2.1.1 Background 
The purpose of this study was to utilise tissue Doppler imaging (TDI) to assess changes in 
ventricular function following repair of congenital heart defects. The relationship between 
TDI indices, myocardial injury and clinical outcome was explored. 
 
2.1.2 Methods 
Forty-five children were studied; thirty-five undergoing elective repair (AVSD n=11, VSD 
n=16, ASD n=8) and ten normal controls. TDI was performed pre-operatively, on 
admission to PICU and day 1. Regional myocardial Doppler signals were acquired from 
the RV free-wall (RV), LV free-wall (LV) and basal septum (S). TDI indices were derived 
by off-line analysis including: (1) Peak systolic velocities [cm/sec]: SaRV, SaLV, SaS  (2) 
Isovolumic velocities [cm/sec]: IVVLV, IVVRV, IVVS and (3) Isovolumic acceleration 
[cm/sec2]:  IVALV, IVARV, IVAS. Troponin-I was measured in study patients at 15 hours 
(day-1) post-operatively. 
 
2.1.3 Results  
Pre-operatively, bi-ventricular systolic TDI velocities in the study group were reduced 
compared with normal controls and displayed a significant step-wise decrease with 
increasing complexity of lesion. Post-operatively, RV velocities were significantly reduced 
and this persisted to day-1 (SaRV PreOp vs. PICU and day-1: 7.7±2.2 vs. 3.4±1.0, p<0.0001 
and 3.55±1.29, p<0.0001). By contrast LV velocities initially declined but recovered 
towards baseline by day-1 (SaLV PreOp vs. PICU and day-1: 5.31±1.50 vs. 3.51±1.23, 
p<0.0001 and 4.70±1.37, p=0.36). Isovolumic parameters in all regions were persistently 
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reduced throughout the post-operative period. Increased Troponin-I release correlated with 
longer x-clamp times (r=0.82, p<0.0001), bypass duration (r=0.83, p<0.0001) and reduced 
RV velocities (r=0.42, p=0.028).  Reduced pre- and post-operative LV velocities were 
associated with longer ventilation (PreOp: r=0.54, p=0.002; PostOp: r=0.42, p=0.026) and 
PICU times (PreOp: r=0.53, p=0.002; PostOp: r=0.48, p=0.01).  
 
2.1.4 Conclusion 
This study identified a relationship between the extent of peri-operative myocardial injury 
and the degree of post-operative RV contractile impairment as measured by tissue Doppler 
imaging. LV TDI velocities correlated with post-operative outcomes. TDI provided an 
assessment of bi-ventricular function that could allow optimised timing of surgical 
correction and post-operative therapies. 
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2.2 Introduction 
Advances in surgical technique and ITU management have contributed to the improved 
survival of children undergoing repair of congenital heart disease. Despite this, peri-
operative myocardial injury and ventricular dysfunction continue to be major contributors 
to morbidity and mortality. 1 
 
Tissue Doppler imaging (TDI), an echocardiography based technique, measures Doppler 
shift frequencies produced by the contraction and relaxation of longitudinal muscle fibres 
that run from the plane of the atrio-ventricular annuli to the heart apex. 2 The resulting 
Doppler spectrum and measured myocardial velocities have allowed quantification of 
systolic and diastolic function in many clinical and experimental studies. 3, 4 More recently 
myocardial acceleration and peak velocity measured during the period of isovolumetric 
contraction have been proposed and validated as systolic contractile indices independent of 
changing loading conditions. 5, 6, 7 
 
In children undergoing congenital heart surgery TDI may offer many potential advantages 
over conventional echocardiography and other ventricular imaging modalities. Of 
particular interest is the ability to quantify right ventricular (RV) function independent of 
its complex, non-geometric shape. 8 Published data on normal TDI parameter values in 
children with normal anatomical hearts is available. 9 To date however, there is little 
information on the pattern of change in TDI parameters that follows cardiac surgery in 
children. 
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The objective of this study was to investigate the variations in systolic TDI parameters of 
myocardial velocity and acceleration that occur before and after congenital heart surgery 
and explore the association between TDI change, myocardial injury and clinical outcome.  
 
2.3  Methods 
Both local and regional research ethical committees approved the study. Informed consent 
was obtained prior to study enrolment. In total, thirty-five subjects with a range of atrial 
and ventricular defects undergoing surgical repair and ten control subjects with structurally 
normal hearts were studied. Neonates and patients with cyanotic heart disease were 
excluded. All patients underwent elective surgery using standard techniques of 
cardiopulmonary bypass with blood cardioplegia. The study group comprised eight 
patients with ASD (5 primum, 3 secundum), sixteen patients with VSD and eleven patients 
with complete AVSD (Table 1).  This population thus provided a study cohort with a range 
of ages, complexity of condition and varying duration of cardiopulmonary bypass and 
cross-clamp times. 
 
Tissue Doppler imaging was performed using a Vivid 7 ultrasound scanner (GE Vingmed, 
Horten, Norway) with a 7-MHz probe by the same, experienced paediatric 
echocardiographer (SL). Measurements were obtained at the following time points: (1) 
Pre-operatively, in operating room under general anaesthesia (PreOp); (2) 1hr post-
operatively following return to paediatric ICU (PICU); and (3) 15hrs post-operatively 
(Day-1). The heart was imaged from a transthoracic 4-chamber view. Colour-coded 
myocardial velocities were recorded from the basal septum and the lateral free walls of 
both ventricles immediately below (0.5cm) the insertion of the mural leaflet of the left and 
right AV valves as previously described. 10 Filters and gains were adjusted to allow a clear 
tissue signal and minimize background noise. Recordings were made simultaneously with 
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ECG at a sweep speed of 100mm/sec. A cine loop of at least three consecutive cardiac 
cycles was recorded and stored digitally for later off-line analysis. Intra-observer and intra-
individual variation was assessed randomly in 10 patients. 
 
An arterial blood sample for cardiac Troponin-I (cTnl) was taken 15 hours post-operatively 
(day-1). cTnI concentration was measured using a commercially available 
chemiluminescent immunoassay (Beckman Coulter AccuTnI, UK) with the upper limit of 
normal being 0.04µg/litre. 
 
2.3.1 Table 1. Characteristic data of patient groups 
 
 
Demographics Control ASD VSD AVSD 
N 10 8● 16 11 
Male 4 3 11 5 
Age (months)  23.6 ± 20.9* 37.8 ± 15.2*  8.0 ± 5.5 6.1 ± 6.0 
Weight (kg)  13.2 ± 2.6* 6.4 ± 2.5 5.1 ± 0.8 
XC (mins) 44.0 ± 30.1 50.1 ± 15.9 108.8 ± 19.8** 
CPB (mins) 73.8 ± 38.3 83.56 ± 20.9 155.2 ± 24.9** 
Ventilation time (hrs) 18.3 ± 21.9 61.1 ± 57.5 107.6 ± 57.4*** 
PICU stay (days) 1.38 ± 0.7 3.89 ± 2.7 6.00 ± 2.6*** 
cTnI (day-1, µg/L)  3.82 ± 3.7 3.83 ± 2.2 12.9 ± 4.3*** 
 
Data expressed as mean ± SD. 
Control, structurally normal heart; ASD, atrial septal defect; VSD, ventricular septal 
defect; AVSD, atrio-ventricular septal defect; XC, cross-clamp; CPB, cardiopulmonary 
bypass; PICU, paediatric intensive care unit; cTnI, cardiac troponin-I  
●5 primum, 3 secundum; *Control and ASD groups were significantly older (ASD; and 
heavier) than VSD and AVSD groups (p<0.01); **Cross-clamp and cardiopulmonary 
bypass duration were significantly longer for AVSD group compared to VSD and ASD 
groups (p<0.0001); ***Ventilation time, PICU stay and cTnI were significantly higher in 
AVSD group compared to VSD and ASD groups (p<0.001).  
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2.3.2 TDI Analysis 
Stored TDI data was displayed (Figure. 1) and analysed using commercially available 
software (Echopac, GE Vingmed). Each TDI parameter was derived by analysis of the TDI 
annular signal and represented the functional description of corresponding ventricle i.e. 
tricuspid valve for right ventricle, mitral valve for left ventricle and basal septum for 
septum. Peak myocardial velocity (Sa) was measured by electronic callipers as the wave 
height during systole. Peak myocardial isovolumic velocity (IVV) was defined as the 
maximum velocity during isovolumetric contraction (Q wave to onset of systolic ejection). 
Isovolumic acceleration (IVA) was calculated by dividing the peak isovolumic velocity by 
the time interval from baseline to peak isovolumic velocity  (Figure 1). 5 All measurements 
were derived from 3 consecutive cardiac cycles with the average recorded. Of note, 
diastolic TDI parameters were invariably more difficult to interpret due to the merging of 
peak early and late (E and A waves depicted below) annular velocities. Intra-observer and 
intra-individual variation in systolic TDI parameter analysis was found to be less than 5%. 
 
2.3.2.1 Figure 1. Normal TDI waveform depicting measured and acquired 
parameters 
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2.4 Statistical Analysis 
Data are expressed as means ± standard deviations. Demographic and outcome data (age, 
bypass and cross-clamp times, cardiac troponin-I, ventilation time, and PICU stay), TDI 
comparisons with controls and the change in TDI parameters with time were all analysed 
by ANOVA with post-hoc Bonferroni correction. Correlations were performed between 
quantitative variables to assess the degree of linear association using Pearson method. All 
analyses were done using Minitab (Version 14) with a significance level of 5%. 
 
2.5 Results 
Within the study group there was no mortality; all patients were discharged without 
significant complication. Study and control patient demographics are summarised in Table 
1. Control and ASD patients were significantly older than VSD and AVSD patients. There 
was an incremental increase in operative duration, troponin release and ventilation/PICU 
times with increasing cardiac complexity. 
 
Post-operative Troponin-I was elevated compared to the normal range. cTnI (µg/L, all 
patients; 6.6 ± 5.3) was significantly higher following AVSD repair compared with VSD 
and ASD groups (Table 1). There was a strong positive correlation between cTnl release 
and both cross-clamp (r=0.82, p<0.0001) and bypass duration (r=0.83, p<0.0001). 
 
2.5.1 TDI Parameters 
Pre-operatively in both control and study patients, all TDI parameters were greater in the 
RV compared with LV and septum, with the highest values in the control group (Table 2). 
Peak myocardial velocities demonstrated an obvious step-wise decrease with increasing 
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complexity of cardiac lesion. By contrast the isovolumetric parameters, particularly in the 
septum, tended to remain more consistent across the cardiac lesion spectrum.  
 
LV, RV and septal peak systolic velocities were all significantly reduced in the immediate 
post-operative period (PICU) but demonstrated a modest trend to recovery by day-1, 
particularly in the LV (Figure 2a). By contrast both isovolumetric parameters, IVA (Figure 
2b) and IVV (Figure 2c) decreased in the early period and continued to decline at day-1.  
 
2.5.1.1 Table 2. Controls versus pre-operative TDI parameters by diagnosis 
 
 
 
 
TDI data expressed as mean ± SD; (TDI velocity versus control: p<0.05▲, p<0.0001◆) 
Sa, peak systolic myocardial velocity; IVV, peak velocity during isovolumetric 
contraction; IVA, isovolumetric acceleration; LV, left ventricle; Sep, basal septum; RV, 
right ventricle; Control, anatomically normal heart; ASD, atrial septal defect; VSD, 
ventricular septal defect; AVSD, atrio-ventricular septal defect 
 
 
 
 
 
 Sa (cm/sec)  IVV (cm/sec)  IVA (cm/sec2) 
 LV Sep RV LV Sep RV LV Sep RV 
Control 7.75±1.70 7.43±0.46 12.65±0.99 6.20±1.56 7.03±0.74 11.86±4.93 300.8±62.4 291.8±110.8 470.8±189.3 
ASD 6.63±1.47 5.21±0.68◆ 8.64±1.89◆ 6.37±1.20 7.61±0.57 9.80±0.83 230.2±153.9 216.4±44.5 263.0±93.0▲ 
VSD 5.46±1.30◆ 4.92±0.98◆ 7.73±2.29◆ 6.86±3.97 7.32±2.45 9.04±3.68 220.9±132.9 233.6±113.7 274.5±116.4▲ 
AVSD 4.19±0.93◆ 4.52±1.41◆ 6.93±2.32◆ 6.17±2.35 6.94±3.00 9.58±2.27 142.2±88.4▲ 218.6±79.6 317.6±111.6▲ 
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2.5.1.2 Figure 2a. Change in peak systolic myocardial velocity 
 
 
2.5.1.3 Figure 2b. Change in isovolumic acceleration 
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2.5.1.4 Figure 2c. Change in isovolumic velocity 
 
 
 
2.5.2 Correlation of TDI parameters with myocardial injury and outcome 
Reduced pre-operative LV systolic velocity correlated with greater cTnI release and longer 
ventilation (r=0.54, p=0.002) and PICU times (r=0.53, p=0.02). Post-operatively reduced RV 
(Figure 3a) and septal systolic and isovolumic velocities were associated with greater cTnI 
release. By comparison there was no correlation between post-operative LV TDI parameters 
and troponin-I release (SaLV r=0.06, p=0.84; IVALV r=0.15, p=0.75). 
 
Post-operatively, longer ventilation and ITU times were associated with reduced LV and 
septal parameters (Figures 3b-c). There were no significant correlations between RV TDI 
parameters and ventilation time (SaRV r=0.12, p=0.65; IVARV r=0.30, p=0.30).  
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2.5.2.1 Figure 3a. RV systolic velocity (PICU) vs. cTnI 
 
 
 
2.5.2.2 Figure 3b. LV systolic velocity (PICU) vs. Ventilation Time 
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2.5.2.3 Figure 3c. Septal systolic velocity (PICU) vs. Ventilation time 
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2.6 Discussion 
The principal findings in this study were; (1) In patients with congenital heart lesions pre-
operative bi-ventricular systolic tissue Doppler parameters were reduced compared to 
normal controls (2) Following cardiac surgery there was a reversible reduction in TDI 
velocities with sustained decline in isovolumic indices (3) Reduced post-operative RV 
velocities were associated with a greater extent of myocardial injury defined by Troponin-I 
release and (4) Reduced pre- and post-operative LV velocities were associated with longer 
ventilation and PICU times. 
 
The assessment of ventricular function following paediatric cardiac surgery is complicated 
by the alteration to loading conditions caused by the elimination of intra-cardiac shunting 
and variation in post-operative pulmonary and systemic vascular resistances. 1 The 
contractile indices of maximal elastance (Emax) and preload-recruitable stoke work 
(PRSW), derived from pressure-volume data, are considered gold standard because of their 
load independence. 11 However the methodology involved in ventricular volume 
measurement, usually by conductance catheter, is invasive and not suitable for routine 
clinical use.  
 
In this study contractility was quantified using absolute (peak systolic and isovolumic 
velocity) and derived (isovolumic acceleration) tissue Doppler indices. Peak systolic 
myocardial velocities have been validated as an index of contractility in animal 
experiments of ischaemia-reperfusion and in studies of inotrope modulation, where 
velocities have correlated closely with fractional shortening measured by sonomicrometry 
and maximum elastance from pressure-volume data. 4, 12 In clinical studies, systolic TDI 
velocities have proved to be reliable indicators of LV and RV function as well as 
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predicting survival in patients with heterogeneous cardiac diseases. 13-15 However, the 
magnitude of systolic myocardial velocities has been shown to be preload- and afterload- 
dependent. 5, 6, 16 Recently peak isovolumic velocity (IVV) and acceleration (IVA) have 
been proposed and validated through animal studies as load-independent contractile indices 
within the physiological range expected post-operatively. 5-7, 17 The potential ability of TDI 
to assess ventricular function independent of load is particularly important when 
considering the RV which in the context of congenital heart disease is frequently 
characterised by pressure or volume loading. 15, 17 Although RV function can be derived 
from volumetric data obtained through cardiac MRI, multi-slice CT or 3D 
echocardiography their load-dependency, invasiveness, high cost, low availability and time 
consuming data analysis limits their use in children. 8 The RV has a preponderance of 
longitudinal muscle fibres which allows optimal alignment of the tissue Doppler signal. 
This permits a sensitive measure of velocity variations within the RV and thus TDI has 
gained favour in its functional assessment. 14, 15, 17, 18 This was confirmed in the present 
study where TDI indices were consistently higher in the RV compared with septum and 
LV for all patients, including controls.  
 
From the pre-operative data it was found that, not only were the patients with cardiac 
lesions observed to have reduced velocities compared to controls but also the extent of 
velocity reduction was greater with increasing cardiac complexity. By contrast the 
variation observed in isovolumic indices, particularly IVV, was much less across the 
disease spectrum consistent with the load-independent character of these parameters. Of 
interest isovolumic acceleration appeared to be most reduced in the specific ventricle likely 
to be volume loaded by the cardiac lesion, i.e. RV with ASD and LV with VSD/AVSD. 
The study also identified that reduced pre-operative LV TDI indices were associated with 
longer ventilation/PICU times, confirming a clinical impression that patients in pre-
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operative heart failure with VSD lesions, with large Qp:Qs and volume loaded LV, are 
likely to require longer post-operative recovery. Previous adult studies have also shown 
that LV systolic velocities may predict survival in patients with congestive heart failure. 19 
Ultimately it may be that LV systolic TDI parameters will have a predictive value in 
determining post-operative course and can be factored into optimising the timing of 
surgery.   
 
In the current study the finding of a reduction in all systolic TDI parameters measured at 
the septum, mitral and tricuspid annuli suggests an overall global impairment of 
contractility in the early post-operative period. Of particular interest was the disparity seen 
between RV and LV TDI parameters post-operatively. LV peak systolic velocities 
recovered towards baseline pre-operative values by 15 hours post-operatively and this 
pattern of change may reflect the nadir in cardiac index described by Wernovsky. 20 
However, peak systolic velocities are an ejection-phase index and therefore load-dependent 
and the initial fall in LV velocities may in part result from diminished LV preload 
following VSD closure. 16 Similarly the observed later velocity recovery may represent a 
reduction in systemic vascular resistance rather than an improvement in intrinsic LV 
contractility per se. 10, 20 By contrast, RV and septal systolic velocities remained reduced 
with no significant recovery between the 2 post-operative time points. Potentially these 
velocities could also be reduced as a consequence of increased RV afterload by elevations 
in pulmonary arterial pressure common in post-operative patients with repaired VSD or 
canal defects. The greater and more significant reduction in RV isovolumic acceleration 
seen post-operatively supports the view that an intrinsic RV contractile impairment existed. 
Likewise the smaller reduction in post-operative LV isovolumic acceleration, although not 
initially statistically significant, could also indicate a contractile dysfunction within the 
LV. Ultimately however, there exists a complex interplay of changes in loading conditions 
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and myocardial contractility that are often interrelated and therefore not possible to 
definitively isolate.   
 
In this study post-operative serum Troponin-I was measured to quantify myocardial injury 
sustained during surgery. Troponin-I has been shown to correlate well with the extent of 
peri-operative myocardial damage and is predictive of post-operative outcome in the 
paediatric population. 21, 22 In this patient group although direct retraction trauma cannot be 
avoided, no ventricular incisions or myocardial resection were performed and therefore 
myocardial injury and cTnI release should relate to the duration of ischemia-reperfusion. 
This was strongly evident in our study with clear correlations between cross-clamp and 
bypass times and cTnI levels. The significant correlations between cTnI levels and RV and 
septal TDI parameters would implicate myocardial injury as the principal mechanism 
behind the reduced contractility. Of interest, although both ventricles were exposed to the 
same ischemic-reperfusion insult, no significant correlations between troponin-I and post-
operative LV TDI parameters were found. This may reflect a vulnerability of the RV to 
myocardial injury in this patient group. In the patients with VSD physiology, pre-operative 
exposure of the RV to systemic pressures will induce myocardial hypertrophy, which has 
been shown to decrease sub-endocardial blood flow and lower concentrations of high 
energy phosphates, factors which may render the ventricle more susceptible to injury 
during the cross-clamp period. 23 The RV is also vulnerable to direct surgical trauma and 
contusion resulting from retraction, ventriculotomy (although not performed in this study) 
and VSD suture placement. Post-operative conduction abnormalities, including right 
bundle branch block may have a more pronounced effect on RV contraction although no 
conduction defects were seen in these patients. 
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In the acute post-operative setting TDI had a predictive value for early outcome with 
reduced LV and septal TDI significantly correlating with longer ventilation time and PICU 
stay. By contrast RV TDI, the ventricle with the most marked post-operative TDI 
reduction, did not demonstrate a correlation with outcome. Although the reasons for this 
remain unclear it may be that the RV TDI was not measured beyond 15 hours post-
operatively and it is possible that subsequent ventricular recovery and appropriate 
modulation of the contractile deficit by inotropes may confound a potential relationship. In 
addition other factors, including renal and pulmonary impairment, may supersede the 
influence of ventricular function on early outcome with respect to ventilation and PICU 
times. 
 
2.7 Clinical implications and future considerations 
Pre-operative TDI quantification of LV systolic function may prove to be a useful adjunct 
in determining the timing of corrective surgery. TDI also has the ability to assess 
contractile dysfunction in the PICU setting, allowing early and ongoing assessment of 
ventricular performance following cardiac surgery. This may enable appropriate 
therapeutic intervention prior to the onset of the systemic manifestations of low cardiac 
output including lactic acidosis and renal failure. Due to its particular sensitivity for RV 
contraction, TDI may provide better evaluation of right ventricular-pulmonary interaction 
post cardiac surgery and assessment of the effectiveness of nitric oxide and other 
intervention strategies. 
 
2.8 Study limitations 
Pulmonary arterial pressures were not directly measured and therefore this influence was 
not evaluated. Never the less, no patient required supportive measures including nitric 
oxide administration in the ITU management. The lower velocity changes and the more 
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variable and inconsistent pattern of change observed in LV post-operatively may reflect a 
misalignment of the Doppler signal with the predominant circular mid-wall fibres found in 
the left ventricle. However, the majority of published studies of TDI quantifying LV 
contraction used longitudinal mitral annular velocities and have satisfactorily predicted 
ventricular function and outcome. 3, 4, 13, 19, 24  
 
TDI parameters were not analysed beyond the first post-operative day and it would have 
been interesting to know if the RV and septal parameters returned to normal during the 
early post-operative period. In a previous study of post-op Fallot’s patients a reduction in 
RV myocardial acceleration persisted late after repair. 17 However this may relate to 
ongoing haemodynamic lesions including chronic pulmonary regurgitation rather than a 
permanent myocardial injury sustained at the time of surgical repair. 
 
2.9  Conclusion 
This study highlights the vulnerability of the RV to ischaemia-reperfusion injury sustained 
during the repair of congenital heart disease, as quantified by TDI. TDI is a readily 
accessible, non-invasive technique that allows real-time evaluation of ventricular function 
after surgery enabeling the clinician to make rapid therapeutic management decisions. 
Through its particular sensitivity to RV contraction, TDI may provide better evaluation of 
the RV-pulmonary interaction after cardiac surgery and the effectiveness of nitric oxide 
and other intervention strategies. Pre-operative evaluation of LV systolic TDI parameters 
may have a role in patient risk stratification and timing of cardiac surgical correction. 
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CHAPTER 3: RENAL FUNCTION 
 
3.1 Abstract 
 
3.1.1 Background 
Cardiopulmonary bypass (CPB) and post-operative low cardiac output are important 
factors in acute renal injury following cardiac surgery. In patients with renal disease 
cystatin C has emerged as a new biomarker marker that is sensitive to changes in 
glomerular filtration rate (GFR) and may provide a better estimate of renal function than 
creatinine alone. In this study we wished to:  
1. Evaluate cystatin C as a means of quantifying renal performance after cardiac surgery 
in children. 
2. Utilize cystatin C to investigate acute changes in renal function following cardiac 
surgery in children and its association with cardiopulmonary bypass factors and peri-
operative myocardial injury. 
 
3.1.2 Methods 
Twenty children, aged 4-58 months (median 5.5, 10 M: 10 F), undergoing surgery (AVSD 
n=7, VSD n=9, ASD n=4) were prospectively studied. Blood samples were collected pre-
operatively and on days 0, 1, 2 and 3 post-operatively to measure serum cystatin C (cysC) 
and creatinine (Cr). GFR was quantified by creatinine clearance during the first and second 
12hr post-operative periods; CrCl0-12 and CrCl12-24 respectively. Recorded CPB parameters 
included bypass duration, the lowest pump flow (Qmin), the lowest hematocrit (Hctmin) and 
the corresponding lowest oxygen delivery (DO2 min). Myocardial injury was quantified 
post-operatively by Troponin-I release. 
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3.1.3 Results  
Serum cystatin C and creatinine increased post-operatively to peak on days 3 and 2 
respectively (cysCDay0 0.8±0.3 vs. cysCDay3 1.5±0.5; p=0.02) (CrPreOp 31.0±6.9 vs. CrDay2 
36.9±12.2; p=0.03). During the first 24hrs after surgery GFR remained unchanged (CrCl0-
12 63.6±37.0 vs. CrCl12-24 65.1±27.5; p=n.s.). In comparison to creatinine, cystatin C 
demonstrated a superior correlation with GFR (cysCDay0 r=0.58 p=0.018; CrDay0 r=0.09 
p=0.74). Receiver-operator cut-off level for cystatin C >1.044mg/l exhibited a 100% 
sensitivity and 67% specificity for detecting renal dysfunction, defined as a GFR 
<55ml/min/1.73m2, compared to 85% sensitivity and 88% specificity for creatinine 
>34µmol/l. Serum cystatin C significantly increased during the first 24hr post-operative 
period (cysCDay0 0.8±0.3 vs. cysCDay1 1.1±0.4; p=0.003) and was strongly associated with 
CPB duration (cysCDay1 r=0.67, p=0.001), Qmin (cysCDay1 r=0.61, p=0.005) and greater 
Troponin-I release (cysCDay1 r=0.73, p<0.001). Lowest DO2 min and Hctmin did not correlate 
with cystatin C.  
 
3.1.4 Conclusions 
This study has shown that in comparison to creatinine, cystatin C provides a better estimate 
of GFR and is more sensitive in detecting significant renal dysfunction in children 
following cardiac surgery. Cystatin C identified a transient post-operative renal 
impairment, the magnitude of which was associated with duration of bypass, low pump 
flows and the degree of myocardial injury. 
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3.2 Introduction 
Acute renal failure (ARF) following cardiopulmonary bypass (CPB) in children is a well 
recognised and serious complication of cardiac surgery whose incidence varies widely, 1to 
31%, depending on the defining criteria. 1-5 When severe enough to require renal 
replacement therapy (RRT) morbidity and mortality are significantly increased despite 
supportive measures. 2, 3 
 
The artificial process of CPB necessary for cardiac surgery is known to trigger multiple 
inflammatory cascades within the body that culminate in a capillary leak syndrome and 
multi-organ dysfunction. 6-8 In an attempt to maximise operating conditions, further 
potential stresses are often inflicted on the kidney through haemodilution, hypothermia, 
hypoperfusion and non-pulsatile flow. 3,9,10 Younger and smaller patients as a group are 
particularly vulnerable due to higher metabolic demands, complex cardiac lesions, longer 
CPB times, reactive pulmonary vasculature and immature organ systems with altered 
homeostasis.2, 5, 7 Evidence also exists of a low cardiac output syndrome (LCOS) that 
occurs 6 to 18 hours after paediatric cardiac surgery which is multi-factorial in aetiology 
and associated with increased mortality due to secondary organ failure. 6, 11 
 
Glomerular filtration rate (GFR), defined as the volume of plasma completely cleared of a 
particular substance by the kidneys in a unit of time, is the best overall indicator of renal 
function. 12-14 The expensive, labour-intensive determinations of GFR by exogenous 
substances such as inulin remain the ‘gold standard’ but have been replaced clinically by 
more straightforward endogenous substances including creatinine. Although the 
measurement of serum creatinine is the most common method for estimating GFR, it often 
fails to identify patients with moderately reduced renal function. 12-15 Cysteine proteases 
are a group of enzymes that degrade polypeptides. In humans they are responsible for 
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apoptosis, MHC class II immune responses, proteasome and lysosomal regulation, pro-
hormone processing and extracellular matrix remodeling important to bone development. 
16-18 Cystatin C (cysC) is a cysteine proteinase inhibitor uniquely expressed in all 
nucleated cells and produced at a constant rate. 16-18 It is considered to be a sensitive 
marker of renal injury and unlike creatinine its levels are not influenced by height, age, 
sex, muscle mass or acute phase reactions highlighting the potential diagnostic importance 
of this novel biomarker.12-14,16-19  
 
The value of cysC in quantifying early renal dysfunction following paediatric cardiac 
surgery in conjunction with measured GFR and serum creatinine has not been tested. This 
important issue has been addressed in this study as well as the association of cysC with 
peri-operative CPB factors, oxygen delivery and myocardial injury. 
 
3.3 Methods 
3.3.1 Patients 
Both local and regional research ethics committees approved the study. Following written 
informed consent the first twenty children enrolled to our prospective observational cohort 
study designed to assess cardiac and renal function, with a range of atrial and ventricular 
septal defects undergoing corrective surgical repair, were prospectively recruited. 
Exclusion criteria included neonates, patients with cyanotic heart disease and pre-operative 
use of mechanical ventilation, inotropes, extracorporeal life support or pre-existing renal 
dysfunction.  
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3.3.2 Data Collection and Definitions 
3.3.2.1 Renal Function 
Serum creatinine (Cr) was measured as part of routine investigations for all patients 
undergoing cardiac surgery pre-operatively, on admission to paediatric intensive care 
(PICU) and days 1, 2 and 3 post-operatively using the Roche Creatinine Plus enzymatic 
assay with a normal range of 18 – 40 µmol/L.  
 
Plasma retained from routine investigations, at the above time points, was stored at -70oC 
until measurement of cysC using a particle-enhanced nephelometric immunoassay 
(PENIA) on a BN ProSpec analyser (Dade Behring Ltd., Milton Keynes, UK) with a 
normal range of 0.54 – 1.06 mg/L.  
 
Urinary creatinine measured by the kinetic Jaffe method on an Abbott AEROSET analyser 
was used to estimate GFR through creatinine clearance (CrCl) during the first and second 
twelve-hour post-operative periods and indexed to body surface area (Normal range 54 – 
86 ml/min/1.73m2). Hourly urine output (ml/kg) was recorded for the first twenty-four 
hours after surgery. 
 
3.3.2.2 Perfusion and Myocardial Injury 
Besides CPB and cross-clamp times (min), the following operative parameters were 
recorded at four time points during surgery (commencement of CPB, at 30 min, at 1hr and 
on removal of cross-clamp): haemoglobin (g/dL), haemoglobin saturation (%) and arterial 
oxygen tension (mmHg) from routine arterial blood gas analysis, pump flow (ml/min/m2), 
mean arterial pressure (mmHg) and oxygen delivery (ml/min/m2). In addition the lowest 
End Organ Effects of Paediatric Cardiopulmonary Bypass         Page 67 of 192 
 
Tony Vassalos  2010 
indexed pump flow (Qmin), lowest haematocrit (Hctmin) and corresponding oxygen delivery 
(DO2 min) that occurred during CPB were also noted. 
 
Oxygen delivery (DO2, ml/min/m2) which is the amount of oxygen delivered to the 
peripheral tissues was calculated by multiplying the indexed pump flow (Q) by the arterial 
oxygen content according to the equation: DO2 = Q x (haemoglobin x 1.34 x haemoglobin 
saturation + 0.003 x arterial oxygen tension). 3  
 
An arterial blood sample for cardiac Troponin-I (cTnl) was taken 15 hours post-operatively 
(Day1). cTnI concentration was measured using a commercially available 
chemiluminescent immunoassay (Beckman Coulter AccuTnI, UK), with the upper limit of 
normal being 0.04µg/litre. 
 
3.3.3 Cardiopulmonary Bypass 
All patients underwent elective surgery by the same surgeon (MHD) using moderate 
hypothermic cardiopulmonary bypass (25-320C) with antegrade, cold, blood cardioplegia. 
The bypass circuit was primed with 4.5% albumin (150 - 200 mls), mannitol (0.5g/kg), 
NaHCO3 (10 – 15 mmol) and heparin (3000 – 5000 iu). Packed red cells were added to the 
prime to achieve a minimum haematocrit of 25%. Acid base was managed with alpha stat 
control. Conventional ultrafiltration (Minntech HPH 400 haemofilter) during re-warming 
occurred in all patients.  
 
Extracorporeal circulation was performed using a Medos 2800 (Chalice Medical, 
Shireoaks, Notinghamshire, UK) oxygenator, Pall AL3 (Chalice Medical, Shireoaks, 
Notinghamshire, UK) arterial filter and Stockert S3 roller pump (Sorin, Gloucester, 
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Gloucestershire, UK). Non-pulsatile perfusion was maintained at 1.0 – 1.8L/min (<12 
months) and 1.8 – 3.0L/min (12 – 58 months): flow = body surface area x 2.4 L/min/m2. 
 
3.4 Statistical Analysis 
Associations between peri-operative variables and measures of post-operative renal 
function (CrCl12-24, CrDay1 and cysCDay1) were initially investigated univariately.  
Creatinine clearance was defined as a dependent binary variable (0 to 1; using cut-off 
values at 55 and 85 ml/min/1.73m2 to further delineate any association with severity of 
renal impairment) and its association with the various independent variables was explored 
using a logistic regression analysis with each possible predictor tested one at a time. For 
continuous outcomes, a general linear model was used in the same way. Significant 
variables from the univariate analyses were then used in multivariate models using 
backwards selection to determine the independent predictors of outcomes.  
 
Parameters of renal function (Cr, cysC and CrCl) were measured over time and a repeated 
measures analysis of variance was performed to test for differences between time points. 
Where differences existed, post-hoc comparisons between time points were completed 
using the Bonferroni correction for multiple testing.  
 
Receiver operating characteristics (ROC) analyses were performed to investigate the 
potential of CrDay1 and cysCDay1 as diagnostic predictors of abnormal CrCL12-24, coded as 
binary, with cut-offs at 55 and 85 ml/min/1.73m2. 
 
All analyses were done using Minitab (version 15) or SPSS (version 17) at a significance 
level of 5%. 
 
End Organ Effects of Paediatric Cardiopulmonary Bypass         Page 69 of 192 
 
Tony Vassalos  2010 
3.5 Results 
Twenty children were recruited to the study with demographic and peri-operative variables as 
outlined in Table 1 and Figures 1a-d. Within this group there was no surgical hospital 
mortality; all patients were discharged home without complication.  
 
3.5.1 Table 1. Demographic characteristics between groups  
 
 
 
AVSD 
(n = 7) 
VSD 
(n = 9) 
ASD 
(n = 4) 
p-value 
 
All Patients 
(n = 20) 
Patient factors Gender (Male) 2 (29%) 6 (67%) 2 (50%) 0.319 10 (50%) 
 Age (mth) 6.5 ± 1.7 8.1 ± 2.1 41.8 ± 6.8 0.005 14.3 ± 15.9 
 Weight (Kg) 6.1 ± 1.5 6.0 ± 2.5 14.0 ± 3.0 0.007 7.7 ± 3.9 
Operative factors XC (min) 106 ± 20 54 ± 17 43 ± 23 <0.001 70.4 ± 33.4 
 BP (min) 147 ± 25 86 ± 25 69 ± 28 <0.001 100 ± 41 
 Hctmin (%) 24.14 ± 3.13 23.43 ± 2.88 22.75 ± 2.36 0.725 23.75 ± 2.73 
 Qmin (ml/min/m2) 2037.4 ± 408 2299.8 ± 430 2551 ± 262 0.111 2250.5 ± 398.7 
 DO2min (ml/min/m2) 244.3 ± 47.7 309.9 ± 49.8 290.6 ± 11.4 0.034 281.0 ± 49.1 
Post-Op factors cTnIDay-1 (µg/L) 11.6 ± 3.6 4.9 ± 2.4 2.2 ± 0.6 <0.001 6.7 ± 4.8 
 Ventilation (hrs) 101 ± 67.4 69.3 ± 66.9 21.3 ± 26 0.05 70.8 ± 65.4 
 PICU stay (days) 5.7 ± 3.0 4.1 ± 3.0 1.3 ± 0.5 0.020 4.1 ± 3 
 Hospital stay (days) 19.1 ± 18.0 8.8 ± 2.5 7.2 ± 2.2 0.035 12.1 ± 11.8 
 
Data expressed as mean ± SD. (p-value: refers to between group comparisons) 
AVSD, atrio-ventricular septal defect; VSD, ventricular septal defect; ASD, atrial septal 
defect; XC, cross-clamp time; BP, cardiopulmonary bypass time; Hctmin, lowest 
haematocrit during bypass; Qmin, lowest indexed pump flow during bypass; DO2min, 
indexed oxygen delivery at lowest haematocrit during bypass; cTnIDay-1 , serum cardiac 
troponin-I on first post-operative day; Post-Op, post-operative; PICU, paediatric intensive 
care unit. 
End Organ Effects of Paediatric Cardiopulmonary Bypass         Page 70 of 192 
 
Tony Vassalos  2010 
3.5.1.1 Figure 1a. Peri-operative pump flow (--- ideal parameter boundaries)  
Mean values interconnected. Wide variation in perfusion flow evident with 
general trend for increasing flows prior to removal of cross-clamp (XC). 
 
 
3.5.1.2 Figure 1b. Peri-operative haematocrit (--- ideal parameter boundaries)  
Mean values interconnected. Wide variation in haematocrit levels evident 
particularly on commencement of bypass (on BP). Increased haematocrit levels 
associated with ultrafiltration prior to cross-clamp removal (XC off). 
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3.5.1.3 Figure 1c. Peri-operative oxygen delivery (--- critical dysoxic threshold)  
Mean values interconnected. Wide variation in oxygen delivery demonstrated 
with increased levels prior to cross-clamp removal (XC off) in conjunction with 
increasing pump flows and haematocrit. 
 
3.5.1.4 Figure 1d. Peri-operative mean arterial pressure (--- ideal parameter boundaries) 
Mean values interconnected. 
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3.5.2 Renal Function 
There was no significant change in measured GFR in the first twenty-four hours after surgery 
(Figure 2). Pre-operatively, serum Cr and cysC were in the normal range for all patients and in 
contrast to CrCl both increased significantly during the early post-operative period continuing 
to peak on days two and three respectively (Figure 3). Serum Cr levels returned to normal by 
day three. This deterioration in renal function was associated with a non-significant drop in 
urine output in the early post-operative period (Figure 4). In comparison to Cr, cysC 
demonstrated a superior correlation to measured GFR in the early post-operative period 
(Figure 5). No patients required post-operative renal replacement therapy. 
 
3.5.2.1 Figure 2. Indexed post-operative Creatinine Clearance 
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3.5.2.2 Figure 3. Peri-operative serum Creatinine and cystatin C 
 
3.5.2.3 Figure 4. Early post-operative urine output (24hrs) 
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3.5.2.4 Figure 5. Correlation of cystatin C and serum Creatinine with CrCl 
 
3.5.3 Univariate Analyses 
CrCl12-24 <85ml/min/1.73m2 was not significantly associated with any of the measured 
variables whereas <55ml/min/1.73m2 correlated with XC (p=0.033) time. cysCDay-1 was 
significantly associated with Qmin (p=0.005; Figure 6a), cTnIDay-1 (p<0.001; Figure 6b), BP and 
XC times (both, p=0.001). cysCDay-1 did not correlate significantly with DO2 min (p=0.47) or 
Hctmin (p=0.336). However, DO2 min <300ml/min/m2 demonstrated a significant association 
with cysCDay-1 (r=-0.68, p=0.007).  
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3.5.3.1 Figure 6a. Correlation of cystatin C and lowest pump flow during CPB 
 
3.5.3.2 Figure 6b. Correlation of cystatin C and cTnI 
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3.5.4 Multivariable Analyses 
XC time (OR 1.07, 95% CI (1.01,1.14)) in association with CrCl12-24 <55ml/min/1.73m2 and 
cTnIDay-1 in association with cysCDay-1 (p=0.01) and CrDay-1 (p<0.001) were the only significant 
independent predictors of early post-operative renal dysfunction in this patient group. 
 
3.5.5 ROC Analyses 
cysCDay1 >1.044mg/l exhibited a 100% sensitivity and 67% specificity for detecting renal 
dysfunction, defined as a GFR<55ml/min/1.73m2, compared to 85% sensitivity and 88% 
specificity for CrDay1 >34µmol/l. DO2 min <242ml/min/m2 exhibited a 72% sensitivity and 
100% specificity for detecting renal dysfunction, defined as a GFR<55ml/min/1.73m2 (Figure. 
7). 
3.5.5.1 Figure 7. ROC  
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3.5.6 Clinical Outcomes 
cysCDay1 was the only marker of post-operative renal injury that significantly correlated with 
ventilation time (p<0.001) and PICU stay (p=0.002). Compared to serum Cr, cysC 
demonstrated superior correlation to overall hospital stay (hospital stay vs. CrDay1 and 
cycCDay1: r=0.62, p=0.005 and r=0.73, p<0.001 respectively). 
 
3.6 Discussion 
Acute renal failure is a common complication after cardiac surgery which continues to be 
associated with significant morbidity and in the presence of replacement therapy, 
mortality. 1-5 In this prospective study, the use of cystatin C to predict early renal 
dysfunction following paediatric cardiac surgery and the related impact of CPB parameters 
was investigated. Our principal findings were that: (1) cystatin C is a more sensitive 
marker of early renal dysfunction than serum creatinine (2) CrCl is not significantly altered 
in the first 24hrs after surgery (3) intra-operative ischaemia-reperfusion and myocardial 
injury were independent predictors of early renal dysfunction and (4) a raised cystatin C 
post-operatively is significantly linked to clinical outcome measures of ventilation time 
and PICU stay. 
 
Serum creatinine and urine output are commonly used to define ARF whose pathophysiology 
involves a broad pattern of peri-operative mechanisms. 1, 4, 5 However, in addition to being 
influenced by age, height, sex and muscle mass creatinine is actively secreted by the proximal 
tubules resulting in as much as a twofold overestimation of GFR.1, 12-18 Importantly, this 
disparity increases as GFR decreases further limiting the ability of creatinine to monitor 
moderate renal dysfunction. As a result, approximately 50% of renal function can be lost 
without an increase in serum creatinine. 12, 14 Urine output is a far less specific marker of renal 
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function and severe ARF can exist despite normal urine production. 1, 5 Changes in urine 
output, in the absence of diuretics, can occur long before biochemical changes are apparent 
making it an important consideration. According to published consensus definitions of ARF, 
no patient in this study developed an acute (<24hrs) post-operative renal injury or failure. 5 
 
Cystatin C is also freely filtered by the glomerulus but unlike creatinine is neither secreted 
by the renal tubules nor reabsorbed into the bloodstream making it an ‘ideal’ endogenous 
marker of renal function.13, 14-19 In adult patients with varying chronic and acute renal 
pathologies, renal transplant, oncology and elderly patients cystatin C has consistently 
been shown to be more sensitive than creatinine in measuring small changes in GFR. 12, 13, 
16-18 The independence of cystatin C on height, gender, age and muscle mass is of 
particular importance in the paediatric population. Pham-Huy et al demonstrated that 
compared to creatinine only cystatin C correlated with measured GFR (99mTc DTPA) in 
children with spina bifida who tend to be of short stature and low muscle mass. 19 Filler et 
al provided evidence that cystatin C is independent of age in 216 paediatric urology 
patients (0.8 – 18 yrs) with normal GFR determined by 51Cr-EDTA clearance. 20 
 
To our knowledge the evaluation of cystatin C as a marker of acute renal injury has not 
been previously reported in this patient group. In keeping with the current evidence this 
study demonstrated that cystatin C (>1.044mg/L) was more sensitive than creatinine 
(100% vs. 85%) in predicting early renal dysfunction defined as CrCl <55 ml/min/1.73m2. 
Furthermore, cystatin C alone correlated significantly with CrCl after cardiac surgery 
allowing earlier identification of at-risk patients with potential implications for reducing 
post-operative morbidity and mortality. Compared to creatinine, cystatin C was more 
significantly associated with post-operative clinical outcomes of ventilation time and PICU 
stay. However serum cystatin C is not currently available on routine biochemical analysis 
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and remains an expensive option (£15-20/test). Future studies demonstrating significant 
reductions in overall hospital stay with cystatin C based perioperative management are 
needed to drive the clinical impetus necessary for the routine availability of this test. 
 
In agreement with previous studies significant intra-operative correlates of early post-
operative renal dysfunction included myocardial injury, pump flow, cross-clamp and CPB 
duration. 2-5 However, after adjusting for possible confounding influences amongst 
variables only cross-clamp time and myocardial injury, measured by cardiac troponin-I, 
were found to be significant independent predictors. Post-operative troponin-I has 
previously been shown to be significantly associated with the extent of peri-operative 
myocardial injury, manifest post-operatively as a low cardiac output, and is predictive of 
outcome including acute renal failure in a similar patient group. 6, 11, 21, 22 Both cystatin C 
and creatinine significantly correlated with troponin-I in this study highlighting the 
importance of maintaining cardiac output during the early post-operative period on renal 
dysfunction. Renal ischaemia, unlike cardiac, is generally silent with signs and symptoms 
unlikely to identify high risk patients making the availability of a sensitive serum 
biomarker an important clinical decision-making tool. 
 
The principal objective of CPB is the delivery of oxygen to the systemic circulation during 
periods of cardio-pulmonary arrest necessary for cardiac surgical repair. In addition to the 
inflammatory cascades and low cardiac output state associated with CPB the renal medulla 
is particularly vulnerable to even minor reductions in oxygen delivery.3, 5-10 Risk of peri-
operative renal injury is further exacerbated in infants due to immature auto-regulatory 
function and reduced renal blood flow. 5, 7, 8 Current evidence suggests that a low 
haematocrit level (<25%) during CPB is associated with post-operative renal dysfunction, 
low cardiac output syndrome, lower psychomotor scores and mortality. 3, 9, 10, 23 Despite 
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mean haematocrit levels of 23.75% in this study only lowest pump flow during CPB was 
significantly linked with post-operative renal impairment as defined by cystatin C. This 
may imply that intra-operative oxygen delivery, which is dependent on both pump flow 
and haematocrit, is of greatest overall importance in preserving post-operative organ 
function.  The significance of oxygen delivery was however not readily apparent in our 
study suggesting either that renal-specific oxygen delivery was maintained or oxygen 
extraction increased during CPB or that a ‘critical threshold’ exists within the renal 
parenchyma that has to be breached before notable damage occurs.  
 
Indeed Boston et al demonstrated an organ-specific hierarchical distribution of oxygen 
delivery during CPB in pigs with oxygen delivery to muscle and visceral organs sacrificed 
to maintain the brain and kidneys. It was not until pump flow dropped to less than 
1.4L/min/m2 that a significant reduction in oxygen delivery to the kidneys was observed. 24 
Interestingly in this study a mean lowest pump flow of 2.2L/min/m2 during CPB was 
significantly associated with acute post-operative renal dysfunction. Evidence of a dysoxic 
threshold exists in adult critical care patients in whom an oxygen delivery of less than 
325ml/min/m2 results in anaerobic metabolism, lactic acidosis and eventual multi-organ 
dysfunction. 3, 25 This concept is further supported in this study where an oxygen delivery 
of less than 300ml/min/m2 became significantly associated with post-operative renal 
impairment.  In addition, ROC analyses demonstrated that a cut-off value of 242ml/min/m2 
exhibited a 72% sensitivity and 100% specificity for detecting renal dysfunction, defined 
as a GFR <55ml/min/1.73m2. This value is within the range quoted in similar studies 
involving adult CPB. 3, 25 Our data therefore defends the hypothesis of an ischaemic insult 
ultimately being responsible for early renal dysfunction after paediatric cardiac surgery 
emphasising the need for improved categorisation and optimisation of perfusion 
parameters during surgery.  
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3.7 Study Limitations 
Blood lactate measurements were not recorded peri-operatively in this study and we are 
therefore unable to demonstrate that patients with critical oxygen delivery developed an 
increased lactic acidosis. The relationship between haematocrit on CPB, related blood 
transfusion and post-operative renal dysfunction was not explored. The incidence of ‘low 
cardiac output syndrome’ which is a recognised cause of post-operative renal dysfunction 
in this patient group was not investigated in this study. 
 
3.8 Conclusion 
This study has shown that in comparison to serum creatinine, cystatin C provides a better 
estimate of GFR in children immediately after corrective cardiac surgery. Early post-
operative renal impairment is independently predicted by ischaemia-reperfusion times and 
the degree of myocardial injury measured by Troponin-I. Oxygen delivery may be an 
important consideration for the future development of perfusion parameters. 
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CHAPTER 4: PULMONARY FUNCTION 
 
4.1  Abstract 
 
4.1.1 Background 
To investigate the acute effects of pre-operative sildenafil on haemodynamics, oxygenation 
and cyclic-guanosine-monophosphate (cGMP) levels in children at risk of pulmonary 
hypertension after cardiac surgery. 
 
4.1.2 Methods 
24 children (median age, 0.4 years) undergoing repair of VSD-type congenital heart 
disease were randomized to oral sildenafil (0.5mg/kg) or placebo 6hrly the day before 
surgery. Blood samples were collected peri-operatively to determine cGMP and NO 
production. Haemodynamic and echocardiography data were acquired at 2 and 24 hours 
post-operatively: (1) Mean pulmonary artery and left atrial pressures (2) Pulmonary 
vascular resistance index (PVRI) = transpulmonary gradient/pulmonary blood flow on 
spectral Doppler and (3) Bi-ventricular systolic tissue Doppler (TDI) velocities (SaLV, 
SaRV). Post-operative oxygenation was assessed by oxygen delivery (DO2) and 
oxygenation index (OI) in PICU and on day-1.  
 
4.1.3 Results 
cGMP (pmol/ml) levels and NO (µM, total nitrate/nitrite) production trended higher in the 
sildenafil group (149.50 (0.5-344.80) vs. 19.30 (0-457.60), p=0.47; 0.70 (0-142.80) vs. 
0.00 (0-52.70), p=0.62) whilst PVRI (WU.m2) remained unchanged at 2 (2.67±0.91 vs. 
2.07±1.98, p=0.43) and 24 hours (2.64±2.28 vs. 1.9±1.12, p=0.43) post-operatively. Bi-
ventricular systolic TDI parameters (cm/sec) were significantly reduced in the sildenafil 
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group both pre- (SaLV 3.78±0.94 vs. 4.55±1.08; SaRV 6.93±1.47 vs. 8.09±2.25, p=0.002) 
and post-operatively (SaLV 2.54±1.74 vs. 3.29±1.16; SaRV 2.32±0.77 vs. 3.20±1.53, 
p=0.002). Post-operative DO2 (ml/min/m2) was significantly reduced in the sildenafil 
group (57.18±21.24 vs. 74.13±35.46, p=0.04) with OI trending higher (5.29±4.60 vs. 
3.38±2.54, p=0.26). 
 
4.1.4 Conclusion 
This study identified that pre-operatively administered sildenafil produced a modest but 
not significant increase in cGMP and NO production without effect on pulmonary vascular 
resistance.  Sildenafil was associated with reduced ventricular contractility and post-
operative oxygenation.  
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4.2 Introduction 
 
In children with ventricular septal defect physiology excessive pulmonary blood flow, at 
systemic pressures, can adversely affect the pulmonary endothelium evident as increased 
pulmonary vascular resistance (PVR) and episodes of pulmonary hypertension (PHT). 1-3 
Pulmonary endothelial dysfunction (PED) can be further exacerbated by subsequent 
cardiopulmonary bypass (CPB) required for repair by several mechanisms including 
cytokine activation and ischaemia-reperfusion injury. 1 Post-operatively, these children can 
demonstrate an increased pulmonary vascular reactivity with acute elevations in PVR 
initiating a cycle of right ventricular failure and  reduced cardiac output. Increased 
pulmonary capillary permeability augments the alveolar-arterial oxygen gradient with 
reduced lung compliance and decreased systemic oxygenation. This often results in 
prolonged ventilation and intensive care stay, that correlates with the degree of PVR 
reversibility. 1-3 
 
In the normal lung, nitric oxide (NO) is produced by the endothelium to regulate vessel 
tone, blood flow and optimise ventilation-perfusion coupling. PED can be defined as a 
failure of the pulmonary endothelium to produce adequate amounts of NO with a loss of 
vascular homeostasis. 2, 3 NO acts through a secondary messenger, intracellular cyclic-
guanosine-monophosphate (cGMP), to vasodilate pulmonary blood vessels and is finally 
oxidised to form nitrate and nitrite. 2, 4 cGMP is metabolized by phosphodiesterase-5 
(PDE-5) which is the predominant phosphodiesterase in normal lung and may be up 
regulated in patients with PED. 2, 4, 5 
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Currently post-operative PED related complications, including PHT, are managed by the 
administration of inhaled NO (iNO). Although this has proved to be clinically effective, 
significant disadvantages do exist with some patients failing to respond and others 
developing life-threatening PHT upon withdrawal. 6,7 Recently oral sildenafil citrate 
(Pfizer, Sandwich, Kent, UK), a potent PDE-5 inhibitor that prevents the breakdown of 
cGMP, has been shown to be as effective as iNO in treating PHT. 8, 9 Oral sildenafil is now 
an established treatment for chronic PHT in children and is considered effective when 
given at therapeutic doses (0.5-2.0mg/kg; 4hrly). 10  
 
To date the consequences of oral sildenafil given pre-operatively to children undergoing 
corrective cardiac surgery has not been evaluated. We hypothesised that the administration 
of sildenafil prior to surgery would augment pulmonary cGMP levels attenuating CPB-
induced post-operative endothelial dysfunction and the clinical consequences that ensue. A 
prospective, randomized, placebo-controlled, double-blind trial was performed to 
determine whether pre-operative oral sildenafil supplementation produces: (1) an effect on 
NO production and plasma cGMP (2) a reduction in PVR index and pulmonary artery 
pressure (3) an effect on cardiac contractility (4) an effect on ventilation and oxygen 
delivery and (5) clinical outcome including adverse events. 
 
4.3 Methods 
 
4.3.1 Patients 
Study approval was obtained from local ethics committee (R&D no. 05/CH/01) and UK 
Medicines and Healthcare products Regulatory Agency (EudraCT No. 2005-001034-32). 
Eligible patients were children over 3 months of age with either ventricular or complete 
atrioventricular septal defects suitable for elective corrective cardiac surgery utilising CPB. 
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Parental consent was obtained. All children underwent elective surgery using standard 
techniques of CPB and blood cardioplegia.  
 
4.3.2 Study Protocol 
Following admission patients were randomised to either placebo or sildenafil by the 
clinical trials pharmacist using a computer-based stratified minimisation algorithm based 
on sex, cardiac diagnosis and the presence or absence of Down’s syndrome (Minim, 
available at www.sghms.ac.uk/depts/phs/guide/randser.htm). 11 All  clinicians and the 
child’s parents were blinded to the treatment allocation. 
 
Sildenafil (2.5mg/ml) and placebo suspensions (Ora Plus suspending vehicle, Ora sweet 
syrup +/- sildenafil) were prepared by the hospital pharmacy. Oral sildenafil (0.5mg/kg) or 
equivalent volume placebo was administered by the clinical trials pharmacist 6hrly the day 
before surgery. Patients were monitored pre-operatively on the ward and post-operatively 
in intensive care (PICU). Compliance and adverse events (systemic hypotension, post 
administration reactions etc.) were reported and monitored by the clinical trials pharmacist. 
 
4.3.3 Data Collection 
Patients returned to PICU after surgery and were sedated (morphine and/or midazolam), 
ventilated and haemodynamically stabilised with dopamine infusion. Residual intracardiac 
shunt or significant atrioventricular valve regurgitation was excluded through intra-
operative epicardial and post-operative transthoracic echocardiography. All other 
intravenous NO-donors, PDE inhibitors and iNO were avoided. Data collection was 
deferred for 2 hours following admission to PICU to allow for rewarming, tracheal 
suctioning, adjustments to sedation and inotropic support. Mean arterial (MAP) and 
pulmonary artery (PA) pressures were recorded for the first 24 hours post-operatively. 
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Inotrope scores and blood lactate levels were documented in all patients at 2 and 24 hours 
post-operatively. 12 Arterial blood gas analysis was undertaken before any data collection 
to allow optimisation of ventilation and correction of acidosis. 12 Echocardiography and 
haemodynamic data collection were carried out at 2 and 24 hours post-operatively under 
standardised conditions (ventilated with an inspired oxygen fraction (FiO2) of 0.65) to 
avoid variation in pulmonary vascular tone. 1, 2  
 
4.3.4 Blood samples 
2mls of blood were aspirated directly from the LA and main PA before (post-heparin) and 
after CPB (pre-protamine). Samples were aliquoted and stored (-70oC) until laboratory 
analysis. cGMP levels were measured using a commercially available competitive enzyme 
immunoassay (R&D Systems, Abingdon, UK) with a calibration range of 0.56 – 3.06 
pmol/ml. Nitrate and nitrite levels were measured using a commercially available 
colorimetric assay kit (BioScience Ltd, Cambridge, UK) with a detection limit of 2.0 µM.  
 
4.3.5 Echocardiography 
All patients underwent transthoracic echocardiography using a Vivid 7 ultrasound scanner 
(GE Vingmed, Horten, Norway) with a 7-MHz probe by the same, experienced paediatric 
echocardiographer (1) pre-operatively, on table under anaesthesia (2) 2hrs and (3) 24hrs 
post-operatively. A cine loop of at least three consecutive cardiac cycles was recorded and 
stored digitally for later off-line analysis (Echopac, GE Vingmed). All echocardiographic 
measurements were repeated 3 times and then averaged. 
 
4.3.5.1 Estimated aortic and pulmonary outflow (L/min/m2) 
Pulsed Doppler 2D echocardiography was used to estimate aortic (QS) and pulmonary (QP) 
outflow according to the formula: Q = (Stroke VolumeDoppler x heart rate). Doppler-
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estimated stroke volume was determined using the velocity time integral of flow through 
the left or right ventricular outflow tract x aortic or pulmonary annular cross-sectional area 
respectively. Both annuli were measured immediately proximal to the point of insertion of 
valve leaflets at maximal systolic leaflet separation (inner diameter).13 
 
4.3.5.2 Post-operative PVRI (Wu.m2) 
Transpulmonary gradient (mean PA - LA pressure measured from respective monitoring 
lines placed in theatre as per study protocol) and estimated pulmonary blood flow on 
spectral Doppler were used to derive PVR from the equation: PVR = (transpulmonary 
gradient / pulmonary blood flow) which was then indexed to body surface area (PVR x 
BSA). 12 
 
4.3.5.3 Tissue Doppler Imaging (TDI) 
Peak myocardial velocities (Sa) were recorded from basal septum (SaS) and lateral free 
walls of both ventricles immediately below (0.5cm) the insertion of the mural leaflet of the 
left (SaMV) and right (SaTV) AV valves. RV (IVARV) and LV (IVALV) isovolumic 
acceleration was calculated for respective ventricles by dividing the peak isovolumic 
velocity by the time interval from baseline to peak isovolumic velocity as previously 
described. 14  
 
4.3.6 Post-operative Oxygenation 
Oxygen delivery (DO2) at 2 and 24hrs post-operatively was calculated using Doppler 
derived systemic CO (QS) and arterial oxygen content according to the equation: DO2 = Qs 
x [Hb x 1.34 x Hb saturation + 0.003 x PaO2 (mmHg)]. Oxygenation index (OI) was 
calculated at the same time using: ventilator mean airway pressure (cm H2O) x 100 x FiO2 
/ PaO2 (mmHg). The period of ventilation (hrs) and length of stay in PICU (hrs) were 
noted. 
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4.4 Statistical Analysis 
The Anderson-Darling test assessed normality. Descriptive statistics are reported as means 
and standard deviations or medians and ranges according to distribution of data. Two-
sample t-tests were used for between group comparisons in normally distributed data, 
otherwise Mann-Whitney tests were performed. A nested general linear model was used to 
examine the effects of drug and time on each outcome variable. If significant, post-hoc 
tests with Bonferroni correction were applied to quantify the effect. All analyses were 
performed using Minitab (version 15, Minitab Ltd, Coventry, Warwickshire, UK) at a 
significance level of 5%. 
 
The power calculation for this study was based on data published by Schulze-Neick et al. 
where a mean PVRI of 8.32 Wu.m2 and standard deviation of 3.464 was observed post-
cardiac surgery. 2 A sample size of 12 patients in each group would have a power of 80% 
to detect a minimum difference in PVRI of 4.14 WUm2 between oral sildenafil and 
placebo groups (nQuery, version 5.0, Statistical Solutions Ltd, Cork, Ireland). 
 
4.5 Results 
 
4.5.1 Patients 
Twenty-eight children were prospectively recruited into the trial at the Royal Hospital for 
Sick Children, Yorkhill Division, Glasgow, UK from June 2006 to January 2008. 4 
children were excluded following theatre cancellation leaving a total of 24 patients (age 
0.26 to 2.26 years, median 0.4 years; mean weight 5.6kg) who completed the trial as 
depicted in Figure 1. Demographic characteristics of the two groups are summarised in 
Table 1. 
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4.5.1.1  Figure 1. Trial Profile 
 
 
4.5.1.2  Table 1. Demographic characteristics between groups 
 
  Sildenafil (n = 11) 
 Placebo 
(n = 13) 
 P-value 
Patient factors Gender (male) 5 (45%)  7 (54%)  0.681 
 Age (years) 0.62 ± 0.57  0.42 ± 0.17  0.286 
 Weight (kg) 5.6 ± 1.3  5.7 ± 2.0  0.884 
 Trisomy 21 present 6 (55%)  6 (46%)  0.681 
       
Diagnosis AVSD 4 (36%)  7 (54%)  0.444 
 VSD 7 (64%)  6 (46%)  0.383 
       
Operative factors XC (mins) 75.1 ± 45.0  77.5 ± 36.9  0.889 
 BP (mins) 126.7 ± 60.9  122.8 ± 46.7  0.864 
 Ventilation (hrs) 93.2 ± 126.0  82.5 ± 56.6  0.799 
 PICU stay (hrs) 128.3 ± 159.2  125.7 ± 75.4  0.961 
 
Data expressed as mean ± SD. 
AVSD, atrio-ventricular septal defect; VSD, ventricular septal defect; XC, cross-clamp 
time; BP, bypass time; PICU, paediatric intensive care unit  
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4.5.2 Adverse Events 
 
There were no post-administration drug reactions and no mortality; all patients were 
discharged home without significant complication. No significant difference in MAP 
(mmHg) existed between sildenafil and placebo groups post-operatively (58.53±3.92 vs. 
57.49±1.65, p=0.15). 
 
4.5.3 Plasma cGMP levels (pmol/ml) 
Compared to placebo, pre-operative cGMP levels sampled from the LA and PA were 
higher in the sildenafil group (LA: 29.9 (0.5-391.5) vs. 5.2 (0-628.9), p=0.44 and PA: 8.7 
(1.1-150.5) vs. 2.6 (0.0-224.9), p=0.32). cGMP levels were also greater in the sildenafil 
group post-operatively on admission to PICU (149.5 (0.5-344.8) vs. 19.3 (0-457.6), 
p=0.47). Overall 0.5mg/kg of oral, pre-operative sildenafil given 4 times the day before 
surgery raised peri-operative plasma cGMP but did not reach statistical significance 
(Figure 2). 
 
4.5.3.1  Figure 2. Plasma cGMP levels 
(PICU sample acquired during routine venous blood sampling) 
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4.5.4 Plasma Nitrate / Nitrite Levels (µM) 
NO breakdown products, within LA, trended higher following CPB in the sildenafil group 
(pre-CPB vs. post-CPB: 0.0 (0-1.0) vs. 0.7 (0-142.8), p=0.057) compared to placebo group 
which remained similar (pre-CPB vs. post-CPB: 0.1 (0-41.4) vs. 0.0 (0-52.7), p=0.80) 
(Table 2). 
 
4.5.4.1  Table 2. Plasma nitrite / nitrate levels 
 
Total plasma nitrite / nitrate levels (µM) Group Time Sample 
Mean StDev Min Median Max 
LA 3.95 11.34 0.00 0.09 41.39 Pre-CPB 
PA 2.36 6.55 0.00 0.00 23.70 
       
LA 5.49 14.34 0.00 0.00 52.73 Post-CPB PA 1.64 2.87 0.00 0.00 10.42 
Placebo 
       
LA 0.09 0.30 0.00 0.00 1.00 Pre-CPB 
PA 0.23 0.75 0.00 0.00 2.47 
       
LA 20.5 44.7 0.00 0.70 142.80 
Sildenafil 
Post-CPB 
PA 6.37 17.31 0.00 0.73 58.37 
 
 
4.5.5 Echocardiography  
 
4.5.5.1 Estimated pulmonary and aortic outflow (L/min/m2)  
Pre-operative Qp:Qs shunt fraction was similar between sildenafil and placebo groups 
(10.49:4.28 vs. 13.23:4.36, p=0.20) (Figure 3a). Doppler derived cardiac index was 
significantly reduced in the sildenafil group compared to control post-operatively in PICU 
(4.78±1.70 vs. 3.62±1.21, p<0.001) and day-1 (4.83±1.71 vs. 4.16±1.71, p<0.001). 
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4.5.5.1.1  Figure 3a. Pre-operative aortic and pulmonary outflow 
 
 
 
 
4.5.5.2 PVRI (Wu.m2) 
Post-operatively, no significant alteration in PVRI was demonstrated in sildenafil patients 
at 2 (2.67±0.91 vs. 2.07±1.98) and 24 hours (2.64±2.28 vs. 1.90±1.12) (Figure 3b). Mean 
PA pressure (mmHg) in sildenafil and placebo groups was similar post-operatively 
(20.72±1.09 vs. 19.88±0.84, p=0.30). 
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4.5.5.2.1  Figure 3b. Post-operative PVRI 
 
 
4.5.5.3 TDI 
LV, RV and septal peak systolic velocities and biventricular isovolumic acceleration were 
all significantly reduced in both groups in the immediate post-operative period. All 
velocities trended towards recovery by day-1, particularly in the LV. Pre- and post-
operative bi-ventricular and septal systolic function were significantly reduced in the 
sildenafil group compared to placebo and this persisted onto day-1 (Figure 4a, b; Table 3). 
RV and  LV isovolumic accelerations were also lower in the sildenafil group but this did 
not reach statistical significance (Table 4). 
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4.5.5.3.1  Figure 4a. LV systolic function 
 
4.5.5.3.2  Figure 4b. RV systolic function 
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4.5.5.3.3  Table 3. Peri-operative TDI peak systolic velocities 
Peak Systolic Myocardial Velocity (cm/sec) Group Variable Time Mean StDev Min Median Max 
LV PreOp 4.55 1.08 3.07 4.47 6.24 
 PICU 3.29 1.16 2.03 2.96 6.44 
 Day-1 3.95 1.60 1.87 3.28 7.33 
       
RV PreOp 8.09 2.25 4.95 7.95 13.55 
 PICU 3.20 1.53 1.12 2.69 6.74 
 Day-1 3.35 1.38 1.56 2.99 5.99 
       
Septum PreOp 4.70 1.03 2.39 4.86 5.8 
 PICU 2.30 1.13 0.83 2.09 4.53 
Placebo 
 Day-1 2.61 1.26 0.97 2.45 4.65 
        
LV PreOp 3.78 0.94 2.36 3.70 5.16 
 PICU 2.54 1.74 1.05 1.97 6.67 
 Day-1 3.10 0.83 1.76 3.33 4.40 
       
RV PreOp 6.93 1.47 4.87 6.77 9.86 
 PICU 2.32 0.77 1.61 1.93 3.98 
 Day-1 2.06 0.75 0.95 2.00 3.60 
       
Septum PreOp 3.91 0.69 2.96 3.85 4.97 
 PICU 1.56 1.11 0.80 1.065 4.39 
Sildenafil 
 Day-1 2.09 0.98 0.55 2.00 3.66 
 
 
4.5.5.3.4  Table 4. Peri-operative TDI isovolumic acceleration 
Isovolumic Myocardial Acceleration (cm/sec2) Group Variable Time Mean StDev Min Median Max 
LV PreOp 154.47 89.06 50.93 126.37 309.18 
 PICU 71.00 21.68 41.95 69.85 101.67 
 Day-1 101.84 61.89 42.04 94.47 259.64 
       
RV PreOp 309.55 107.74 177.34 282.44 527.17 
 PICU 133.50 55.75 50.33 132.63 227.92 
Placebo 
 Day-1 103.92 53.28 42.49 97.70 200.19 
        
LV PreOp 162.73 51.83 82.33 157.77 265.40 
 PICU 64.40 14.54 46.01 68.51 79.46 
 Day-1 90.71 37.18 51.83 84.48 158.5 
       
RV PreOp 303.88 84.16 187.66 290.12 489.43 
 PICU 116.66 59.20 63.78 108.22 229.82 
Sildenafil 
 Day-1 135.07 69.45 55.92 117.07 290.70 
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4.5.6 Inotrope Scores 
No significant difference in inotrope score existed between sildenafil and placebo patients 
at 2 (5.73±5.12 vs. 5.15±4.36, p=0.884) and 24 (5.55±4.61 vs. 5.62±5.59, p=0.884) hours 
post-operatively. 
  
4.5.7 Post-operative oxygenation 
OI trended higher in the sildenafil group compared with control on admission to PICU 
(5.3±4.6 vs. 3.4±2.5) with further increases in both groups on day-1 (5.7±4.3 vs. 4.8±3.4, 
Figure 4c). DO2 (ml/min/m2) was significantly reduced in the sildenafil group compared 
with control on admission to PICU (57.18±21.24 vs. 74.13±35.46) and on to day-1 
(56.98±23.64 vs. 72.13±33.00, Figure 4d) (Table 5). No significant differences in 
ventilation time (hrs) or PICU stay (hrs) were found between sildenafil and placebo groups 
(Table 1). Subgroup analysis of T21 patients demonstrated no significant differences in 
post-operative OI (p=0.09), DO2 (0.07), ventilation time (p=0.07) or PICU stay (p=0.141). 
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4.5.7.1  Figure 4c. Peri-operative Oxygenation Index 
 
 
4.5.7.2  Figure 4d. Post-operative Oxygen Delivery 
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4.5.7.3  Table 5. PaO2 values at 2 and 24 hours post-operatively 
 
 
 
 
 
 
 
 
 
 
4.5.8 Lactate 
No significant differences were seen in blood lactate levels (mmol/L) between sildenafil 
and placebo patients at 2 (1.1±0.2 vs. 1.2±0.4, p=0.307) and 24 (1.2±0.3 vs. 1.1±0.3, 
p=0.307) hours post-operatively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PaO2 (mmHg) Group Time Mean StDev Min Median Max 
2 hrs 178.17 59.03 90.00 179.25 321.00 Placebo 24 hrs 93.41 25.88 32.25 100.50 126.00 
       
2 hrs 142.57 49.34 71.25 141.00 221.60 Sildenafil 
24 hrs 91.53 28.61 54.75 86.13 135.00 
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4.6 Discussion 
 
In children with congenital heart disease post-operative pulmonary endothelial dysfunction 
and pulmonary hypertension continue to be an important cause of morbidity, prolonged 
PICU stay and in severe cases mortality.1-5 The purpose of this study was to investigate 
whether administrating sildenafil prior to paediatric cardiac surgery mitigates clinical 
consequences of post-operative pulmonary endothelial dysfunction by maintaining cGMP 
levels. Our principal findings were that pre-operative sildenafil dosing resulted in: (1) 
modest elevations in plasma cGMP levels both pre- and post- CPB but this did not reach 
statistical significance (2) increased post-CPB NO production (3) no significant effects on 
post-operative PVRI (4) a significant reduction in peri-operative bi-ventricular contractility 
and (5) a significant reduction in post-operative oxygen delivery. 
 
Although children with VSD or AVSD operated on at 6 months of age or less are unlikely 
to demonstrate classical clinical pulmonary hypertensive crises post-operatively the 
clinical consequences of pulmonary endothelial dysfunction are commonplace. 1 The 
endothelial injury following CPB is primarily related to ischaemia-reperfusion and 
cytokine activation characterized by capillary permeability leading to decreased 
oxygenation manifest as increased alveolar-arterial oxygen gradient and decreased lung 
compliance. 1-3, 5, 15 The pulmonary endothelium plays an important role in vasomotor tone, 
inhibiting platelet aggregation and neutrophil adhesion through the release of vasoactive 
factors including NO. 5, 9, 16 CPB results in PDE-5 over activity, activation of NO 
antagonists, reduction in NO precursors and production of vasoconstrictive factors. 1-4 
Ultimately this can increase right ventricular afterload, adversely affecting right ventricular 
function and increasing the duration of ventilation. 1 Many centers will now liberally use 
iNO and sildenafil in the post-operative setting to manage these complications.  
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Sildenafil is a potent and selective inhibitor of 3’5’-cGMP-specific PDE-5 with 
substantially lower affinity for the other PDE isoenzymes. Tissue distribution of PDE-5 
and hence site of action of sildenafil is well defined (corpus cavernosum, pulmonary 
vasculature, platelets, skeletal and visceral muscle). Sildenafil is rapidly absorbed orally 
with an absolute bioavailability of 40%. It undergoes hepatic metabolism with an 
elimination half-life of 3 to 5 hours. 17, 18 Children in the active arm of our study received 
0.5mg/kg of oral sildenafil 6hrly, the day before surgery. This dose was based on our own 
clinical experience and current best available evidence that (0.025-0.66mg/kg) of 
intravenous sildenafil and (0.25-1mg/kg; 6hrly) of oral sildenafil, safely and significantly 
reduces PHT in this patient group. 2, 15, 16, 19 
 
In this study the direct effect of sildenafil on pulmonary endothelial function was assessed 
by measuring plasma cGMP and NO production via its breakdown products nitrates and 
nitrites. Our study demonstrated that although sildenafil increased cGMP levels both pre- 
and post- bypass, the effect was modest and variable between patients. The effects of 
sildenafil on plasma cGMP levels is not widely reported particularly in relation to peri-
operative paediatric cardiac surgery. Atz et al demonstrated that rebound pulmonary 
hypertension on withdrawal of iNO following paediatric cardiac surgery was attenuated by 
sildenafil. In their study, post-operative oral sildenafil (0.33mg/kg), in association with 
iNO, resulted in cGMP levels of up to 45 pmol/ml. 7 Sildenafil infusions used pre-
operatively by Schulze-Neick et al produced a non-significant increase in plasma cGMP 
(44±18 pmol/ml) associated with significant reductions in PVRI. 2  
 
In this study NO products inclined to be higher post-CPB in the sildenafil group, 
suggesting a greater capacity of the pulmonary endothelium in these patients to respond to 
the CPB mediated injury. 1-3, 5, 15 Interestingly, compared to sildenafil patients, NO 
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products tended to be higher in the placebo group pre-CPB. It is possible that increased 
cGMP levels induced by sildenafil in the treatment group down-regulated NO production 
pre-CPB. Again, in a similar  pattern to cGMP, there was considerable variation amongst 
sildenafil treated patients and the NO response. These findings support the conclusion that 
sildenafil administered at 0.5mg/kg was associated with a biological effect at the 
pulmonary endothelial level.   
 
Despite trends in the sildenafil group, to higher cGMP levels pre-CPB (108 pmol/ml) and 
increased NO production post-CPB no significant haemodynamic effect on PVRI or post-
operative PA pressure was apparent. The reasons for this are likely to be multi-factorial. 
The majority of children recruited to the trial were under 6 months and therefore at low 
risk for post-operative PHT crises. Furthermore, none of the children recruited to the trial 
had pre-existing PHT by echo criteria (bi-directional flow at VSD). It is possible that in a 
more at-risk group (longstanding VSD with pre-operative PHT) sildenafil may have had a 
significant impact on PA pressures and PVRI. Alternatively, larger doses of oral sildenafil 
may have been required pre-operatively to produce a measureable pulmonary vasodilatory 
effect. Intra-individual variations in the response to oral sildenafil have been demonstrated 
in some patients with persistently high PVR despite increasing vasodilator therapy. 15 This 
supports our findings of patient variation in cGMP and NO production in the sildenafil 
group. However, it should be noted that other studies with a similar patient cohort have 
demonstrated reductions in PVR with sildenafil administrated during the post-operative 
phase. 1, 2, 15  
 
An important finding of this study was that bi-ventricular systolic function was 
significantly reduced in the sildenafil group compared to placebo. This contractile change 
was measured using tissue Doppler peak systolic velocities, which are limited by their 
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load-dependant; right ventricular velocities could be reduced by acute elevations in 
afterload. 14, 20, 21 However, this mechanism is not supported by the study findings of 
similar post-operative PA pressures between groups. Furthermore the velocities were 
reduced in all myocardial areas measured. Post-operatively, this was associated with a 
significant reduction in cardiac index in the sildenafil group which also impacted on 
oxygen delivery. To our knowledge such a negative inotropic effect has not been described 
in any clinical studies although transient falls in systemic blood pressure are widely 
reported. One possible explanation for the impaired contractility demonstrated in the 
sildenafil group could have been an increase in intra-cardiac shunting and subsequent 
volume loading through reduced PVR. However the Qp:Qs derived by spectral Doppler, 
on-table immediately prior to surgery, did not indicate an increased shunt volume in 
sildenafil group compared with placebo.  
 
Experimental models of isolated cardiomyocytes, perfused rodent hearts and human 
studies of normal and heart failure patients at the time of cardiac catheterisation have 
shown that elevated levels of cGMP (produced through iNO or oral sildenafil) can 
suppress contractility by decreasing myocardial calcium sensitivity, cAMP inhibition and 
blunting the contractile response to adrenergic stimulation. 17, 22-24 We propose that this is 
relevant in the context of paediatric cardiac surgery where myocardial contraction is 
modulated by endogenous and exogenous catecholamine stimuli and may explain why pre-
operative sildenafil inhibits peri-operative contractility in this patient group. Ultimately, 
the reduced contractility seen in the sildenafil group was not clinically apparent in terms of 
increased inotrope usage, ventilation time or intensive care stay.  
 
In this study the pre-operative administration of oral sildenafil resulted in a significant 
deterioration in post-operative tissue oxygenation. This was demonstrated through 
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increasing post-operative oxygenation index and significant reduction in oxygen delivery 
from admission to PICU. In contrast to iNO which is selectively delivered to ventilating 
areas of the lung, the systemic administration of sildenafil acts throughout the pulmonary 
vasculature with resulting dose-dependent increase in ventilation-perfusion mismatch seen 
in both human and animal studies. 1, 2, 15, 25 Stocker et al showed that intravenous sildenafil 
(0.35mg/kg) resulted in a significant decrease in PaO2 post-operatively associated with 
increased oxygenation index and alveolar-arterial gradient. 15 Crucially these deleterious 
effects on oxygenation were not reversed by iNO and the trial was terminated early. 
Similarly Schulze-Neick et al demonstrated significant dose-dependent increases in intra-
pulmonary shunt ratio during sildenafil infusion in children following corrective cardiac 
surgery. 2 Kleinsasser et al investigated the dose dependent effects of oral sildenafil (25-
100mg) on pulmonary function in anaesthetised and ventilated pigs. All doses of sildenafil 
caused significant increases in intrapulmonary shunt flow measured by inert gases and 
reflected through marked decreases in PaO2. 25 This is further exacerbated by the acute lung 
injury, related to the systemic inflammatory response, that is associated with CPB. 5 The 
effects on post-operative oxygenation were well tolerated in our stable group of study 
patients and were not associated with prolonged ventilation or PICU stay. However, in a 
group of children with higher ventilatory requirements or borderline pulmonary function a 
similar degree of impairment could have adverse effects. 
 
Certain limitations of this study should be mentioned. Intra-pulmonary shunt was not 
measured as part of the study and as such we can only infer this probable hypoxic 
mechanism. Pre-operative PVRI was also not measured and as such the compounding 
effects of CPB could not be excluded or evaluated. Peri-operative plasma sildenafil 
concentrations were not measured making it impossible to comment on the intra-individual 
variations in drug levels post-operatively and the effects if any of CPB. 
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4.7 Conclusion 
Oral sildenafil (0.5mg/kg) administered before elective cardiac surgery in children with 
VSD physiology resulted in modest elevations in plasma cGMP levels and post-operative 
NO production but no effect on pulmonary haemodynamics or clinical outcome. 
Significant impairments to global peri-operative systolic function and post-operative 
oxygenation would caution the use of pre-operative sildenafil. 
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CHAPTER 5: FINAL DISCUSSION 
 
The aim of this thesis was primarily to investigate end organ effects of modern day 
cardiopulmonary bypass in children with common congenital heart defects undergoing 
elective repair utilising cardiopulmonary bypass. End organ function was investigated 
through two prospective clinical trials which in turn examined the relationships between 
tissue Doppler imaging and myocardial injury, cystatin C and renal dysfunction and 
sildenafil and pulmonary endothelial dysfunction.  
 
It is clear from Chapter 2 that myocardial dysfunction is commonplace following 
paediatric cardiac surgery with some recovery of at least left ventricular function evident 
within twenty four hours after surgery. TDI appears to offer a sensitive, non-invasive, load-
independent, real time assessment of peri-operative myocardial function which until the 
completion of this study was not routinely used within the Department of Paediatric 
Cardiac Surgery, Yorkhill Hospital. Indeed there are very few studies published in the 
literature which characterise the typical pattern of change of these parameters within this 
patient population.  
 
Right ventricular dysfunction is often clinically difficult to treat and the unique ability of 
TDI to examine the longitudinal fibres predominating in this ventricle makes it a very 
attractive tool in this regard. This study has demonstrated that TDI parameters can be 
easily and reliably obtained within the paediatric population allowing the possibility for 
pre-operative risk stratification and earlier post-operative optimisation, further preventing 
additional end organ effects of low cardiac output. As mentioned previously TDI 
parameters were not analysed beyond the first post-operative day and it would be 
interesting to see when and if bi-ventricular systolic function returned to normal pre-
operative values. With the advent of 3D echocardiography absolute and derived TDI 
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parameters are likely to play an important role in the assessment of myocardial function in 
children in the future. 
 
Despite extensive and ongoing research in the prediction and treatment of acute renal 
injury in the post-operative paediatric cardiac surgery population there has been limited 
success in altering patient outcomes. Wide ranging definitions of injury and the limited 
availability of reliable serum biomarkers further complicates this problem. Cystatin C is a 
novel biomarker which, as demonstrated in chapter 3 of this thesis, is a sensitive measure 
of early post-operative renal injury that may be in a position to play a pivotal role in the 
identification, classification and customisation of treatment therapies. Moreover, this 
research has shown that cystatin C is also predictive of other clinical outcomes including 
ventilation time and intensive care stay further enhancing its profile.  
 
This is one of the very few studies in the literature which has investigated the effectiveness 
of cystatin C in such a patient group and the findings are therefore clinically important. 
The independence of cystatin C of age, sex and mass is a key prerequisite of the paediatric 
population and immediately separates it from the most commonly used serum marker, 
creatinine. However, the assay used to measure cystatin C is relatively expensive and only 
available in specialised centres in the UK making it difficult for clinicians to routinely 
access at present. As a result, despite growing evidence the likelihood of this biomarker 
predominating within the clinical environment remains to be seen. 
 
When compared to medicine as a whole the specialty of paediatric cardiac surgery is still 
in its youth. However, 50 years have passed since the advent of cardiopulmonary bypass 
and still there are no defining guidelines regarding optimal perfusion. In chapter 3 of this 
thesis in addition to exploring the use of cystatin C as a marker of renal injury its 
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association with intra-operative perfusion-related factors of renal injury was investigated. 
The relative ease with which renal injury can be monitored makes it an attractive organ to 
assess perfusion. In keeping with the published literature this research demonstrated that an 
ischaemic insult was the most likely intra-operative mechanism responsible for post-
operative renal dysfunction. A critical dysoxic threshold was apparent below which 
significant injury occurred. Interestingly, oxygen delivery during cardiopulmonary bypass 
is not currently calculated, even though the individual variables of the equation are all 
noted by the perfusionist, and furthermore does not represent a parameter by which 
perfusion is altered. This is an important clinical consideration which can be drawn from 
this work and is currently being taken forward within the Department of Paediatric Cardiac 
Surgery at Yorkhill Hospital. Further work in this area would be merited in the form of a 
trial specifically designed to evaluate whether targeting a specific oxygen delivery during 
bypass improves outcome overall. 
 
In chapter 4 of this thesis the vicious circle of pulmonary hypertension, right ventricular 
failure and decreased oxygenation often seen post-operatively in children with high flow 
pulmonary physiology was investigated. The administration of pre-operative oral sildenafil 
to this patient group, particularly as a randomised clinical trial, has not been previously 
undertaken. The minimal effect of pre-operative sildenafil on pulmonary vascular 
resistance seen in this study is not surprising when one considers that none of the children 
enrolled in the trial had or indeed developed post-operative pulmonary hypertension. 
However, some of the findings were both surprising and concerning with regards to peri-
operative ventricular function. Considering the relatively routine use of this drug within the 
paediatric intensive care environment the consistent reduction in peri-operative ventricular 
function demonstrated in our trial raises significant clinical concerns and future work in 
this area is needed to further clarify or refute these findings. One of the main limitations of 
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this trial was that intra-cardiac shunt was not formally assessed and although data 
regarding Doppler-derived pulmonary and systemic flows was available a sildenafil related 
increase in shunt as the cause of ventricular impairment was not conclusively exclude. 
 
In addition to the concerns raised regarding contractility pre-operative sildenafil was also 
associated with reduced oxygen delivery and a trend for increasing ventilatory 
requirements post-operatively. Although not formally analysed in this trial several other 
studies have demonstrated the association between systemic sildenafil therapy and 
ventilation perfusion uncoupling. Furthermore the impact of the systemic inflammatory 
response, to the process of cardiopulmonary bypass, on pulmonary function was not 
addressed in this chapter or as part of this thesis. This is an important limitation which 
should be factored into any further studies specifically addressing this issue. 
 
In conclusion this thesis has, through a prospective observational study and a randomised 
controlled trial, successfully considered some key issues and developments in the 
management and assessment of end organ dysfunction commonly seen after paediatric 
heart surgery. Several important contributions to clinical knowledge have been made with 
as many questions raised for future deliberation. 
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CHAPTER 6: APPENDICIES 
 
6.1  Prospective Observational Study  
6.1.1 Appendix 1: Local Research Ethics Committee Approval 
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6.1.2 Appendix 2: Data Entry Proforma 
 
 
  
 
 
 
PATIENT FACTORS 
1. Age (Months)  5. BSA (m
2)  
2. Weight (Kg)  6. WCC (Preop)  …./….  
3. Height (cm)  7. Admitted         /         / 
4. Sex (M/F)  8. Discharged        /         / 
 
 
 
PREOPERATIVE FACTORS 
 1. Cardiac Diagnosis 
 
 2. Non-Cardiac 
Diagnosis 
 
 3. Cardiac Catheter 
(PAP/AO/PVR 
 PCWP/Qp:Qs)  
 4. Signs / Symptoms 
(L > R Shunt) 
 
 5. Medication 
 
6. Aspirin / Warfarin / 
Sildenafil  
 
 
 
 
 
 
 
 
 
Patient ID: 
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OPERATIVE FACTORS  
1. DATE ….. / ….. / ….. 7. CPB Temp (minimum rectal)  
2. XC time (mins)  8. UF volume (mls)  
3. BP time (mins)  
4. Surgeon & Anaesthetist                                              / 
  5. 
Inotropes 
(coming off)   
6. 
Aprotinin Regimen L =  P = M = 
 
 
 
 
RENAL OUTCOMES 
                       Postop Day  PreOp 
Day…  
…/… 
Th 
1st 
12hrs 
Th 2nd 
12hrs 
1 
.../... 
2 
…/.. 
3 
…/.. 
4 
…/.. 
5 
…/.. 
6 
…/.. 
7 
…/.. 
1. SCr (µmol/l) (18-40)           
2. CrCl (54-86) (ml/min/1.73m2)           
(Normal values in 
parenthesis) 
 
1hr  
 
2hrs 
 
3hrs 
 
4hrs 
 
5hrs 
 
Total Urine 
1st 24hr 
Diuretics 
(Inf / 
Bolus) 
3. Urine (mls)      
 
 
4. Dopamine (µg/kg/min)         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Timing 
Test 
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RESPIRATORY OUTCOMES 
 Post 
Intubation 
Post 
CPB 
2 hrs 
Postop 
4hrs 
Postop 
8am 
Day 1 
 
1. 
Oxygenation 
Index (OI)      
2. 
Dynamic Compliance  
(CL) (ml/cmH2O/kg)      
(Hrs) 3. Mech. Ventilation  
(Days) 
Sildenafil 
(dose/days) 
(Hrs) 
4. 
Period in PICU  
(Days) 
Hospital  
Stay 
(days) 
 
 
 
Oxygenation Index: Mean airway pressure (cmH2O x 100 x FiO2 / PaO2 (mmHg)) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Timing 
Test 
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ECHOCARDIOGRAPHIC OUTCOMES 
 
Pre-Op <1hr post return to PICU Day 1 Post-Op 
1. LVEDD (mm) [23 +/- 3]    
LVESD (mm) [14 +/- 2]    
RVEDD (mm) [9-13]    
LV % FC [38.9 +/- 4.1]    
LV EF % [52-65] (1-18yr olds)    
M
-m
ode [m
ean +/- SD
] VP (cm/sec) [54.6 +/- 14] (2mn – 6yrs)    
2. Peak AO (LVOT) (cm/sec)  median 107.0
* [73-141]    
Peak PA (RVOT) (cm/sec) median 84.4* [63.8-70.5]    
AO annular diameter [11-13mm]    
PA annular diameter [8.4 – 11.6mm] (up to 10kg)    
VTIPA (stroke distance cm) [heart rate] 
    
VTIAO (stroke distance cm) [heart rate] 
    
MV Peak E wave (cm/sec) [79.7 +/- 18.8]    
SPEC
TR
A
L 
MV Peak A wave (cm/sec) [65.3 +/- 13.3]    
3. MV E/A Ratio [1.24 +/- 0.3]    
4. Regurgitation (L + R AV) (Y/N)      
5. Sa: Lateral Mitral (5.7 +/- 1.6) [5.3 – 6.1]    
Sa: Lateral Tricuspid (10.2 +/- 5.5) [8.8 – 11.7]       
Sa: Septum (5.4 +/- 1.2) [5.1 – 5.7]    
IVA (cm/sec2) [248 +/- 35]    
Ea: Lateral Mitral (9.7 +/- 3.3) [8.8 – 10.5]    
Ea: Lateral Tricuspid (13.8 +/- 8.2) [11.7 – 15.9]    
Ea: Septum (8.1 +/- 2.5) [7.5-8.7]    
Aa: Lateral Mitral (5.7 +/- 1.8) [5.3 – 6.2]    
Aa: Lateral Tricuspid (9.8 +/- 2.4) [9.1 - 10.5]    
Aa: Septum (6.1 +/- 1.5) [5.7 – 6.4]    
TD
I cm
/sec  (m
ean +/- SD
)  [95%
 C
I] E/Ea Ratio (L AV valve) (8.8 +/- 2.7) [8.1 – 9.5]    
(Normal values in parenthesis) 
 
 
 
Test Timing 
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Timing 1
st 24Hrs Post-Op  Pre-
op <1 
Hr 4hr 8hr 
12 
Hr 
16 
Hr 
20 
Hr 
24 
Hr 
       
1. 
TEMP (OC) 
Periph / 
Core 
        
2. INOTROPE Score         
3. LA pressure         
 
 
 
HAEMATOLOGY OUTCOMES 
 1hr  Post-op 
2hr 
Post-op 
3hr  
Post-op 
4hr 
Post-op 
5hr 
Post-op 
Total 1st  
24 hrs   
1. Chest Tube Drainage (ml)         
 Intra-operatively Post-operatively 
2. PRC (units/ml)   
3. FFP (units/ml)   
4. Platelets  (units/ml)   
5. 
Other: 
 
 
 
 
 
 
 
 
COMMENTS / COMPLICATIONS: 
- 
- 
- 
 
 
 
 
Test 
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6.1.3  Appendix 3: Lab Specimen Data Proforma 
 
CPB SAMPLES                                                         ALIQUOT Nos. 
1. 5mins into CPB 
 
         
2. 30mins into CPB 
 
         
3. 2mins off X-clamp 
 
         
4. Coming off 
 
         
 
 
 
RETAINED PLASMA  
Pre-OP 
Samples 
Aliquot Nos. 
          
Volume P (µL)           
Day 1 Samples 
Aliquot Nos.           
Volume D1 
(µL)           
Day 2 Sample 
Aliquot Nos.           
Volume D2 
(µL)           
Post-Op 
Samples Th D1 D2 D3 D4 D5 D6 D7 …… …… 
Tick if present           
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6.1.4  Appendix 4: Patient Protocol 
 
PRE-ASSESSMENT  
 
- Study introduced to parents by consultant cardiac surgeon at the clinic 
- Routine cardiology investigations (echocardiography) 
 
ADMISSION/PRE-OPERATIVELY 
 
- Study re-introduced to parents by consultant cardiac surgeon  
- If parents agreeable, study discussed in greater detail by principal investigator 
- Parental consent for study obtained 
- Plasma retained from routine bloods (day 2 pre-op)  
 
POST-OPERATIVELY (PICU) 
 
- Plasma retained from routine bloods on admission to PICU 
- Transthoracic echocardiography and Doppler tissue imaging <2hr post admission to 
PICU 
- Two 12hr urine collections into provided containers (over 1st 24hrs) 
- Transthoracic echocardiography and Doppler tissue imaging (day 1 post op) 
- Plasma retained from routine bloods (day 1 post-op) 
- Plasma retained from routine bloods (day 2 post-op – if still in PICU) 
 
POST-OPERATIVELY (WARD) 
 
- Plasma retained from routine bloods (prior to discharge) 
 
 
DISCHARGE 
 
- Patient’s involvement in the study ends on hospital discharge 
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6.1.5 Appendix 5: Echocardiography Protocol 
 
TIMING: pre-operatively vs. <2hr admission to PICU and day-1 post-operatively 
 
1. M-MODE & SPECTRAL DOPPLER 
 
SYSTOLIC FUNCTION  
(M-MODE) 
SYSTOLIC FUNCTION  
(SPECTRAL DOPPLER) 
- LVEDD - Peak AO (aortic, LVOT) velocity 
- LVESD - Peak PA (pulmonary, RVOT) velocity 
- RVEDD - AO annular diameter 
- Fractional Shortening (% FS) - PA annular diameter 
- Ejection Fraction (EF %) - VTIPA 
 - VTIAO 
 
DIASTOLIC FUNCTION 
(SPECTRAL DOPPLER) 
- E & A wave velocity across mitral valve 
- Note any regurgitation 
 
 
2. TISSUE DOPPLER IMAGING 
 
SYSTOLIC FUNCTION  
- Sa wave velocity at septum, lateral mitral and tricuspid annuli 
- IVA isovolumic acceleration at lateral tricuspid and mitral annuli 
 
DIASTOLIC FUNCTION 
- Ea and Aa wave velocity at septum, lateral mitral and tricuspid annuli 
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6.1.6 Appendix 6: Parent Information Sheet 
Version 2 (01 February 2005) 
 
1. Study Title: End organ effects of paediatric cardiopulmonary bypass 
 
2. Lay Title: Effects of heart surgery, requiring the use of the heart-lung bypass machine, 
on the function of vital body organs in children 
 
3. Invitation paragraph: You and your child are being invited to take part in a research 
study. Before you decide it is important for you to understand why the research is being 
done and what it will involve. Please take time to read the following information 
carefully and discuss it with others if you wish. Ask us if there is anything that is not 
clear or if you would like more information. Take time to decide whether or not you 
wish to take part. 
 
 
 
Thank you for reading this. 
 
 
 
 
Q1. What is the purpose of the study? 
 
Ans: The purpose of this initial (pilot) study is to investigate the effects of heart surgery 
using the heart-lung bypass machine on the function of the heart, lungs and kidneys. 
 
Q2. Why have I been chosen? 
 
Ans: Participation in this study is being offered to all parents with children aged over 3 
months with inborn acyanotic heart disease who require heart surgery using the heart-lung 
bypass machine. 
 
Q3. Do I have to take part? 
 
Ans: NO. It is up to you to decide whether or not you wish your child to take part.  If you 
do decide to take part you will be given this information sheet to keep and be asked to sign 
a consent form. If you decide to take part you are still free to withdraw at any time and 
without giving a reason.  A decision to withdraw at any time, or a decision not to take part, 
will not affect the standard of care you receive. 
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Q4. What will happen to my child, if my child takes part?  
 
Ans:  If you decide that you would like your child to take part: 
- Your child’s surgery and treatment will follow the normal practice of your consultant 
heart surgeon.  
- Your child’s progress before and after surgery will be closely monitored.  
 
(a) Data from ward charts, intensive care charts and routine blood results will be 
recorded.  
(b) Images from routine echocardiography used before and after surgery to assess the 
heart’s function will be studied on the computer.  
(c) Urine samples normally discarded in intensive care will be sent to the laboratory 
to measure markers of kidney function.  
(d) Blood samples taken for routine tests will be stored and used to test for markers 
of heart, lung and kidney function. 
 
 - Your child will remain part of the study until the day of discharge (usually 5 days). 
- You and your child will not need to visit your GP or attend any additional clinics. 
- Your child will not need to take any specific medications. 
 
Q5. What do I have to do? 
 
Ans: There are no associated restrictions with taking part in this study. Your child’s stay in 
hospital should follow the normal course.  
 
Q6. What is the drug or procedure that is being tested? 
 
Ans: There are no drugs or procedures being tested in this initial (pilot) study.  
 
Q8. What are the side effects of any treatment received when taking part? 
 
Ans: Your child will not be receiving any treatment specifically related to this study.  
 
Q9. What are the possible disadvantages and risks of taking part? 
 
Ans: This initial study is mainly an observational study aimed at following your child’s 
progress through hospital more closely. It is not associated with any specific therapy and 
we do not foresee any potential risks to them. 
 
Q10. What are the possible benefits of taking part? 
 
Ans: By taking part in the study your child’s progress through hospital will be closely 
monitored. As a result we would expect that any change to your child’s condition would be 
detected at an early stage and the clinical team could make the relevant decisions earlier. 
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Q11. What if new information becomes available? 
 
Ans: All relevant additional information on the function of the heart, lungs or kidneys 
found during the study will be made available to the clinical team caring for your child to 
allow them to make the appropriate clinical decisions early. 
 
Q12. What happens when the research study stops? 
 
Ans: The research study stops when your child is discharged from hospital. There is no 
further participation or responsibility.  
 
Q13. What if something goes wrong? 
 
Ans: If taking part in this research project harms your child, there are no special 
compensation arrangements.  If you are harmed due to someone’s negligence, then you 
may have grounds for a legal action but you may have to pay for it.  Regardless of this, if 
you wish to complain, or have any concerns about any aspect of the way you have been 
approached or treated during the course of this study, the normal National Health Service 
complaints mechanisms should be available to you. 
 
 
Q14. Will my taking part in this study be kept confidential? 
 
Ans: All information that is collected about your child during the course of the research 
will be kept strictly confidential. Any information about your child which leaves the 
hospital/surgery will have his/her name and address removed so that he/she cannot be 
recognised from it. 
 
Q15. What will happen to the results of the research study? 
 
Ans: The results of this initial study will hopefully serve as a basis for further more 
specific research into this area. Any publications that arise should be available to everyone 
on-line. The information may also be used in presentations to local charities and parent 
groups. You will not be specifically identified in any report or publication. 
 
Q16. Who is organising and funding the research? 
 
Ans: Laboratory tests associated with this study are being funded locally.  
 
Q17. Who has reviewed the study? 
 
Ans: The Research Ethics Committee based in Yorkhill Hospital has reviewed the study. 
The study has also been reviewed by the doctors and other clinical staff involved in your 
child’s care. 
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Q18. Who can I contact for further information? 
 
Ans:  If there is anything you do not understand or feel you would like further information 
on please do not hesitate to contact either of the persons named below through the Cardiac 
Surgery secretaries at Yorkhill Hospital (0141 201 0251). 
- Mr Tony Vassalos, Research Fellow, Department of Cardiac Surgery, Yorkhill 
- Mr Mark Danton, Consultant Paediatric Cardiac Surgeon, Yorkhill 
 
Q19. With whom can I register any complaints? 
 
Ans:  Any complaints should be directed to the complaints officer or research fellow 
detailed below. All complaints will follow the standard NHS complaints mechanism. 
- Mrs Kate Colquhoun, Complaints Officer, Yorkhill NHS Trust, Dalnair Street, Glasgow 
G3 8SJ. (0141 201 9278) 
- Mr Tony Vassalos, Research Fellow, Department of Cardiac Surgery, Level 5 Children’s 
Hospital, Yorkhill NHS Trust, Dalnair Street, Glasgow G3 8SJ. 
 
 
All patients precipitating in this study will be given a copy of the information sheet and a 
signed consent form to keep. 
 
Thank you for your co-operation and patience. 
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6.1.7 Appendix 7: Parent Consent Form 
Centre Number: : 
Study Number: 05/CA/01 
Patient Identification Number for this trial: 
 
CONSENT FORM 
 
 
Title of Project: End organ effects of paediatric cardiopulmonary bypass 
 
 
 
Name of Researcher: Mr Tony Vassalos 
 
 
 
 
    
 Please initial box 
 
1. I confirm that I have read and understand the information sheet dated 1 February 2005 
February 2005 (version 2) for the above study and have had the opportunity to ask 
opportunity to ask questions. 
 
2. I understand that my child’s participation is voluntary and that I am free to withdraw at 
withdraw at any time, without giving any reason, without my child’s medical care or legal 
medical care or legal rights being affected. 
 
3. I understand that sections of my child’s medical notes may be looked at by responsible 
by responsible individuals from the Yorkhill Division or from regulatory authorities where 
authorities where it is relevant to my child taking part in research. I give permission for 
permission for these individuals to have access to my child’s records. 
 
4. I give permission for my child to take part in the above study.  
 
 
 
 
 
 
_________________________ ________________ ____________________ 
Name of Parent or Guardian Date Signature 
 
 
 
_________________________ ________________ ____________________ 
Researcher Date Signature   
 
 
 
 
 1 for parent/guardian;  1 for researcher;  1 to be kept with hospital notes 
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6.2 Randomised Controlled Trial 
6.2.1 Appendix 1: Study Protocol 
A phase IV, randomised, double-blind, placebo-controlled, single-centre study of the 
pre-operative effect of Sildenafil Citrate on pulmonary related complications 
following cardiopulmonary bypass in children undergoing cardiac surgical repair 
 
 
Sponsor: NHS Greater Glasgow 
   Yorkhill Division, Royal Hospital for Sick Children 
   Dalnair Street, Glasgow G3 8SJ 
 
Chief Investigator:   Mr Tony Vassalos (CI), Research Fellow Cardiac Surgery 
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List of Abbreviations (In order of appearance) 
 
• CI : chief investigator 
• PI : principal investigator 
• cGMP : cyclic guanosine monophosphate 
• PVRI :  pulmonary vascular resistance index 
• PED :  pulmonary endothelial dysfunction 
• CPB :  cardiopulmonary bypass 
• PICU :  pediatric intensive care unit 
• NO :  nitric oxide 
• PDE5 :  phosphodiesterase-5 
• iNO : inhaled nitric oxide 
• Tmax : time from administration to peak plasma concentration 
• Cmax : peak plasma concentration 
• Vss : volume of distribution 
• CLcr : creatinine clearance 
• AUC : area under the plasma concentration-time curve 
• IC50 : half-maximal inhibition 
• RCT :  randomised controlled trial 
• CHD : congenital heart disease 
• PVR : pulmonary vascular resistance 
• NYHA : New York Heart Association 
• WUm2 : woods units per metre squared body surface area 
• PA :  pulmonary artery 
• LA :  left atrium 
• VTIPA :  velocity time integral of the pulmonary artery 
• TDI :  tissue Doppler imaging 
• RV :  right ventricle 
• IVA :  peak myocardial acceleration during isovolumetric contraction 
• IVC :  isovolumetric contraction 
• OI :  oxygenation index 
• ERS :  European Respiratory Society 
• ELISA :  enzyme linked immunosorbent assay 
• VCAM-1 :  vascular cell adhesion molecule  
• REC : Research Ethics Committee 
• SAE : serious adverse event 
• ASD : atrial septal defect 
• VSD : ventricular septal defect 
• AV Canal : atrioventricular defect 
• ECMO : extra-corporeal membrane oxygenation 
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STUDY SUMMARY 
 
 
Title:  Does pre-operative Sildenafil protect against pulmonary related complications following 
cardiopulmonary bypass? A randomised trial in children undergoing cardiac surgical repair 
 
Short Title: Randomised trial of pre-operative Sildenafil in children 
 
Lay Title:  Will giving the drug Sildenafil to children before open heart surgery improve the function 
of the lungs after surgery? 
 
Design: Phase IV, randomised, double-blind, placebo-controlled 
 
Duration: 12 months 
 
Centre: Single-centre 
 
 
Research Hypothesis 
Oral Sildenafil (Viagra, Pfizer) given pre-operatively to children with left to right 
intracardiac shunts, undergoing corrective surgery utilizing cardiopulmonary bypass, will 
amplify cGMP levels in the pulmonary endothelium and reduce post-operative pulmonary 
dysfunction.  
 
Number of subjects 
A sample size of 12 in each group will have 80% power to detect a minimum difference in 
PVRI of 4.14 WUm2 between the control and intervention groups. This computation is 
based on data published by Schulze-Neick et al. (Circulation 2003:108[suppl II];II-167-II-
173) where a mean of 8.32 WUm2 and standard deviation of 3.464 was observed in the 
post-operative group. The sample size calculation was done using nQuery, version 5.0, 
under the supervision of Dr David Young (Senior Statistician, Yorkhill Hospital). 
 
Inclusion Criteria 
-   pediatric patients undergoing open heart surgery utilising cardiopulmonary bypass to 
correct acyanotic congenital heart disease 
-  age >3 months 
- parents that show a good understanding of their child's condition and are happy for their 
child to participate in the study 
 
Exclusion Criteria 
-  patients with known organ dysfunction prior to surgery (pulmonary, renal or hepatic) 
-  communication barriers resulting in poor basic comprehension of the proposed study (e.g. 
language barrier) 
-  patients with cyanotic heart disease 
- patients undergoing heart surgery without the use of cardiopulmonary bypass 
-  patients who do not tolerate oral Sildenafil (e.g. Vomiting) or whose surgery is 
subsequently cancelled 
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Study Product 
- Name : Sildenafil Citrate (Viagra, Pfizer) 
- Dose :  0.5mg/kg (Max 100mg/day) 
- Route :  Oral (suspension) 
- Regimen :  6hrly (day before surgery only), 4 doses total 
 
Reference Therapy 
Alternatively, an identical and inactive Placebo (equal volume) will be given 6hrly the day 
before surgery. 
 
Data Analysis 
Data will be tested for normality and two-sample t-tests or Mann-Whitney tests done 
accordingly. Analysis will be done on an intention-to-treat basis with any missing values 
being replaced by previous recorded measures, or based on group averages as appropriate. 
All analyses will be done using Minitab (version 14) with a significance level of 5% and 
results displayed as between-group effect sizes with 95% confidence intervals. Analysis 
will be carried out under the supervision of Dr David Young (Senior Statistician, Yorkhill 
Hospital). 
 
Introduction 
This document is a clinical research protocol. The research trial detailed within will be 
conducted in compliance with the principles of the Declaration of Helsinki (1989), the 
principles of ICH-GCP and all applicable regulatory requirements. 
 
 Background 
Specific congenital heart defects such as ventricular septal defects that result in left to right 
intracardiac shunting lead to excessive blood flow through the pulmonary circulation. This 
has an adverse effect on the pulmonary endothelium clinically manifest as episodes of 
pulmonary hypertension and hemodynamic instability. This phenomenon of ‘pulmonary 
endothelial dysfunction’ (PED) is exacerbated by cardiopulmonary bypass (CPB) utilised 
during surgical repair. [1] Post-operatively such patients are prone to developing pulmonary 
infiltrations, decreased oxygenation and pulmonary hypertension with associated right-
sided heart failure and hemodynamic instability. This often results in a prolonged stay in 
intensive care (PICU) and is associated with significant morbidity and mortality. [1, 2] 
 
In the normal lung, nitric oxide (NO) is produced by the endothelium to regulate blood 
flow and optimise ventilation. PED is defined as a failure of the pulmonary endothelium to 
produce adequate amounts of NO. [2] This failure is amplified by cardiac surgery and is 
thought to be a specific consequence of a more generalised inflammatory response to CPB. 
NO acts through a secondary messenger, intracellular cyclic guanosine monophosphate 
(cGMP), to dilate pulmonary blood vessels. cGMP is metabolized by phosphodiesterase-5 
(PDE5) which is the predominant phosphodiesterase in normal lung and may be up 
regulated in patients with PED. [2, 3, 4]  
 
Administration of inhaled NO (iNO) is currently the standard treatment for post-operative 
pulmonary hypertension. Although this has proved to be clinically effective, significant 
disadvantages do exist with some patients failing to respond and others developing life-
threatening pulmonary hypertension upon withdrawal. [5, 6] Recently Sildenafil (Viagra, 
Pfizer), a potent PDE-5 inhibitor that prevents the breakdown of cGMP, has been 
introduced as a potential new therapy and has been shown to be as effective as iNO in 
treating pulmonary hypertension. [7, 8] Sildenafil, however, does not require a special 
delivery system and does not cause life-threatening rebound pulmonary hypertension. Oral 
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Sildenafil is now an established treatment for chronic pulmonary hypertension in children 
and is safe and effective when given at therapeutic doses (0.5-2.0mg/kg; 4hrly). [9] 
Currently, Sildenafil is used on an ‘ad hoc’ basis in our PICU to treat post-operative 
pulmonary hypertension with or without iNO.  
 
Our hypothesis is that oral Sildenafil liquid (0.5mg/kg) administered 6hrly the day before 
surgery will maintain intracellular cGMP levels during the insult of cardiopulmonary 
bypass, protecting the pulmonary endothelium and avoiding the consequences of PED in 
the post-operative period. To date, the limited number of trials reporting the use of 
Sildenafil have been small in number and not specifically related to surgery. [10] 
Furthermore, the pre-operative role of Sildenafil in protecting the pulmonary endothelium 
has not been previously addressed. 
 
Investigational Medicinal Product (direct from Pfizer) 
Generic Name: Sildenafil Citrate (Discovered in 1989) 
Trade Name: Viagra 
Chemical Name: 1-[4-ethoxy-3-(6,7-dihydro-1-methyl-7-oxo-3-
propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl) 
phenylsulfonyl 
Molecular Formula: C22H30N6O4S·C6H8O7 
Molecular Weight: 666.7 (citrate salt) 
Pharmacological Class: cyclic guanosine monophosphate (cGMP)-specific 
phosphodiesterase type 5 (PDE5) inhibitor 
Formulation and Dose: Oral Suspension; 0.5mg/kg; 6hrly (Max 100mg/day) 
Route of Administration: Oral 
Structure: 
 
 Rationale 
Normally, stimulation of the pulmonary vascular endothelium causes local release of NO 
which in turn regulates pulmonary blood flow to optimize ventilation. NO activates the 
enzyme guanylate cyclase, which in turn results in increased levels of cyclic guanosine 
monophosphate (cGMP), producing smooth muscle relaxation in the pulmonary 
vasculature and reducing pulmonary vascular resistance. Sildenafil has no direct relaxant 
effect on isolated pulmonary blood vessels, but enhances the effect of NO by inhibiting 
phosphodiesterase type 5 (PDE5), which is responsible for degradation of cGMP.  
 
Studies in vitro have shown that Sildenafil is selective for PDE5. Its effect is more potent 
on PDE5 than on other known phosphodiesterases (10-fold for PDE6, >80-fold for PDE1, 
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>700-fold for PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11). The 
approximately 4,000-fold selectivity for PDE5 versus PDE3 is important because PDE3 is 
involved in control of cardiac contractility. Sildenafil is only about 10-fold as potent for 
PDE5 compared to PDE6, an enzyme found in the retina which is involved in the 
phototransduction pathway of the retina. This lower selectivity is thought to be the basis 
for abnormalities related to color vision observed with higher doses or plasma levels. 
PDE5 is found in high concentrations in human corpus cavernosum and pulmonary 
vascular smooth muscle. PDE5 is also found in lower concentrations in other tissues 
including platelets, vascular and visceral smooth muscle, and skeletal muscle. The 
inhibition of PDE5 in these tissues by sildenafil may be the basis for the enhanced platelet 
antiaggregatory activity of nitric oxide observed in vitro, an inhibition of platelet thrombus 
formation in vivo and peripheral arterial-venous dilatation in vivo. 
 
 Pharmacokinetics and Metabolism 
Sildenafil is rapidly absorbed after oral administration, with absolute bioavailability of 
about 40%. Its pharmacokinetics are dose-proportional over the recommended dose range. 
It is eliminated predominantly by hepatic metabolism (mainly cytochrome P450 3A4) and 
is converted to an active N-demethylated metabolite with properties similar to the parent, 
sildenafil. The concomitant use of potent cytochrome P450 3A4 inhibitors (e.g., 
erythromycin, ketoconazole, itraconazole) as well as the nonspecific CYP inhibitor, 
cimetidine, is associated with increased plasma levels of sildenafil. Both sildenafil and the 
metabolite have terminal half lives of about 4 hours.  
 
 Absorption and Distribution 
Sildenafil is rapidly absorbed. Maximum observed plasma concentrations are reached 
within 30 to 120 minutes (median 60 minutes) of oral dosing in the fasted state. When 
Sildenafil is taken with a high fat meal, the rate of absorption is reduced, with a mean 
delay in Tmax of 60 minutes and a mean reduction in Cmax of 29%. The mean steady 
state volume of distribution (Vss) for sildenafil is 105 L, indicating distribution into the 
tissues. Sildenafil and its major circulating N-desmethyl metabolite are both approximately 
96% bound to plasma proteins. Protein binding is independent of total drug concentrations.  
 
 Metabolism and Excretion 
Sildenafil is cleared predominantly by the CYP3A4 (major route) and CYP2C9 (minor 
route) hepatic microsomal isoenzymes. The major circulating metabolite results from N-
desmethylation of sildenafil, and is itself further metabolized. This metabolite has a PDE 
selectivity profile similar to sildenafil and an in vitro potency for PDE5 approximately 
50% of the parent drug. Plasma concentrations of this metabolite are approximately 40% 
of those seen for sildenafil, so that the metabolite accounts for about 20% of sildenafil’s 
pharmacologic effects. After either oral or intravenous administration, sildenafil is 
excreted as metabolites predominantly in the feces (approximately 80% of administered 
oral dose) and to a lesser extent in the urine (approximately 13% of the administered oral 
dose). Similar values for pharmacokinetic parameters were seen in normal volunteers and 
in the patient population, using a population pharmacokinetic approach. 
 
 Pharmacokinetics in Special Populations 
- Renal Insufficiency: In volunteers with mild (CLcr=50-80 mL/min) and moderate 
(CLcr=30-49 mL/min) renal impairment, the pharmacokinetics of a single oral dose of 
Sildenafil (50 mg) were not altered. In volunteers with severe (CLcr=<30 mL/min) renal 
impairment, sildenafil clearance was reduced, resulting in approximately doubling of AUC 
and Cmax compared to age-matched volunteers with no renal impairment. 
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- Hepatic Insufficiency: In volunteers with hepatic cirrhosis (Child-Pugh A and B), 
sildenafil clearance was reduced, resulting in increases in AUC (84%) and Cmax (47%) 
compared to age-matched volunteers with no hepatic impairment.  
 
Therefore, hepatic impairment and severe renal impairment are associated with increased 
plasma levels of sildenafil. A starting oral dose of 25 mg should be considered in those 
patients. 
 
Pre-clinical Data 
Sildenafil is a potent and selective inhibitor of 3’5’-cGMP-specific PDE-5 with a half-
maximal inhibition (IC50) of PDE-5 activity at a concentration of 3.5nmol/L. Sildenafil has 
a substantially lower affinity for the other PDE isoenzymes (at least 11 isoforms of PDE 
have been discovered) manifested by the much higher concentrations needed to inhibit 
50% of their activities (IC50). The tissue distribution of PDE-5 is well defined and the 
effects of Sildenafil can be expected to be limited to these tissues (corpus cavernosum, 
platelets, skeletal muscle, vascular and visceral smooth muscle).[11-13] The estimated 
degree of PDE-5 inhibition in humans after oral dosing would be as follows: 25mg 
(~11nmol/L free drug) would give approximately 76% inhibition; 50 mg (~22nmol/L free 
drug) approximately 86% inhibitions and 100mg (~47nmol/L free drug) approximately 
93% inhibition. These estimations are based on a number of assumptions, one of which is 
that the inhibition of the enzyme is sigmoid with respect to inhibitor concentration.[14] 
 
 Clinical Data to Date 
In the levels of clinical evidence, the randomised controlled trial (RCT) is generally 
considered the best approach to ascertain the value of a particular therapy. To date only 
one RCT has investigated the effects of Sildenafil in children undergoing corrective 
cardiac surgery for congenital heart disease (CHD). Stocker et al [15] investigated the acute 
effects of intravenous Sildenafil in 16 ventilated infants at risk of pulmonary hypertension 
after cardiac surgery on haemodynamics, oxygenation and its interaction with iNO. The 
study was completed in 15 patients. Seven infants received iNO (20ppm) first with the 
addition of intravenous Sildenafil (0.35mg/kg over 20mins) after 20mins. Eight infants 
received Sildenafil first, iNO was added after 20mins. In infants receiving iNO first, iNO 
lowered the PVRI from 3.45 to 2.95 units (p<0.01); Sildenafil further reduced PVRI to 
2.45 units (p<0.05). In those receiving Sildenafil first, PVRI was reduced from 2.84 to 
2.35 units (p<0.05) with Sildenafil and fell to 2.15 units (p<0.01) with the addition of iNO. 
In both groups, these potentially beneficial effects were associated with a significant 
reduction in systemic blood pressure and deterioration in oxygenation that was not 
improved by iNO (p<0.05). The latter effects were well tolerated by all study patients and 
were not associated with any clinical decline. 
 
In a prospective non-randomised study, Schulze-Neick et al [2] compared the effects of iNO 
before and after specific PDE-5 inhibition by intravenous Sildenafil in pre- and post-
operative children with increased pulmonary vascular resistance (PVR) due to CHD. 12 
children (0.2-15.7yrs) with CHD and increased mean pulmonary artery pressure and 12 
children (0.11-0.65yrs) with increased PVR were studied during cardiac catheterisation or 
within 2hrs after return from cardiac surgery, respectively. All were sedated, tracheally 
intubated and paralysed. In the pre-operative group 0.33-0.66mg/kg of intravenous 
Sildenafil more effectively reduced PVR than iNO (11.5% versus 4.3%) (p<0.05). This 
result was repeated in the post-operative group where intravenous Sildenafil 0.025-
0.25mg/kg more effectively reduced PVR than iNO (25.8% versus 14.6%) (p=0.09). This 
was however associated with a clinically insignificant increase in intrapulmonary shunting 
post-operatively (p=0.04).  
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Kothari et al [16] reported the outcome of long-term oral Sildenafil therapy in 14 patients 
with severe pulmonary artery hypertension, 5 of whom had surgery for CHD. Sildenafil 
was started at low dose and empirically increased such that the upper dosage limit of 
Sildenafil was not strictly defined but left to the functional improvement in individual 
cases (75-300mg/day). On a mean follow up 7.3 +/- 2.4 months oral Sildenafil was well 
tolerated and produced a significant and sustained improvement in exercise performance 
(Six-minute walk test), New York Heart Association (NYHA) functional class, right 
ventricular and pulmonary artery pressures (p<0.002). Two patients died during follow up 
despite clinical improvement. 
 
Humpl et al [17] performed a 12 month open-label, single-drug, pilot study into the effects 
of oral Sildenafil in 14 children (5.3-18yrs) with pulmonary artery hypertension, 7 of 
whom had had surgery for CHD. The median time from cardiac surgical repair to start of 
Sildenafil therapy was 7 years. Oral Sildenafil (0.25mg/kg for 2 doses and then increased 
to 1mg/kg; 4 times daily) was commenced after baseline assessment of haemodynamics by 
cardiac catheterisation and exercise performance (Six-minute walk test). Exercise 
performance was repeated in all children at 6 weeks and at 3, 6 and 12 months. Cardiac 
catheterisation was repeated in 9 children after a median follow up of 10.8 months (6-
15.3). Oral Sildenafil improved exercise performance at 6 months (278+/-114 to 443+/-
107m) (p=0.02) and at 12 months (432+/-156m) (p=0.005). A plateau was reached 
between 6 and 12 months (p=0.48). Mean pulmonary artery pressure decreased from a 
median of 60mmHg to 50mmHg (p=0.014) and mean PVR decreased from 15WUm2 to 
12WUm2 (p=0.024). Sildenafil was well tolerated and no patient withdrew. There was no 
change in urea, creatinine, liver function tests or platelet count.  
 
 Dose Rationale and Risk/Benefits 
Clinical evidence relating to the efficacy of Sildenafil in reducing pulmonary hypertension 
due to congenital heart disease is limited and described in detail above. The current best 
available evidence suggests that a dosing range of 0.025-0.66mg/kg of intravenous 
Sildenafil and 0.25-1mg/kg (6hrly) of oral Sildenafil would safely and significantly reduce 
pulmonary hypertension in this patient group. Our personal clinical experience to date also 
supports the opinion that oral Sildenafil (commenced at 0.5mg/kg and increased up to 
2mg/kg; 6hrly) is a safe and effective treatment for post-operative pulmonary hypertension 
in this patient group with or without iNO.   
 
In general, Sildenafil has been very well tolerated in all clinical trials with the most 
commonly reported adverse events being headache, flushing, dyspepsia and nasal 
congestion. Adverse events were generally transient and mild to moderate. Furthermore, 
no serious adverse events were judged to be related to Sildenafil therapy. [18, 19] Oral 
Sildenafil is now an established treatment for chronic pulmonary hypertension in children 
and is safe and effective when given at therapeutic doses (0.5-2.0mg/kg; 4hrly). [9]  
 
It is on this basis that the dosing regimen for oral Sildenafil in the proposed trial was 
chosen: 0.5mg/kg; 6hrly. Due to the sigmoidal dose-related response of Sildenafil and in 
an attempt to reduce the risk of potential adverse effects we elected a dosing regimen 
representative of the lower end of our normal post-operative prescribing practice. 
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 Study Objectives 
- Primary Objective: Does pre-operative administration of Sildenafil (Viagra, Pfizer) 
reduce the lung injury associated with cardiopulmonary bypass in children undergoing 
corrective surgical repair of congenital heart disease? 
 
- Secondary Objectives: To further delineate the mechanism(s) of action of Sildenafil in 
this setting. Specifically, does pre-operative Sildenafil: 
− reduce post-operative pulmonary vascular resistance index? 
− improve post-operative oxygenation? 
− affect cardiac contractility? 
− increase peri-operative cGMP levels? 
 
 Study Design 
 
 General Design 
- Phase IV, randomised, double-blind, placebo-controlled, single-centre study 
 
 Primary Study Endpoints 
The efficacy of pre-operative Sildenafil given to children undergoing corrective heart 
surgery for congenital heart disease in reducing PVRI, the systemic inflammatory response 
to CPB and improving oxygenation post-operatively. 
 
 Primary Safety Endpoints 
- Anaphylaxis 
- Clinically significant hemodynamic instability pre-operatively 
 
 End of Study Definition 
The study will end when 24 patients with completed data sets have been enrolled or in the 
event that criteria for stopping the study early are met. 
 
 Subject Selection and Withdrawal 
 
 Inclusion criteria 
-   pediatric patients undergoing open heart surgery utilising cardiopulmonary bypass to 
correct acyanotic congenital heart disease 
-  age >3 months 
- parents that show a good understanding of their child's condition and are happy for their 
child to participate in the study 
 
 Exclusion criteria 
-  patients with known organ dysfunction prior to surgery (pulmonary, renal or hepatic) 
-  communication barriers resulting in poor basic comprehension of the proposed study (e.g. 
language barrier) 
-  patients with cyanotic heart disease 
- patients undergoing heart surgery without the use of cardiopulmonary bypass 
-  patients who do not tolerate oral Sildenafil (e.g. Vomiting) or whose surgery is 
subsequently cancelled 
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 Subject Enrolment 
- Identification: patients who fulfill the inclusion criteria on paper will be invited to take 
part in this randomized clinical trial.  
- Introduction: the randomized trial will be introduced to the identified patient's parents by 
their consultant cardiac surgeon at the pre-assessment clinic. A patient information sheet 
will also be available for those who want one. Patients will be electively admitted to the 
cardiology ward 48hrs prior to surgery as is the current practice. The chief investigator 
will introduce himself at that time to potential participants and their families to further 
discuss the randomized clinical trial and potential recruitment. 
- Recruitment: during the pre-operative period a comprehensive explanation specifically 
discussing potential risks and benefits will be given to parents regarding their child. 
Thereafter, they will be offered the opportunity to participate and complete the informed 
consent. There will be no obligation to take part in the trial. Everyone involved appreciates 
and understands the emotional turmoil associated with this type of surgery. 
 
Early Withdrawal of Subjects 
 
 When and How to Withdraw Subjects 
Subjects will be withdrawn from the trial prior to the expected completion where: 
- their subsequent surgery is cancelled 
- there is a failure of the subject to adhere to protocol requirements 
- the study drug is not tolerated (e.g. Vomiting) 
- subject consent is withdrawn 
 
We do not anticipate abrupt withdrawal from the trial to impact subject safety or clinical 
management thereafter. 
  
 Data Collection and Follow-up for Withdrawn Subjects 
There will be no specific follow up associated with participation in this randomised trial. 
In the event that a subject is withdrawn from the trial due to their surgery being cancelled 
or intolerability to the study drug their data will not be included in the final analysis and 
they will be replaced. Where a subject’s consent is withdrawn and in the event that the 
study drug has been successfully administered an attempt will be made to obtain 
permission to record survival data up to the protocol-described end of subject 
participation. Serious adverse events will be recorded in all cases irrespectively. 
 
 Study Drug 
 
 Description 
- Sildenafil (Viagra, Pfizer), is a potent and selective inhibitor of cGMP-specific PDE5. It is 
rapidly absorbed orally with dose-proportional peak plasma concentrations within 1 hour 
of administration. It is eliminated predominantly by hepatic metabolism (mainly 
cytochrome P450 3A4) and is converted to an active metabolite with properties similar to 
parent. The elimination half-life for both Sildenafil and its active metabolite is 3 to 5 
hours. Sildenafil is excreted as metabolites predominantly in the faeces (~80%) and to a 
lesser extent in the urine (~13%). Hepatic and severe renal impairment are associated with 
increased plasma levels. 
- Drug product will appear as: ‘Sildenafil / Placebo Suspension of 2.5 mg/ml’. Total 
volume, expiry date and date dispensed will be stated on the drug product bottle.  
  
  
End Organ Effects of Paediatric Cardiopulmonary Bypass         Page 141 of 192 
 
Tony Vassalos  2010 
 
  
 Treatment Regimen 
Sildenafil regimen prescribed: 0.5mg/kg, orally, 6hrly (4 doses; Max 100mg/day), day 
before surgery 
 
 Method for Assigning Subjects to Treatment Groups 
Randomisation of the patients to receive oral Sildenafil or equivalent volume of Placebo 
liquid will be undertaken by the clinical trials technician using a minimisation programme 
(MINIM). Only the clinical trials technician will know which subjects have received the 
active drug. This will be disclosed at the interim analysis, in the event of an emergency 
and at the end of the trial to the chief investigator once all data has been recorded and 
analysed. Each subject will be given a specific number upon trial entry, the identity of 
which will only be known by the chief investigator and the clinical trials technician.  
 
Preparation and Administration of Study Drug  
 
Placebo  
The placebo suspension will be prepared by the Pharmacy Production Unit based at the 
Western Infirmary Glasgow (IMP Licence Number 18324). The ingredients of this 
suspension include Ora Plus Suspending Vehicle and Ora Sweet Syrup Sugar Free.  
 
Sildenafil 
The Sildenafil suspension (2.5mg/ml) will be prepared by Pharmacy Production Unit 
based at the Western Infirmary Glasgow (IMP Licence Number 18324). The ingredients of 
this suspension include Sildenafil tablets (25-100mg), Ora Plus Suspending Vehicle and 
Ora Sweet Syrup Sugar Free.  
 
Administration 
Upon successful informed consent, a study specific prescription sheet will be completed 
for each participant. Following randomisation an appropriately labelled bottle (Sildenafil / 
Placebo) will be dispensed by the Pharmacy Department in Yorkhill and stored in a locked 
locker at the participant’s bed space on the Cardiology Ward (5A). The appropriate dose 
detailed on the label and prescribed on the drug Kardex will then be administered by the 
nursing staff. The suspension will be placed in the participant’s mouth either directly (oral 
syringe) or using a spoon as per normal practice. 
 
 Subject Compliance Monitoring 
Compliance to the study treatment regimen will be overlooked by the clinical trials 
technician, ward pharmacist and the chief investigator. As the study regimen only involves 
4 doses we expect subject compliance to be easily monitored. Any subject that is non-
compliant with the study treatment regimen will be withdrawn from the trial. 
 
 Prior and Concomitant Therapy 
The concomitant use of potent cytochrome P450 3A4 inhibitors (e.g., erythromycin, 
ketoconazole, itraconazole) as well as the nonspecific CYP inhibitor, cimetidine, is 
associated with increased plasma levels of Sildenafil and will be avoided the day before 
surgery. Otherwise all patients will be managed according to the normal practice of the 
Cardiology/Cardiac Surgery Departments at Yorkhill Hospital. 
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 Packaging 
 
 Placebo 
The placebo suspension supplied by the Pharmacy Production Unit, Glasgow in 3 x 50ml, 
amber bottles. The bottles will be clearly labelled and transported individually as required 
in a small cardboard box wrapped in bubble-wrap.  
 
 Sildenafil 
Sildenafil suspension supplied by the Pharmacy Production Unit, Glasgow in 3 x 50ml, 
amber bottles and received in bulk-pack by courier. Each batch will have a corresponding 
batch number and expiry date. Bottles will be wrapped in bubble-wrap and packed into a 
cardboard box for transportation. 
 
Blinding of Study Drug 
Randomisation for this study will be undertaken by the clinical trial technician once 
informed consent has been obtained using the minimisation programme MINIM. The 
participants will therefore be placed into either the active (Sildenafil) arm or inactive 
(Placebo) arm of the study. This will be recorded by the clinical trials technician on 
individual patient study files held in the clinical trials department. The code will be broken 
for interim analysis, in the event of an emergency and then at the end of the trial.  
 
 Receiving, Storage, Dispensing and Return 
 
 Receipt of Drug Supplies 
The Study medication bottles will be delivered to pharmacy stores by courier.  Packed in 
cardboard box, bottles will be wrapped in bubble wrap. The pharmacy store staff will 
check the delivery receipt and match with corresponding order.  After the paper work has 
been checked and completed the clinical trials department will accept delivery and 
complete the drug accountability record sheet before supplies are stored in a locked 
cupboard in the Clinical Trials Department. 
 
 Storage 
Sildenafil and corresponding placebo suspension will be stored (below 25° C) in a locked 
cupboard in the Clinical Trials Department at Yorkhill Hospital. The expiry date for both 
is 28 days. Temperatures will be checked and recorded Monday-Friday. 
 
 Dispensing of Study Drug 
The Study medication will be dispensed into 50ml, amber glass bottles with 22mm click 
lock caps. The label will contain all the information required to meet the applicable 
regulatory requirements. A register of pharmacy personnel dispensing and checking trial 
medication will be completed and filed in the Study filing cabinet. A dispensing record 
and prescription sheet will be completed and checked for each patient. 
 
 Return or Destruction of Study Drug 
Study medication that has been returned or expired will be checked and recorded before 
destruction. Each trial subject will have a returns record sheet and drug container disposal 
procedure. Certification of destruction is retained with the Directory of Pharmacy, Mr 
James Wallace. 
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 Study Procedures 
The trial will be introduced to the parents by their consultant cardiac surgeon at the pre-
assessment clinic. Upon admission to the ward for elective surgery the parents will meet 
the chief investigator if willing to discuss the trial further. If consent is given, the 
pharmacy will randomise patients to receive Sildenafil or Placebo using a minimisation 
programme (MINIM). The corresponding suspension (0.5mg/kg Sildenafil or equivalent 
volume placebo) will be dispensed to be taken 6hrly (orally) the day before surgery. 
Complete surgical repair and associated medical care thereafter will be undertaken 
according to the normal practice of Cardiology/Cardiac Surgery Departments at Yorkhill 
Hospital. Participation in the trial will end upon hospital discharge. 
 
- Data collection under standardised conditions (FiO2 0.65) will occur at 2hrs and 24hrs 
post-operatively in the paediatric intensive care unit to assess: 
 
Pulmonary Haemodynamics: 
 
• Measured indices:  
- Pressure catheter measurements: pulmonary artery (PA) and left atrial (LA) pressures 
recorded from routine invasive monitoring lines placed in theatre. 
 
• Echocardiography: 
- Velocity time integral (VTIPA): spectral Doppler of the right ventricular outflow tract will 
be used together with the pulmonary annular measurement to estimate pulmonary blood 
flow. 
- Tissue Doppler Imaging (TDI): load independent assessment of right ventricular (RV) 
function. Pulsed wave TDI in the apical 4-chamber view will be used to obtain the Sa, Ea 
and Aa wave velocities and the peak myocardial IVC acceleration at the lateral tricuspid 
annulus. Each parameter will be measured over 3 consecutive cardiac cycles and the 
average value used in the analysis (100mm/s sweep speed). On and off-line analysis will 
be used to assess RV systolic and diastolic function.  
 
Peak myocardial IVC acceleration (IVA): represents global myocardial contractility and is 
calculated by dividing peak myocardial velocity during isovolumetric contraction (IVC) 
by the time interval from the onset of this wave to the time at peak velocity. The period of 
IVC is taken as the onset of the QRS complex, on simultaneous ECG, to the beginning of 
the Sa wave. This index has been shown to be a sensitive indicator of RV systolic function. 
 
• Derived indices: 
- Transpulmonary gradient: calculated by subtracting the LA pressure from the PA pressure 
measurement 
 
- Pulmonary vascular resistance index (PVRI) (WUm2): is derived from the transpulmonary 
gradient and estimated pulmonary blood flow on spectral Doppler. The value is 
standardised against body surface area.  
 
 Ventilation:  
 
• Oxygenation Index (OI) Calculation: [mean airway pressure (cm H20) x 100 x FiO2 / PaO2 
(mmHg)] where the mean airway pressure is recorded off the ventilator, Fi02 refers to the 
inspired oxygen concentration (standardised at 65%) and PaO2 refers to the arterial 
oxygen concentration. A number of different indices have been used to quantify the 
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severity of respiratory illness in ventilated patients. The OI is generally preferred because 
it is incorporates a measure of ventilator pressures. 
 
• Oxygen delivery (DO2) Calculation: Oxygen delivery calculated post-operatively using 
Doppler derived CO (QS) and arterial oxygen content according to the equation: DO2 = Qs 
x [Haemoglobin x 1.34 x Haemoglobin saturation + 0.003 x arterial oxygen tension 
(mmHg)]. 
 
• Period of ventilation & length of stay in PICU: data extracted directly from PICU charts 
 
cGMP:  
 
- cGMP levels: measured using commercially available radioimmunoassay (Du Pont 
Speciality Diagnostics).  
 
Statistical Plan 
 
Statistical Methods and Sample Size Determination 
A sample size of 12 in each group will have 80% power to detect a minimum difference in 
PVRI of 4.14 WUm2 between the control and intervention groups. This computation is 
based on data published by Schulze-Neick et al. (Circulation 2003:108[suppl II];II-167-II-
173) where a mean of 8.32 WUm2 and standard deviation of 3.464 was observed in the 
post-operative group. The sample size calculation was done using nQuery, version 5.0, 
under the supervision of Dr David Young (Senior Statistician, Yorkhill Hospital). 
 
A mid-point analysis of the data will be undertaken to evaluate trends and any unforeseen 
adverse effects. The interim and complete data set will be tested for normality and two-
sample t-tests or Mann-Whitney tests done accordingly. Analysis will be done on an 
intention-to-treat basis with any missing values being replaced by previous recorded 
measures, or based on group averages as appropriate. All analyses will be done using 
Minitab (version 14) with a significance level of 5% and results displayed as between-
group effect sizes with 95% confidence intervals. Analysis will be carried out under the 
supervision of Dr David Young. 
 
 Safety and Adverse Events 
 
Definitions 
Research participant safety will be closely monitored during the study as is the case in all 
pediatric cardiac surgical cases. This will involve routine case conference, physical 
examination, echocardiography +/- cardiac catheterisation, monitoring of vital signs and 
blood tests pre-operatively. All participants will undergo routine intra-operative 
echocardiography to assess the cardiac surgical repair. Thereafter all participants will be 
admitted to PICU where they will be invasively monitored, undergo routine post-operative 
echocardiography and overlooked by the cardiac surgery, cardiology and intensive care 
teams. Normally children with intracardiac shunts undergoing cardiac surgical correction 
are expected to remain in PICU for 48hrs post-operatively before being transferred to the 
Cardiology Ward prior to discharge around day 7. Adverse event recording will be 
undertaken throughout the admission. 
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Potential Serious Adverse Events Associated with Study Population 
 
Pre-operative 
- Cardiac arrhythmias 
- Episodic pulmonary hypertension 
- Eisenmenger Syndrome 
- Embolism 
- Left / Right sided heart failure 
- Endocarditis 
- Anaphylaxic reaction to anaesthetic agents 
 
Intra-operative 
- Cardiopulmonary bypass circuit failure +/- air embolus, circulatory arrest, multi-organ 
dysfunction 
- Myocardial infarction  
- Mortality (1% for ASD/VSD; <5% for AV Canal) 
 
Post-operative 
- Cardiac Tamponade +/- Re-sternotomy 
- Cardiac arrhythmias 
- Episodic severe pulmonary hypertension 
- Myocardial infarction 
- Right / Left sided heart failure +/- multi-organ dysfunction, prolonged inotropic support or 
extra-corporeal membrane oxygenation (ECMO) 
- Cerebral injury (hypoxic, embolic, hemorrhagic)  
- Acute renal failure +/- renal replacement therapy 
- Hepatic failure 
- Ischaemic gastrointestinal tract 
- Sternal wound infection +/- Mediastinitis 
- Systemic sepsis +/- multi-organ dysfunction 
- Coagulopathies 
- Tension Pneumothorax / Simple Pneumothorax / Chylothorax 
 
 
Potential Adverse Events Associated with Sildenafil Toxicity (directly from Pfizer) 
 
ADVERSE EVENTS REPORTED BY ≥2% OF PATIENTS TREATED WITH VIAGRA 
AND MORE FREQUENT ON DRUG THAN PLACEBO IN PRN FLEXIBLE-DOSE PHASE II/III 
STUDIES 
 
Percentage of Patients Reporting Event Adverse Event 
VIAGRA  [N=734] PLACEBO  [N=725] 
Headache 16% 4% 
Flushing 10% 1% 
Dyspepsia 7% 2% 
Nasal Congestion 4% 2% 
Urinary Tract Infection 3% 2% 
Abnormal Vision† 3% 0% 
Diarrhea 3% 1% 
Dizziness 2% 1% 
Rash 2% 1% 
†Abnormal Vision: Mild and transient, predominantly color tinge to vision, but also increased sensitivity to light or 
blurred vision. In these studies, only one patient discontinued due to abnormal vision. 
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 Potential Risks or Hazards for Research Participants 
The mainstay of surgical and medical management of all research participants before, 
during and after surgery will follow the normal clinical practice of their consultant cardiac 
surgeon, cardiologist and intensive care team. Possible disadvantages and risks would 
therefore be related to taking 4 oral doses of Sildenafil liquid (0.5mg/kg) the day before 
surgery. As we are not currently aware of any significant clinical side effects associated 
with oral Sildenafil at this dosage we do foresee any clinical disadvantages or side effects. 
We do not anticipate any potential for pain, discomfort, distress, inconvenience or changes 
to lifestyle directly related to taking part in this study. 
 
 Potential Benefit to Research Participants 
We anticipate that pre-operative Sildenafil will protect the lungs during cardiopulmonary 
bypass to improve lung function and reduce related complications post-operatively. 
Clinically this may manifest as reduced episodic pulmonary hypertension, improved 
hemodynamics, reduced ventilation period, reduced requirements of Sildenafil or iNO and 
reduced overall intensive care and hospital stay. All children undergoing corrective heart 
surgery are closely monitored throughout their admission. Although this will also be the 
case for all research participants they will undergo a more detailed echocardiographic 
assessment both before and after surgery, providing additional clinical information that 
may be beneficial to the caring medical team. 
 
Recording of Adverse Events 
Adverse event reporting will be undertaken throughout the admission period. All events 
will be evaluated for seriousness, followed until resolution, recorded and stored in the 
master file. Each individual adverse event will be discussed in detail by the CI, project 
supervisors and the Sponsor. Any serious adverse event that occurs after the study period 
and is considered to be related to the study treatment or study participation will be 
recorded and reported immediately. 
 
 Reporting of Serious Adverse Events 
All serious adverse events will be reported to the Sponsor by telephone (Dr Alison Wood, 
ext 86935) within 24 hrs of the event. A serious adverse event (SAE) form will also be 
completed by the PI and given to the Sponsor, a copy of which will be stored in the master 
file. 
 
 Study Sponsor Notification by Investigator 
All safety and adverse events (as defined in the Protocol) will be reported by the CI to the 
Sponsor via the arrangements set up by the Yorkhill R&D Office within 24hrs. 
 
 MHRA and REC Notification by Sponsor 
The Sponsor has delegated the task of reporting safety and adverse events to the MHRA 
and the REC to the Yorkhill R&D Department, who undertake to meet appropriate time-
lines for reporting to the relevant authorities. 
 
 Annual Safety Reports 
The Sponsor has delegated the task of providing the MHRA and the REC with an annual 
safety report on the investigational medicinal product used in the study to the Yorkhill 
R&D Department who will undertake to meet appropriate time-lines for reporting to the 
relevant authorities. 
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 Unblinding Procedures 
Any concerns with study participants should be highlighted to the CI or consultant cardiac 
surgeon responsible for their care in the first instance. In the event that the code needs to 
be broken to ensure subject’s safety the clinical trials technician will be available during 
normal working hours (9am-5pm) to provide the relevant information (Ms Sarah Casey, 
ext 89367). Between the hours of 5pm and 9am and during the weekend the on-call 
pharmacist at Yorkhill will undertake this responsibility. 
 
Stopping Rules 
The mainstay of clinical care will be unchanged by the participation in this study. Criteria 
for electively stopping the trial prematurely would be dependent on new contraindications 
to giving pre-operative Sildenafil arising in the literature or directly from the 
manufacturer. Adverse advents will be monitored throughout the trial by the CI and the 
pharmacy department at Yorkhill. In addition a midpoint review of the trial data will be 
undertaken to highlight any unforeseen issues. 
 
Medical Safety Monitoring 
The CI will undertake the responsibility of overseeing the safety of the study. In this 
respect a monitoring form will be constructed in conjunction with the clinical trials 
pharmacist and the R&D Department at Yorkhill Hospital prior to commencement of the 
study and attached to the protocol. This will include a regular assessment of the number 
and type of serious adverse events. 
 
 Data Handling and Record Keeping 
 
Confidentiality 
Information about study subjects will be kept confidential and managed according to the 
requirements of the Data Protection Act (1998). Informed consent will be obtained from 
the parents of research participants in accordance with regulations outlined in the stated 
act. In the event that authorisation to collect or use confidential information is revoked by 
a subject’s parents, the investigator, by regulation, will retain the ability to use all 
information collected prior to the revocation or subject authorisation. Additional attempts 
will be made in this situation to obtain permission to collect information on vital status at 
the end of the study. 
 
Individual patient’s samples will be labelled with an allocated patient number to maintain 
anonymity during analysis. All samples will be stored for the duration of the trial within 
the laboratory at Yorkhill. The CI and lab supervisor will have access to the stored 
samples. Results will be stored on a Yorkhill desktop computer based in Cardiology. 
 
Source Documentation 
All source documentation will be held by the CI in a trial master file. 
 
Case Report Forms 
An appropriate datasheet, detailing all mandatory data fields, will be constructed prior to 
commencement of the trial and attached to the study protocol. All missing data will be 
explained. 
 
Archiving/Record Retention 
Data will be archived for 10 years from the end of the study, in accordance with MRC 
guidelines on Good Research Practice. 
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 Study Monitoring, Auditing and Inspecting 
 
 Study Monitoring Plan 
The study will be largely self-monitored by the research team, following a monitoring plan 
agreed with the Sponsor of the study, NHS Greater Glasgow, Yorkhill Division. In 
addition, members of the Yorkhill R&D Department may attend study team meetings to 
discuss monitoring reports. 
 
 Auditing and Inspecting 
The PI will permit study-related monitoring, auditing and inspections by ethics 
committees, the Sponsor, regulatory bodies and the R&D Department of all study-related 
documents. 
 
Ethical Considerations 
This protocol and any amendments will be submitted to a properly constituted Research 
Ethics Committee (REC) in agreement with local legal prescriptions, for formal approval 
of study conduct. A copy of the documented decision of the REC concerning the conduct 
of the study will be provided to the Sponsor before commencement of the study. 
 
Parent’s whose children meet the entry criteria and who are willing to discuss the study 
further will be provided with a consent form describing this study and providing sufficient 
information to enable an informed decision about their child’s participation in this study. 
(Appendix 2) This consent form will be submitted with the protocol for review and 
approval by the REC for the study. The formal consent of a subject, using the REC-
approved consent form will be obtained before that subject is submitted to any study 
procedure. The consent form will be signed by the subject’s parents and the PI. 
 
Study Finances 
The study is being funding from a successful research grant application to the Yorkhill 
Children’s Foundation. As the study will not commence until R&D Management approval 
has been obtained, the study will be covered by the NHS CNORIS arrangements for acts 
of negligence. 
 
 Publication policy 
The primary responsibility for publication of the results of this study is held by the PI. 
Approval must be obtained directly from the PI before any information can be used or 
passed onto a third party. 
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6.2.2 Appendix 2: Investigational Medicinal Product Dossier (IMPD) 
 
 
 
 
 
INVESTIGATIONAL MEDICINAL PRODUCT DOSSIER (IMPD) 
 
 
 
 
 
 
Sponsor: NHS Greater Glasgow 
  Yorkhill Division, Royal Hospital for Sick Children 
  Dalnair Street, Glasgow G3 8SJ 
 
 
Drug Substance: VIAGRA (Sildenafil Citrate - discovered in 1989) 
 
 
Edition No: 1 
 
 
Date: 6 December 2005 
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LIST OF ABBREVIATIONS 
 
• cGMP : cyclic guanosine monophosphate 
• PDE5 : phosphodiesterase type 5 
• NO : nitric oxide 
• Tmax : time from administration to peak plasma concentration 
• Cmax : peak plasma concentration 
• Vss : volume of distribution 
• CLcr : creatinine clearance 
• AUC : area under the plasma concentration-time curve 
• ECG : electrocardiography 
• ED : erectile dysfunction 
• IIEF : the international index of erectile function 
• CABG : coronary artery bypass grafting 
• TURP : transurethral resection of the prostate 
• NAION : non-arteritic anterior ischaemic optic neuropathy 
• HIV : human immunodeficiency virus 
• MRHD : maximum recommended human daily dose 
• MTD : maximum tolerated dose 
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VIAGRA® (sildenafil citrate) 
Tablets 
 
 
1. DESCRIPTION 
VIAGRA®, an oral therapy for erectile dysfunction, is the citrate salt of sildenafil, a 
selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific 
phosphodiesterase type 5 (PDE5). Sildenafil citrate is designated chemically as 1-
[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1Hpyrazolo[4,3-d]pyrimidin-5-yl)-4-
ethoxyphenyl]sulfonyl]-4-methylpiperazine citrate and has the following structural 
formula:  
 
 
 
 
 
Sildenafil citrate is a white to off-white crystalline powder with a solubility of 3.5 
mg/mL in water and a molecular weight of 666.7. VIAGRA (sildenafil citrate) is 
formulated as blue, film-coated rounded-diamond-shaped tablets equivalent to 25 
mg, 50 mg and 100 mg of sildenafil for oral administration. In addition to the active 
ingredient, sildenafil citrate, each tablet contains the following inactive ingredients: 
microcrystalline cellulose, anhydrous dibasic calcium phosphate, croscarmellose 
sodium, magnesium stearate, hypromellose, titanium dioxide, lactose, triacetin, 
and FD & C Blue #2 aluminum lake. 
 
2. CLINICAL PHARMACOLOGY 
2.1 Mechanism of Action 
The physiologic mechanism of erection of the penis involves release of nitric oxide 
(NO) in the corpus cavernosum during sexual stimulation. NO then activates the 
enzyme guanylate cyclase, which results in increased levels of cyclic guanosine 
monophosphate (cGMP), producing smooth muscle relaxation in the corpus 
cavernosum and allowing inflow of blood. Sildenafil has no direct relaxant effect on 
isolated human corpus cavernosum, but enhances the effect of nitric oxide (NO) 
by inhibiting phosphodiesterase type 5 (PDE5), which is responsible for 
degradation of cGMP in the corpus cavernosum. When sexual stimulation causes 
local release of NO, inhibition of PDE5 by sildenafil causes increased levels of 
cGMP in the corpus cavernosum, resulting in smooth muscle relaxation and inflow 
of blood to the corpus cavernosum. Sildenafil at recommended doses has no 
effect in the absence of sexual stimulation. 
Studies in vitro have shown that sildenafil is selective for PDE5. Its effect is more 
potent on PDE5 than on other known phosphodiesterases (10-fold for PDE6, >80-
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fold for PDE1, >700-fold for PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, 
and PDE11). The approximately 4,000-fold selectivity for PDE5 versus PDE3 is 
important because PDE3 is involved in control of cardiac contractility. Sildenafil is 
only about 10-fold as potent for PDE5 compared to PDE6, an enzyme found in the 
retina which is involved in the phototransduction pathway of the retina. This lower 
selectivity is thought to be the basis for abnormalities related to color vision 
observed with higher doses or plasma levels (see Pharmacodynamics). In addition 
to human corpus cavernosum smooth muscle, PDE5 is also found in lower 
concentrations in other tissues including platelets, vascular and visceral smooth 
muscle, and skeletal muscle. The inhibition of PDE5 in these tissues by sildenafil 
may be the basis for the enhanced platelet antiaggregatory activity of nitric oxide 
observed in vitro, an inhibition of platelet thrombus formation in vivo and peripheral 
arterial-venous dilatation in vivo.  
 
2.2 Pharmacokinetics and Metabolism 
VIAGRA is rapidly absorbed after oral administration, with absolute bioavailability 
of about 40%. Its pharmacokinetics are dose-proportional over the recommended 
dose range. It is eliminated predominantly by hepatic metabolism (mainly 
cytochrome P450 3A4) and is converted to an active metabolite with properties 
similar to the parent, sildenafil. The concomitant use of potent cytochrome P450 
3A4 inhibitors (e.g., erythromycin, ketoconazole, itraconazole) as well as the 
nonspecific CYP inhibitor, cimetidine, is associated with increased plasma levels 
of sildenafil (see DOSAGE AND ADMINISTRATION). Both sildenafil and the 
metabolite have terminal half lives of about 4 hours. 
 
Mean sildenafil plasma concentrations measured after the administration of a 
single oral dose of 100 mg to healthy male volunteers is depicted below: 
 
 
Figure 1: Mean Sildenafil Plasma Concentrations n Healthy Male Volunteers. 
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2.3  Absorption and Distribution 
VIAGRA is rapidly absorbed. Maximum observed plasma concentrations are 
reached within 30 to 120 minutes (median 60 minutes) of oral dosing in the fasted 
state. When VIAGRA is taken with a high fat meal, the rate of absorption is 
reduced, with a mean delay in Tmax of 60 minutes and a mean reduction in Cmax 
of 29%. The mean steady state volume of distribution (Vss) for sildenafil is 105 L, 
indicating distribution into the tissues. Sildenafil and its major circulating N-
desmethyl metabolite are both approximately 96% bound to plasma proteins. 
Protein binding is independent of total drug concentrations. Based upon 
measurements of sildenafil in semen of healthy volunteers 90 minutes after 
dosing, less than 0.001% of the administered dose may appear in the semen of 
patients.  
 
2.4 Metabolism and Excretion 
Sildenafil is cleared predominantly by the CYP3A4 (major route) and CYP2C9 
(minor route) hepatic microsomal isoenzymes. The major circulating metabolite 
results from N-desmethylation of sildenafil, and is itself further metabolized. This 
metabolite has a PDE selectivity profile similar to sildenafil and an in vitro potency 
for PDE5 approximately 50% of the parent drug. Plasma concentrations of this 
metabolite are approximately 40% of those seen for sildenafil, so that the 
metabolite accounts for about 20% of sildenafil’s pharmacologic effects. After 
either oral or intravenous administration, sildenafil is excreted as metabolites 
predominantly in the feces (approximately 80% of administered oral dose) and to a 
lesser extent in the urine (approximately 13% of the administered oral dose). 
Similar values for pharmacokinetic parameters were seen in normal volunteers 
and in the patient population, using a population pharmacokinetic approach. 
 
2.5 Pharmacokinetics in Special Populations 
Geriatrics: Healthy elderly volunteers (65 years or over) had a reduced clearance 
of sildenafil, with free plasma concentrations approximately 40% greater than 
those seen in healthy younger volunteers (18-45 years). 
 
Renal Insufficiency: In volunteers with mild (CLcr=50-80 mL/min) and moderate 
(CLcr=30-49 mL/min) renal impairment, the pharmacokinetics of a single oral dose 
of VIAGRA (50 mg) were not altered. In volunteers with severe (CLcr=<30 mL/min) 
renal impairment, sildenafil clearance was reduced, resulting in approximately 
doubling of AUC and Cmax compared to age-matched volunteers with no renal 
impairment. 
 
Hepatic Insufficiency: In volunteers with hepatic cirrhosis (Child-Pugh A and B), 
sildenafil clearance was reduced, resulting in increases in AUC (84%) and Cmax 
(47%) compared to age-matched volunteers with no hepatic impairment. 
 
Therefore, age >65, hepatic impairment and severe renal impairment are 
associated with increased plasma levels of sildenafil. A starting oral dose of 25 mg 
should be considered in those patients (see DOSAGE AND ADMINISTRATION). 
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3. PHARMACODYNAMICS 
3.1 Effects of VIAGRA on Erectile Response 
In eight double-blind, placebo-controlled crossover studies of patients with either 
organic or psychogenic erectile dysfunction, sexual stimulation resulted in 
improved erections, as assessed by an objective measurement of hardness and 
duration of erections (RigiScan®), after VIAGRA administration compared with 
placebo. Most studies assessed the efficacy of VIAGRA approximately 60 minutes 
post dose. The erectile response, as assessed by RigiScan®, generally increased 
with increasing sildenafil dose and plasma concentration. The time course of effect 
was examined in one study, showing an effect for up to 4 hours but the response 
was diminished compared to 2 hours. 
 
3.2 Effects of VIAGRA on Blood Pressure 
Single oral doses of sildenafil (100 mg) administered to healthy volunteers 
produced decreases in supine blood pressure (mean maximum decrease in 
systolic/diastolic blood pressure of 8.4/5.5 mmHg). The decrease in blood 
pressure was most notable approximately 1-2 hours after dosing, and was not 
different than placebo at 8 hours. Similar effects on blood pressure were noted 
with 25 mg, 50 mg and 100 mg of VIAGRA, therefore the effects are not related to 
dose or plasma levels within this dosage range. Larger effects were recorded 
among patients receiving concomitant nitrates (see CONTRAINDICATIONS). 
 
 
Figure 2: Mean Change from Baseline in Sitting Systolic Blood Pressure, Healthy Volunteers. 
 
 
3.3 Effects of VIAGRA on Cardiac Parameters 
Single oral doses of sildenafil up to 100 mg produced no clinically relevant 
changes in the ECGs of normal male volunteers. Studies have produced relevant 
data on the effects of VIAGRA on cardiac output. In one small, open-label, 
uncontrolled, pilot study, eight patients with stable ischemic heart disease 
underwent Swan-Ganz catheterization. A total dose of 40 mg sildenafil was 
administered by four intravenous infusions. 
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The results from this pilot study are shown in Table 1; the mean resting systolic 
and diastolic blood pressures decreased by 7% and 10% compared to baseline in 
these patients. Mean resting values for right atrial pressure, pulmonary artery 
pressure, pulmonary artery occluded pressure and cardiac output decreased by 
28%, 28%, 20% and 7% respectively. Even though this total dosage produced 
plasma sildenafil concentrations which were approximately 2 to 5 times higher 
than the mean maximum plasma concentrations following a single oral dose of 
100 mg in healthy male volunteers, the hemodynamic response to exercise was 
preserved in these patients. 
 
TABLE 1. HEMODYNAMIC DATA IN PATIENTS WITH STABLE ISCHEMIC HEART 
DISEASE AFTER IV ADMINISTRATION OF 40 MG SILDENAFIL 
 
 
 
In a double-blind study, 144 patients with erectile dysfunction and chronic stable 
angina limited by exercise, not receiving chronic oral nitrates, were randomized to 
a single dose of placebo or VIAGRA 100 mg 1 hour prior to exercise testing. The 
primary endpoint was time to limiting angina in the evaluable cohort. The mean 
times (adjusted for baseline) to onset of limiting angina were 423.6 and 403.7 
seconds for sildenafil (N=70) and placebo, respectively. These results 
demonstrated that the effect of VIAGRA on the primary endpoint was statistically 
non-inferior to placebo.  
 
3.4 Effects of VIAGRA on Vision  
At single oral doses of 100 mg and 200 mg, transient dose-related impairment of 
color discrimination (blue/green) was detected using the Farnsworth-Munsell 100-
hue test, with peak effects near the time of peak plasma levels. This finding is 
consistent with the inhibition of PDE6, which is involved in phototransduction in the 
retina. An evaluation of visual function at doses up to twice the maximum 
recommended dose revealed no effects of VIAGRA on visual acuity, intraocular 
pressure, or pupillometry.  
 
4. CLINICAL STUDIES 
In clinical studies, VIAGRA was assessed for its effect on the ability of men with 
erectile dysfunction (ED) to engage in sexual activity and in many cases 
specifically on the ability to achieve and maintain an erection sufficient for 
satisfactory sexual activity. VIAGRA was evaluated primarily at doses of 25 mg, 50 
mg and 100 mg in 21 randomized, double-blind, placebo-controlled trials of up to 6 
months in duration, using a variety of study designs (fixed dose, titration, parallel, 
crossover). VIAGRA was administered to more than 3,000 patients aged 19 to 87 
years, with ED of various etiologies (organic, psychogenic, and mixed) with a 
mean duration of 5 years. VIAGRA demonstrated statistically significant 
End Organ Effects of Paediatric Cardiopulmonary Bypass         Page 159 of 192 
 
Tony Vassalos  2010 
improvement compared to placebo in all 21 studies. The studies that established 
benefit demonstrated improvements in success rates for sexual intercourse 
compared with placebo.  
 
The effectiveness of VIAGRA was evaluated in most studies using several 
assessment instruments. The primary measure in the principal studies was a 
sexual function questionnaire (the International Index of Erectile Function - IIEF) 
administered during a 4-week treatment-free run-in period, at baseline, at follow-
up visits, and at the end of double-blind, placebo-controlled, at-home treatment. 
Two of the questions from the IIEF served as primary study endpoints; categorical 
responses were elicited to questions about (1) the ability to achieve erections 
sufficient for sexual intercourse and (2) the maintenance of erections after 
penetration. The patient addressed both questions at the final visit for the last 4 
weeks of the study. The possible categorical responses to these questions were 
(0) no attempted intercourse, (1) never or almost never, (2) a few times, (3) 
sometimes, (4) most times, and (5) almost always or always. Also collected as part 
of the IIEF was information about other aspects of sexual function, including 
information on erectile function, orgasm, desire, satisfaction with intercourse, and 
overall sexual satisfaction. Sexual function data were also recorded by patients in 
a daily diary. In addition, patients were asked a global efficacy question and an 
optional partner questionnaire was administered. 
 
The effect on one of the major end points, maintenance of erections after 
penetration, is shown in Figure 3, for the pooled results of 5 fixed-dose, dose-
response studies of greater than one month duration, showing response according 
to baseline function. Results with all doses have been pooled, but scores showed 
greater improvement at the 50 and 100 mg doses than at 25 mg. The pattern of 
responses was similar for the other principal question, the ability to achieve an 
erection sufficient for intercourse. The titration studies, in which most patients 
received 100 mg, showed similar results. Figure 3 shows that regardless of the 
baseline levels of function, subsequent function in patients treated with VIAGRA 
was better than that seen in patients treated with placebo. At the same time, on-
treatment function was better in treated patients who were less impaired at 
baseline. 
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Figure 3. Effect of VIAGRA and Placebo on Maintenance of Erection by Baseline Score 
 
 
The frequency of patients reporting improvement of erections in response to a 
global question in four of the randomized, double-blind, parallel, placebo-controlled 
fixed dose studies (1797 patients) of 12 to 24 weeks duration is shown in Figure 4. 
These patients had erectile dysfunction at baseline that was characterized by 
median categorical scores of 2 (a few times) on principal IIEF questions. Erectile 
dysfunction was attributed to organic (58%; generally not characterized, but 
including diabetes and excluding spinal cord injury), psychogenic (17%), or mixed 
(24%) etiologies. Sixty-three percent, 74%, and 82% of the patients on 25 mg, 50 
mg and 100 mg of VIAGRA, respectively, reported an improvement in their 
erections, compared to 24% on placebo. In the titration studies (n=644) (with most 
patients eventually receiving 100 mg), results were similar. 
 
 
Figure 4. Percentage of Patients Reporting an Improvement in Erections. 
 
The patients in studies had varying degrees of ED. One-third to one-half of the 
subjects in these studies reported successful intercourse at least once during a 4-
week, treatment-free run-in period.  
In many of the studies, of both fixed dose and titration designs, daily diaries were 
kept by patients. In these studies, involving about 1600 patients, analyses of 
patient diaries showed no effect of VIAGRA on rates of attempted intercourse 
(about 2 per week), but there was clear treatment-related improvement in sexual 
function: per patient weekly success rates averaged 1.3 on 50-100 mg of VIAGRA 
vs. 0.4 on placebo; similarly, group mean success rates (total successes divided 
by total attempts) were about 66% on VIAGRA vs about 20% on placebo. 
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During 3 to 6 months of double-blind treatment or longer-term (1 year), open-label 
studies, few patients withdrew from active treatment for any reason, including lack 
of effectiveness. At the end of the long-term study, 88% of patients reported that 
VIAGRA improved their erections.  
 
Men with untreated ED had relatively low baseline scores for all aspects of sexual 
function measured (again using a 5-point scale) in the IIEF. VIAGRA improved 
these aspects of sexual function: frequency, firmness and maintenance of 
erections; frequency of orgasm; frequency and level of desire; frequency, 
satisfaction and enjoyment of intercourse; and overall relationship satisfaction.  
 
One randomized, double-blind, flexible-dose, placebo-controlled study included 
only patients with erectile dysfunction attributed to complications of diabetes 
mellitus (n=268). As in the other titration studies, patients were started on 50 mg 
and allowed to adjust the dose up to 100 mg or down to 25 mg of VIAGRA; all 
patients, however, were receiving 50 mg or 100 mg at the end of the study. There 
were highly statistically significant improvements on the two principal IIEF 
questions (frequency of successful penetration during sexual activity and 
maintenance of erections after penetration) on VIAGRA compared to placebo. On 
a global improvement question, 57% of VIAGRA patients reported improved 
erections versus 10% on placebo. Diary data indicated that on VIAGRA, 48% of 
intercourse attempts were successful versus 12% on placebo. 
 
One randomized, double-blind, placebo-controlled, crossover, flexible-dose (up to 
100 mg) study of patients with erectile dysfunction resulting from spinal cord injury 
(n=178) was conducted. The changes from baseline in scoring on the two end 
point questions (frequency of successful penetration during sexual activity and 
maintenance of erections after penetration) were highly statistically significantly in 
favor of VIAGRA. On a global improvement question, 83% of patients reported 
improved erections on VIAGRA versus 12% on placebo. Diary data indicated that 
on VIAGRA, 59% of attempts at sexual intercourse were successful compared to 
13% on placebo.  
 
Across all trials, VIAGRA improved the erections of 43% of radical prostatectomy 
patients compared to 15% on placebo.  
 
Subgroup analyses of responses to a global improvement question in patients with 
psychogenic etiology in two fixed-dose studies (total n=179) and two titration 
studies (total n=149) showed 84% of VIAGRA patients reported improvement in 
erections compared with 26% of placebo. The changes from baseline in scoring on 
the two end point questions (frequency of successful penetration during sexual 
activity and maintenance of erections after penetration) were highly statistically 
significantly in favor of VIAGRA. Diary data in two of the studies (n=178) showed 
rates of successful intercourse per attempt of 70% for VIAGRA and 29% for 
placebo. 
 
A review of population subgroups demonstrated efficacy regardless of baseline 
severity, etiology, race and age. VIAGRA was effective in a broad range of ED 
patients, including those with a history of coronary artery disease, hypertension, 
other cardiac disease, peripheral vascular disease, diabetes mellitus, depression, 
coronary artery bypass graft (CABG), radical prostatectomy, transurethral 
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resection of the prostate (TURP) and spinal cord injury, and in patients taking 
antidepressants / antipsychotic and antihypertensive / diuretics. 
 
Analysis of the safety database showed no apparent difference in the side effect 
profile in patients taking VIAGRA with and without antihypertensive medication. 
This analysis was performed retrospectively, and was not powered to detect any 
pre-specified difference in adverse reactions. 
 
5. INDICATION AND USAGE 
VIAGRA is indicated for the treatment of erectile dysfunction. 
 
6. CONTRAINDICATIONS 
Consistent with its known effects on the nitric oxide/cGMP pathway (see 
CLINICAL PHARMACOLOGY), VIAGRA was shown to potentiate the hypotensive 
effects of nitrates, and its administration to patients who are using organic nitrates, 
either regularly and/or intermittently, in any form is therefore contraindicated.  
 
After patients have taken VIAGRA, it is unknown when nitrates, if necessary, can 
be safely administered. Based on the pharmacokinetic profile of a single 100 mg 
oral dose given to healthy normal volunteers, the plasma levels of sildenafil at 24 
hours post dose are approximately 2 ng/ml (compared to peak plasma levels of 
approximately 440 ng/mL) (see CLINICAL PHARMACOLOGY: Pharmacokinetics 
and Metabolism). In the following patients: age >65, hepatic impairment (e.g., 
cirrhosis), severe renal impairment (e.g., creatinine clearance <30 mL/min), and 
concomitant use of potent cytochrome P450 3A4 inhibitors (erythromycin), plasma 
levels of sildenafil at 24 hours post dose have been found to be 3 to 8 times higher 
than those seen in healthy volunteers. Although plasma levels of sildenafil at 24 
hours post dose are much lower than at peak concentration, it is unknown whether 
nitrates can be safely co-administered at this time point. VIAGRA is 
contraindicated in patients with a known hypersensitivity to any component of the 
tablet. 
 
7. WARNINGS 
There is a potential for cardiac risk of sexual activity in patients with preexisting 
cardiovascular disease. Therefore, treatments for erectile dysfunction, including 
VIAGRA, should not be generally used in men for whom sexual activity is 
inadvisable because of their underlying cardiovascular status. 
VIAGRA has systemic vasodilatory properties that resulted in transient decreases 
in supine blood pressure in healthy volunteers (mean maximum decrease of 
8.4/5.5 mmHg), (see CLINICAL PHARMACOLOGY: Pharmacodynamics). While 
this normally would be expected to be of little consequence in most patients, prior 
to prescribing VIAGRA, physicians should carefully consider whether their patients 
with underlying cardiovascular disease could be affected adversely by such 
vasodilatory effects, especially in combination with sexual activity. 
 
Patients with the following underlying conditions can be particularly sensitive to the 
actions of 
vasodilators including VIAGRA – those with left ventricular outflow obstruction 
(e.g. aortic stenosis, idiopathic hypertrophic subaortic stenosis) and those with 
severely impaired autonomic control of blood pressure. There is no controlled 
clinical data on the safety or efficacy of VIAGRA in the following groups; if 
prescribed, this should be done with caution. 
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•  Patients who have suffered a myocardial infarction, stroke, or life-threatening 
arrhythmia within the last 6 months; 
•  Patients with resting hypotension (BP <90/50) or hypertension (BP >170/110); 
•  Patients with cardiac failure or coronary artery disease causing unstable angina; 
•  Patients with retinitis pigmentosa (a minority of these patients have genetic 
disorders of retinal phosphodiesterases). 
 
Prolonged erection greater than 4 hours and priapism (painful erections greater 
than 6 hours in duration) have been reported infrequently since market approval of 
VIAGRA. In the event of an erection that persists longer than 4 hours, the patient 
should seek immediate medical assistance. If priapism is not treated immediately, 
penile tissue damage and permanent loss of potency could result. 
 
The concomitant administration of the protease inhibitor ritonavir substantially 
increases serum concentrations of sildenafil (11-fold increase in AUC). If VIAGRA 
is prescribed to patients taking ritonavir, caution should be used. Data from 
subjects exposed to high systemic levels of sildenafil are limited. Visual 
disturbances occurred more commonly at higher levels of sildenafil exposure. 
Decreased blood pressure, syncope, and prolonged erection were reported in 
some healthy volunteers exposed to high doses of sildenafil (200-800 mg). To 
decrease the chance of adverse events in patients taking ritonavir, a decrease in 
sildenafil dosage is recommended (see Drug Interactions, ADVERSE 
REACTIONS and DOSAGE AND ADMINISTRATION). 
 
8. PRECAUTIONS 
8.1 General 
The evaluation of erectile dysfunction should include a determination of potential 
underlying causes and the identification of appropriate treatment following a 
complete medical assessment.  
 
Before prescribing VIAGRA, it is important to note the following: 
 
Patients on multiple antihypertensive medications were included in the pivotal 
clinical trials for VIAGRA. In a separate drug interaction study, when amlodipine, 5 
mg or 10 mg, and VIAGRA, 100 mg were orally administered concomitantly to 
hypertensive patients mean additional blood pressure reduction of 8 mmHg 
systolic and 7 mmHg diastolic were noted (see Drug Interactions). 
 
When the alpha blocker doxazosin (4 mg) and VIAGRA (25 mg) were 
administered simultaneously to patients with benign prostatic hyperplasia (BPH), 
mean additional reductions of supine blood pressure of 7 mmHg systolic and 7 
mmHg diastolic were observed. When higher doses of VIAGRA and doxazosin (4 
mg) were administered simultaneously, there were infrequent reports of patients 
who experienced symptomatic postural hypotension within 1 to 4 hours of dosing. 
Simultaneous administration of VIAGRA to patients taking alpha-blocker therapy 
may lead to symptomatic hypotension in some patients. Therefore, VIAGRA doses 
above 25 mg should not be taken within 4 hours of taking an alpha-blocker. 
 
The safety of VIAGRA is unknown in patients with bleeding disorders and patients 
with active peptic ulceration. 
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VIAGRA should be used with caution in patients with anatomical deformation of 
the penis (such as angulation, cavernosal fibrosis or Peyronie’s disease), or in 
patients who have conditions which may predispose them to priapism (such as 
sickle cell anemia, multiple myeloma, or leukemia). 
 
The safety and efficacy of combinations of VIAGRA with other treatments for 
erectile dysfunction have not been studied. Therefore, the use of such 
combinations is not recommended. 
 
In humans, VIAGRA has no effect on bleeding time when taken alone or with 
aspirin. In vitro studies with human platelets indicate that sildenafil potentiates the 
antiaggregatory effect of sodium nitroprusside (a nitric oxide donor). The 
combination of heparin and VIAGRA had an additive effect on bleeding time in the 
anesthetized rabbit, but this interaction has not been studied in humans. 
 
8.2 Information for Patients 
Physicians should discuss with patients the contraindication of VIAGRA with 
regular and/or 
intermittent use of organic nitrates. Physicians should discuss with patients the 
potential cardiac risk of sexual activity in patients with preexisting cardiovascular 
risk factors. Patients who experience symptoms (e.g., angina pectoris, dizziness, 
nausea) upon initiation of sexual activity should be advised to refrain from further 
activity and should discuss the episode with their physician. 
 
Physicians should advise patients to stop use of all PDE5 inhibitors, including 
VIAGRA, and seek medical attention in the event of a sudden loss of vision in one 
or both eyes. Such an event may be a sign of non-arteritic anterior ischemic optic 
neuropathy (NAION), a cause of decreased vision including permanent loss of 
vision, that has been reported rarely post-marketing in temporal association with 
the use of all PDE5 inhibitors. It is not possible to determine whether these events 
are related directly to the use of PDE5 inhibitors or to other factors. Physicians 
should also discuss with patients the increased risk of NAION in individuals who 
have already experienced NAION in one eye, including whether such individuals 
could be adversely affected by use of vasodilators, such as PDE5 inhibitors (see 
POST-MARKETING EXPERIENCE/Special Senses). Physicians should warn 
patients that prolonged erections greater than 4 hours and priapism (painful 
erections greater than 6 hours in duration) have been reported infrequently since 
market approval of VIAGRA. In the event of an erection that persists longer than 4 
hours, the patient should seek immediate medical assistance. If priapism is not 
treated immediately, penile tissue damage and permanent loss of potency may 
result. 
 
Physicians should advise patients that simultaneous administration of VIAGRA 
doses above 25 mg and an alpha-blocker may lead to symptomatic hypotension in 
some patients. Therefore, VIAGRA doses above 25 mg should not be taken within 
four hours of taking an alpha-blocker. 
 
The use of VIAGRA offers no protection against sexually transmitted diseases. 
Counseling of patients about the protective measures necessary to guard against 
sexually transmitted diseases, including the Human Immunodeficiency Virus (HIV), 
may be considered. 
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9. Drug Interactions 
9.1 Effects of Other Drugs on VIAGRA 
In vitro studies: Sildenafil metabolism is principally mediated by the cytochrome 
P450 (CYP) 
isoforms 3A4 (major route) and 2C9 (minor route). Therefore, inhibitors of these 
isoenzymes may reduce sildenafil clearance. 
 
In vivo studies: Cimetidine (800 mg), a nonspecific CYP inhibitor, caused a 56% 
increase in plasma sildenafil concentrations when coadministered with VIAGRA 
(50 mg) to healthy volunteers. 
 
When a single 100 mg dose of VIAGRA was administered with erythromycin, a 
specific CYP3A4 inhibitor, at steady state (500 mg bid for 5 days), there was a 
182% increase in sildenafil systemic exposure (AUC). In addition, in a study 
performed in healthy male volunteers, co-administration of the HIV protease 
inhibitor saquinavir, also a CYP3A4 inhibitor, at steady state (1200 mg tid) with 
VIAGRA (100 mg single dose) resulted in a 140% increase in sildenafil Cmax and 
a 210% increase in sildenafil AUC. VIAGRA had no effect on saquinavir 
pharmacokinetics. Stronger CYP3A4 inhibitors such as ketoconazole or 
itraconazole would be expected to have still greater effects, and population data 
from patients in clinical trials did indicate a reduction in sildenafil clearance when it 
was co-administered with CYP3A4 inhibitors (such as ketoconazole, erythromycin, 
or cimetidine) (see DOSAGE AND ADMINISTRATION). 
 
In another study in healthy male volunteers, co-administration with the HIV 
protease inhibitor ritonavir, which is a highly potent P450 inhibitor, at steady state 
(500 mg bid) with VIAGRA (100 mg single dose) resulted in a 300% (4-fold) 
increase in sildenafil Cmax and a 1000% (11-fold) increase in sildenafil plasma 
AUC. At 24 hours the plasma levels of sildenafil were still approximately 200 
ng/mL, compared to approximately 5 ng/mL when sildenafil was dosed alone. This 
is consistent with ritonavir’s marked effects on a broad range of P450 substrates. 
VIAGRA had no effect on ritonavir pharmacokinetics (see DOSAGE AND 
ADMINISTRATION). 
 
Although the interaction between other protease inhibitors and sildenafil has not 
been studied, their concomitant use is expected to increase sildenafil levels.  
 
It can be expected that concomitant administration of CYP3A4 inducers, such as 
rifampin, will decrease plasma levels of sildenafil.  
 
Single doses of antacid (magnesium hydroxide/aluminum hydroxide) did not affect 
the bioavailability of VIAGRA.  
 
Pharmacokinetic data from patients in clinical trials showed no effect on sildenafil 
pharmacokinetics of CYP2C9 inhibitors (such as tolbutamide, warfarin), CYP2D6 
inhibitors (such as selective serotonin reuptake inhibitors, tricyclic 
antidepressants), thiazide and related diuretics, ACE inhibitors, and calcium 
channel blockers. The AUC of the active metabolite, N-desmethyl sildenafil, was 
increased 62% by loop and potassium-sparing diuretics and 102% by nonspecific 
beta-blockers. These effects on the metabolite are not expected to be of clinical 
consequence. 
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9.2 Effects of VIAGRA on Other Drugs 
In vitro studies: Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 
2C9, 2C19, 2D6, 2E1 and 3A4 (IC50 >150 µM). Given sildenafil peak plasma 
concentrations of approximately 1 µM after recommended doses, it is unlikely that 
VIAGRA will alter the clearance of substrates of these isoenzymes.  
 
In vivo studies: When VIAGRA 100 mg oral was coadministered with amlodipine, 5 
mg or 10 mg oral, to hypertensive patients, the mean additional reduction on 
supine blood pressure was 8 mmHg  systolic and 7 mmHg diastolic. No significant 
interactions were shown with tolbutamide (250 mg) or warfarin (40 mg), both of 
which are metabolized by CYP2C9. 
 
VIAGRA (50 mg) did not potentiate the increase in bleeding time caused by aspirin 
(150 mg). 
 
VIAGRA (50 mg) did not potentiate the hypotensive effect of alcohol in healthy 
volunteers with mean maximum blood alcohol levels of 0.08%. 
 
In a study of healthy male volunteers, sildenafil (100 mg) did not affect the steady 
state pharmacokinetics of the HIV protease inhibitors, saquinavir and ritonavir, 
both of which are CYP3A4 substrates. 
 
9.3 Carcinogenesis, Mutagenesis, Impairment of Fertility 
Sildenafil was not carcinogenic when administered to rats for 24 months at a dose 
resulting in total systemic drug exposure (AUCs) for unbound sildenafil and its 
major metabolite of 29- and 42-times, for male and female rats, respectively, the 
exposures observed in human males given the Maximum Recommended Human 
Dose (MRHD) of 100 mg. Sildenafil was not carcinogenic when administered to 
mice for 18-21 months at dosages up to the Maximum Tolerated Dose (MTD) of 
10 mg/kg/day, approximately 0.6 times the MRHD on a mg/m2 basis.  
 
Sildenafil was negative in in vitro bacterial and Chinese hamster ovary cell assays 
to detect mutagenicity, and in vitro human lymphocytes and in vivo mouse 
micronucleus assays to detect clastogenicity. 
 
There was no impairment of fertility in rats given sildenafil up to 60 mg/kg/day for 
36 days to females and 102 days to males, a dose producing an AUC value of 
more than 25 times the human male AUC. There was no effect on sperm motility 
or morphology after single 100 mg oral doses of VIAGRA in healthy volunteers. 
 
9.4 Pregnancy, Nursing Mothers and Pediatric Use 
VIAGRA is not indicated for use in newborns, children, or women. 
 
9.5 Pregnancy Category B.  
No evidence of teratogenicity, embryotoxicity or fetotoxicity was observed in rats 
and rabbits which received up to 200 mg/kg/day during organogenesis. These 
doses represent, respectively, about 20 and 40 times the MRHD on a mg/m2 basis 
in a 50 kg subject. In the rat pre- and postnatal development study, the no 
observed adverse effect dose was 30 mg/kg/day given for 36 days. In the 
nonpregnant rat the AUC at this dose was about 20 times human AUC. There are 
no adequate and well-controlled studies of sildenafil in pregnant women. 
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9.6 Geriatric Use 
Healthy elderly volunteers (65 years or over) had a reduced clearance of sildenafil 
(see CLINICAL PHARMACOLOGY: Pharmacokinetics in Special Populations). 
Since higher plasma levels may increase both the efficacy and incidence of 
adverse events, a starting dose of 25 mg should be considered (see DOSAGE 
AND ADMINISTRATION). 
 
10 ADVERSE REACTIONS 
10.1 Pre-marketing experience 
VIAGRA was administered to over 3700 patients (aged 19-87 years) during clinical 
trials worldwide. Over 550 patients were treated for longer than one year. 
 
In placebo-controlled clinical studies, the discontinuation rate due to adverse 
events for VIAGRA (2.5%) was not significantly different from placebo (2.3%). The 
adverse events were generally transient and mild to moderate in nature. 
 
In trials of all designs, adverse events reported by patients receiving VIAGRA were 
generally similar. In fixed-dose studies, the incidence of some adverse events 
increased with dose. The nature of the adverse events in flexible-dose studies, 
which more closely reflect the recommended dosage regimen, was similar to that 
for fixed-dose studies. 
 
 
When VIAGRA was taken as recommended (on an as-needed basis) in flexible-
dose, placebo-controlled clinical trials, the following adverse events were reported: 
 
TABLE 2. ADVERSE EVENTS REPORTED BY ≥2% OF PATIENTS TREATED WITH VIAGRA 
AND MORE FREQUENT ON DRUG THAN PLACEBO IN PRN FLEXIBLE-DOSE PHASE II/III 
STUDIES 
 
 
 
†Abnormal Vision: Mild and transient, predominantly color tinge to vision, but also increased 
sensitivity to light or blurred vision. In these studies, only one patient discontinued due to abnormal 
vision. 
 
 
 
 
Other adverse reactions occurred at a rate of >2%, but equally common on 
placebo: respiratory tract infection, back pain, flu syndrome, and arthralgia. 
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In fixed-dose studies, dyspepsia (17%) and abnormal vision (11%) were more 
common at 100 mg than at lower doses. At doses above the recommended dose 
range, adverse events were similar to those detailed above but generally were 
reported more frequently. 
 
The following events occurred in <2% of patients in controlled clinical trials; a 
causal relationship to VIAGRA is uncertain. Reported events include those with a 
plausible relation to drug use; omitted are minor events and reports too imprecise 
to be meaningful: 
 
Body as a whole: face edema, photosensitivity reaction, shock, asthenia, pain, 
chills, accidental fall, abdominal pain, allergic reaction, chest pain, accidental 
injury.  
 
Cardiovascular: angina pectoris, AV block, migraine, syncope, tachycardia, 
palpitation, hypotension, postural hypotension, myocardial ischemia, cerebral 
thrombosis, cardiac arrest, heart failure, abnormal electrocardiogram, 
cardiomyopathy. 
 
Digestive: vomiting, glossitis, colitis, dysphagia, gastritis, gastroenteritis, 
esophagitis, stomatitis, dry mouth, liver function tests abnormal, rectal 
hemorrhage, gingivitis. 
Hemic and Lymphatic: anemia and leukopenia. 
 
Metabolic and Nutritional: thirst, edema, gout, unstable diabetes, hyperglycemia, 
peripheral edema, hyperuricemia, hypoglycemic reaction, hypernatremia. 
Musculoskeletal: arthritis, arthrosis, myalgia, tendon rupture, tenosynovitis, bone 
pain, myasthenia, synovitis. 
 
Nervous: ataxia, hypertonia, neuralgia, neuropathy, paresthesia, tremor, vertigo, 
depression, insomnia, somnolence, abnormal dreams, reflexes decreased, 
hypesthesia. 
 
Respiratory: asthma, dyspnea, laryngitis, pharyngitis, sinusitis, bronchitis, sputum 
increased, cough increased. 
 
Skin and Appendages: urticaria, herpes simplex, pruritus, sweating, skin ulcer, 
contact dermatitis, exfoliative dermatitis.  
 
Special Senses: mydriasis, conjunctivitis, photophobia, tinnitus, eye pain, 
deafness, ear pain, eye hemorrhage, cataract, dry eyes. 
 
Urogenital: cystitis, nocturia, urinary frequency, breast enlargement, urinary 
incontinence, abnormal ejaculation, genital edema and anorgasmia. 
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10.3 Post-marketing experience 
Cardiovascular and cerebrovascular: serious cardiovascular, cerebrovascular, and 
vascular events, including myocardial infarction, sudden cardiac death, ventricular 
arrhythmia, cerebrovascular hemorrhage, transient ischemic attack, hypertension, 
subarachnoid and intracerebral hemorrhages, and pulmonary hemorrhage have 
been reported post-marketing in temporal association with the use of VIAGRA. 
Most, but not all, of these patients had preexisting cardiovascular risk factors. 
Many of these events were reported to occur during or shortly after sexual activity, 
and a few were reported to occur shortly after the use of VIAGRA without sexual 
activity. Others were reported to have occurred hours to days after the use of 
VIAGRA and sexual activity. It is not possible to determine whether these events 
are related directly to VIAGRA, to sexual activity, to the patient’s underlying 
cardiovascular disease, to a combination of these factors, or to other factors (see 
WARNINGS for further important cardiovascular information). 
 
Other events reported post-marketing to have been observed in temporal 
association with VIAGRA and not listed in the pre-marketing adverse reactions 
section above include: 
 
Nervous: seizure and anxiety. 
 
Urogenital: prolonged erection, priapism (see WARNINGS) and hematuria. 
 
Special Senses: diplopia, temporary vision loss/decreased vision, ocular redness 
or bloodshot appearance, ocular burning, ocular swelling/pressure, increased 
intraocular pressure, retinal vascular disease or bleeding, vitreous 
detachment/traction, paramacular edema and epistaxis.  
 
Non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased 
vision including permanent loss of vision, has been reported rarely post-marketing 
in temporal association with the use of phosphodiesterase type 5 (PDE5) 
inhibitors, including VIAGRA. Most, but not all, of these patients had underlying 
anatomic or vascular risk factors for developing NAION, including but not 
necessarily limited to: low cup to disc ratio (“crowded disc”), age over 50, diabetes, 
hypertension, coronary artery disease, hyperlipidemia and smoking. It is not 
possible to determine whether these events are related directly to the use of PDE5 
inhibitors, to the patient’s underlying vascular risk factors or anatomical defects, to 
a combination of these factors, or to other factors (see 
PRECAUTIONS/Information for Patients). 
 
11. OVERDOSAGE 
In studies with healthy volunteers of single doses up to 800 mg, adverse events 
were similar to those seen at lower doses but incidence rates were increased. 
 
In cases of overdose, standard supportive measures should be adopted as 
required. Renal dialysis is not expected to accelerate clearance as sildenafil is 
highly bound to plasma proteins and it is not eliminated in the urine. 
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12. DOSAGE AND ADMINISTRATION 
For most patients, the recommended dose is 50 mg taken, as needed, 
approximately 1 hour before sexual activity. However, VIAGRA may be taken 
anywhere from 4 hours to 0.5 hour before sexual activity. Based on effectiveness 
and toleration, the dose may be increased to a maximum recommended dose of 
100 mg or decreased to 25 mg. The maximum recommended dosing frequency is 
once per day. 
 
The following factors are associated with increased plasma levels of sildenafil: age 
>65 (40% increase in AUC), hepatic impairment (e.g., cirrhosis, 80%), severe 
renal impairment (creatinine clearance <30 mL/min, 100%), and concomitant use 
of potent cytochrome P450 3A4 inhibitors [ketoconazole, itraconazole, 
erythromycin (182%), saquinavir (210%)]. Since higher plasma levels may 
increase both the efficacy and incidence of adverse events, a starting dose of 25 
mg should be considered in these patients. 
 
Ritonavir greatly increased the systemic level of sildenafil in a study of healthy, 
non-HIV infected volunteers (11-fold increase in AUC, see Drug Interactions.) 
Based on these pharmacokinetic data, it is recommended not to exceed a 
maximum single dose of 25 mg of VIAGRA in a 48 hour period. VIAGRA was 
shown to potentiate the hypotensive effects of nitrates and its administration in 
patients who use nitric oxide donors or nitrates in any form is therefore 
contraindicated.  
 
Simultaneous administration of VIAGRA doses above 25 mg and an alpha-blocker 
may lead to symptomatic hypotension in some patients. Doses of 50 mg or 100 
mg of VIAGRA should not be taken within 4 hours of alpha-blocker administration. 
A 25 mg dose of VIAGRA may be taken at any time. 
 
 
13. HOW SUPPLIED 
VIAGRA® (sildenafil citrate) is supplied as blue, film-coated, rounded-diamond-
shaped tablets containing sildenafil citrate equivalent to the nominally indicated 
amount of sildenafil as follows: 
 
 
 
Recommended Storage: Store at 25°C (77°F); excursions permitted to 15-30°C 
(59-86°F) [see USP Controlled Room Temperature]. 
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14. PATIENT SUMMARY OF INFORMATION ABOUT 
(Sildenafil citrate) tablets 
 
This summary contains important information about VIAGRA®. It is not meant to 
take the place of your doctor’s instructions. Read this information carefully before 
you start taking VIAGRA. Ask your doctor or pharmacist if you do not understand 
any of this information or if you want to know more about VIAGRA. 
 
This medicine can help many men when it is used as prescribed by their doctors. 
However, VIAGRA is not for everyone. It is intended for use only by men who have 
a condition called erectile dysfunction. VIAGRA must never be used by men who 
are taking medicines that contain nitrates of any kind, at any time. This includes 
nitroglycerin. If you take VIAGRA with any nitrate medicine your blood pressure 
could suddenly drop to an unsafe or life threatening level. 
 
WHAT IS VIAGRA? 
VIAGRA is a pill used to treat erectile dysfunction (impotence) in men. It can help 
many men who have erectile dysfunction get and keep an erection when they 
become sexually excited (stimulated). You will not get an erection just by taking 
this medicine. VIAGRA helps a man with erectile dysfunction get an erection only 
when he is sexually excited. 
 
HOW SEX AFFECTS THE BODY 
When a man is sexually excited, the penis rapidly fills with more blood than usual. 
The penis then expands and hardens. This is called an erection. After the man is 
done having sex, this extra blood flows out of the penis back into the body. The 
erection goes away. If an erection lasts for a long time (more than 6 hours), it can 
permanently damage your penis. You should call a doctor immediately if you ever 
have a prolonged erection that lasts more than 4 hours. Some conditions and 
medicines interfere with this natural erection process. The penis cannot fill with 
enough blood. The man cannot have an erection. This is called erectile 
dysfunction if it becomes a frequent problem. During sex, your heart works harder. 
Therefore sexual activity may not be advisable for people who have heart 
problems. Before you start any treatment for erectile dysfunction, ask your doctor if 
your heart is healthy enough to handle the extra strain of having sex. If you have 
chest pains, dizziness or nausea during sex, stop having sex and immediately tell 
your doctor you have had this problem.  
 
HOW VIAGRA WORKS 
VIAGRA enables many men with erectile dysfunction to respond to sexual 
stimulation. When a man is sexually excited, VIAGRA helps the penis fill with 
enough blood to cause an erection. After sex is over, the erection goes away. 
 
VIAGRA IS NOT FOR EVERYONE 
As noted above (How Sex Affects the Body), ask your doctor if your heart is 
healthy enough for sexual activity. If you take any medicines that contain nitrates – 
either regularly or as needed – you should never take VIAGRA. If you take 
VIAGRA with any nitrate medicine or recreational drug containing nitrates, your 
blood pressure could suddenly drop to an unsafe level. You could get dizzy, faint, 
or even have a heart attack or stroke. Nitrates are found in many prescription 
medicines that are used to treat angina (chest pain due to heart disease) such as: 
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•  nitroglycerin (sprays, ointments, skin patches or pastes, and tablets that are 
swallowed 
or dissolved in the mouth) 
 
•  isosorbide mononitrate and isosorbide dinitrate (tablets that are swallowed, 
chewed, or 
dissolved in the mouth) 
 
Nitrates are also found in recreational drugs such as amyl nitrate or nitrite 
(“poppers”). If you are not sure if any of your medicines contain nitrates, or if you 
do not understand what nitrates are, ask your doctor or pharmacist. VIAGRA is 
only for patients with erectile dysfunction. VIAGRA is not for newborns, children, or 
women. Do not let anyone else take your VIAGRA. VIAGRA must be used only 
under a doctor’s supervision. 
 
WHAT VIAGRA DOES NOT DO 
•  VIAGRA does not cure erectile dysfunction. It is a treatment for erectile 
dysfunction. 
•  VIAGRA does not protect you or your partner from getting sexually transmitted 
diseases, including HIV—the virus that causes AIDS. 
•  VIAGRA is not a hormone or an aphrodisiac. 
 
WHAT TO TELL YOUR DOCTOR BEFORE YOU BEGIN VIAGRA 
Only your doctor can decide if VIAGRA is right for you. VIAGRA can cause mild, 
temporary lowering of your blood pressure. You will need to have a thorough 
medical exam to diagnose your erectile dysfunction and to find out if you can 
safely take VIAGRA alone or with your other medicines. Your doctor should 
determine if your heart is healthy enough to handle the extra strain of having sex. 
 
Be sure to tell your doctor if you: 
•  have ever had any heart problems (e.g., angina, chest pain, heart failure, irregular 
heart 
 beats, heart attack or narrowing of the aortic valve) 
•  have ever had a stroke 
•  have low or high blood pressure 
•  have ever had severe vision loss 
•  have a rare inherited eye disease called retinitis pigmentosa 
•  have ever had any kidney problems 
•  have ever had any liver problems 
•  have ever had any blood problems, including sickle cell anemia or leukemia 
•  are allergic to sildenafil or any of the other ingredients of VIAGRA tablets 
•  have a deformed penis, Peyronie’s disease, or ever had an erection that lasted 
more than 
 4 hours 
•  have stomach ulcers or any types of bleeding problems 
•  are taking any other medicines 
 
VIAGRA AND OTHER MEDICINES 
Some medicines can change the way VIAGRA works. Tell your doctor about any 
medicines you are taking. Do not start or stop taking any medicines before 
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checking with your doctor or pharmacist. This includes prescription and 
nonprescription medicines or remedies: 
 
•  Remember, VIAGRA should never be used with medicines that contain nitrates 
(see VIAGRA Is Not for Everyone). 
•  If you are taking alpha-blocker therapy for the treatment of high blood pressure or 
prostate problems, you should not take a dose of greater than 25 mg of VIAGRA 
at the same time (within 4 hours) as you take your dose of alpha-blocker. 
•  If you are taking a protease inhibitor, your dose may be adjusted (please see 
Finding the Right Dose for You). 
•  VIAGRA should not be used with any other medical treatments that cause 
erections. These treatments include pills, medicines that are injected or inserted 
into the penis, implants or vacuum pumps. 
 
FINDING THE RIGHT DOSE FOR YOU 
VIAGRA comes in different doses (25 mg, 50 mg and 100 mg). If you do not get 
the results you expect, talk with your doctor. You and your doctor can determine 
the dose that works best for you. 
 
•  Do not take more VIAGRA than your doctor prescribes. 
•  If you think you need a larger dose of VIAGRA, check with your doctor. 
•  VIAGRA should not be taken more than once a day. 
 
If you are older than age 65, or have serious liver or kidney problems, your doctor 
may start you at the lowest dose (25 mg) of VIAGRA. If you are taking protease 
inhibitors, such as for the treatment of HIV, your doctor may recommend a 25 mg 
dose and may limit you to a maximum single dose of 25 mg of VIAGRA in a 48 
hour period. If you are taking alpha-blocker therapy, you should not take a dose of 
greater than 25 mg of VIAGRA at the same time (within 4 hours) as your dose of 
alphablocker.  
 
HOW TO TAKE VIAGRA 
Take VIAGRA about one hour before you plan to have sex. Beginning in about 30 
minutes and for up to 4 hours, VIAGRA can help you get an erection if you are 
sexually excited. If you take VIAGRA after a high-fat meal (such as a 
cheeseburger and french fries), the medicine may take a little longer to start 
working. VIAGRA can help you get an erection when you are sexually excited. You 
will not get an erection just by taking the pill. 
 
POSSIBLE SIDE EFFECTS 
Like all medicines, VIAGRA can cause some side effects. These effects are 
usually mild to moderate and usually don’t last longer than a few hours. Some of 
these side effects are more likely to occur with higher doses. The most common 
side effects of VIAGRA are headache, flushing of the face, and upset stomach. 
Less common side effects that may occur are temporary changes in color vision 
(such as trouble telling the difference between blue and green objects or having a 
blue color tinge to them), eyes being more sensitive to light, or blurred vision. 
 
In rare instances, men taking PDE5 inhibitors (oral erectile dysfunction medicines, 
including VIAGRA) reported a sudden decrease or loss of vision in one or both 
eyes. It is not possible to determine whether these events are related directly to 
these medicines, to other factors such as high blood pressure or diabetes, or to a 
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combination of these. If you experience sudden decrease or loss of vision, stop 
taking PDE5 inhibitors, including VIAGRA, and call a doctor right away. In rare 
instances, men have reported an erection that lasts many hours. You should call a 
doctor immediately if you ever have an erection that lasts more than 4 hours. If not 
treated right away, permanent damage to your penis could occur (see How Sex 
Affects the Body). 
 
Heart attack, stroke, irregular heart beats, and death have been reported rarely in 
men taking VIAGRA. Most, but not all, of these men had heart problems before 
taking this medicine. It is not possible to determine whether these events were 
directly related to VIAGRA. VIAGRA may cause other side effects besides those 
listed on this sheet. If you want more information or develop any side effects or 
symptoms you are concerned about, call your doctor. 
 
ACCIDENTAL OVERDOSE 
In case of accidental overdose, call your doctor right away. 
 
STORING VIAGRA 
Keep VIAGRA out of the reach of children. Keep VIAGRA in its original container. 
Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP 
Controlled Room Temperature]. 
 
FOR MORE INFORMATION ON VIAGRA 
VIAGRA is a prescription medicine used to treat erectile dysfunction. Only your 
doctor can decide if it is right for you. This sheet is only a summary. If you have 
any questions or want more information about VIAGRA, talk with your doctor or 
pharmacist, visit www.viagra.com, or call 1-888-4VIAGRA. 
 
© 2005, Pfizer Inc June 2005 
Distributed by 
LAB-0221-2 Revised June 2005 
Pfizer Labs 
Division of Pfizer Inc, NY, NY 10017 
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6.2.3 Appendix 3: Medicines and Healthcare products Regulatory Agency 
Approval 
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6.2.4 Appendix 4: Local and Regional Ethics Approval 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
End Organ Effects of Paediatric Cardiopulmonary Bypass         Page 178 of 192 
 
Tony Vassalos  2010 
 
6.2.5 Appendix 5: Parent Information Sheet 
VERSION 2 (18/01/2006) 
 
Study Title: Does pre-operative Sildenafil protect against pulmonary related 
complications following cardiopulmonary bypass? A randomised trial in children 
undergoing cardiac surgical repair. 
 
Lay Title: Will giving the drug Sildenafil to children before open-heart surgery 
improve the function of the lungs after surgery? 
 
Invitation paragraph: You and your child are being invited to take part in a research 
study. Before you decide it is important for you to understand why the research is 
being done and what it will involve. Please take time to read the following information 
carefully and discuss it with family, medical or nursing staff if you wish. Ask us if 
there is anything that is not clear or if you would like more information. Take time to 
decide whether or not you wish to take part. 
 
Thank you for reading this. 
 
 
Q1. What is the purpose of the study? 
 
Ans: The purpose of this study is to investigate whether giving the drug Sildenafil 
(Viagra, Pfizer) to children before open-heart surgery improves the function of the 
lungs after surgery. 
 
Q2. Why have I been chosen? 
 
Ans: Participation in this study is being offered to all parents with children aged over 3 
months undergoing heart surgery to correct inborn heart defects that allow increased 
blood flow within the lungs and may be associated with lung related complications 
(pulmonary hypertension) after surgery. 
 
Q3. Do I have to take part? 
 
Ans: NO. It is up to you to decide whether or not you wish your child to take part.  If 
you do decide to take part you will be given this information sheet to keep and be 
asked to sign a consent form. If you decide to take part you are still free to withdraw at 
any time and without giving a reason.  A decision to withdraw at any time, or a 
decision not to take part, will not affect the standard of care your child receives. 
 
Q4. What will happen to my child, if my child takes part?  
 
Ans: If you decide that you would like your child to take part: 
- The day immediately before surgery your child will be randomly (like the toss of a 
coin) put into a group that is either given the drug Sildenafil (1/2 teaspoon liquid) or 
Placebo (1/2 teaspoon inactive liquid), 6hrly (4 doses) by the ward nursing staff. 
This will be given in addition to their normal medications. 
- Otherwise, your child’s surgical and medical care both before, during and after 
surgery will follow the normal practice of their consultant heart surgeon. 
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- Your child’s progress before, during and after surgery will be closely monitored.  
 
(e) Data from ward charts, intensive care charts and routine blood results will be recorded.  
(f) Images from routine echocardiography used before, during and after surgery to assess 
the heart’s function will be studied on the computer.  
(g) Any blood that remains after routine investigations have been carried out by the 
laboratory at Yorkhill will be stored and used to measure markers of inflammation / 
infection. No extra blood will be taken from your child specifically for the trial. 
 
- Your child will remain part of the trial until the day of discharge (usually 5 
days). 
- You and your child will not need to visit your GP or attend any additional 
clinics. Your child’s GP will however be informed of your child’s participation 
in this trial. 
 
Q5. What do I have to do? 
 
Ans: There are no associated restrictions with taking part in this study. Your child’s 
stay in hospital should follow the normal course.  
 
Q6. What is the drug or procedure that is being tested? 
 
Ans: The drug being tested is called Sildenafil (Viagra, Pfizer). Some children 
undergoing heart surgery to correct inborn heart defects that allow increase blood flow 
within the lungs are prone to lung related complications (pulmonary hypertension) 
after surgery. Oral Sildenafil liquid (0.5mg/kg) is routinely used in our pediatric 
intensive care unit after heart surgery to treat these complications. We hope that giving 
4 doses of oral Sildenafil (0.5mg/kg, equivalent to ½ teaspoon liquid per dose) the day 
before surgery will prevent or reduce lung related complications after surgery. 
 
Q7. What are the side effects of any treatment received when taking part? 
 
Ans: Sildenafil is not licensed in the UK for the treatment of pulmonary hypertension. 
Sildenafil is however effectively and regularly used after heart surgery in our pediatric 
intensive care unit to treat post-operative pulmonary hypertension. Clinical trials 
assessing the use of Sildenafil in children undergoing heart surgery are limited but to 
date there are no clinically significant side effects reported in giving oral Sildenafil 
(0.5mg-2mg/kg; 6hrly) to children. This opinion is also supported by our own clinical 
experience. Although some children in the trial will receive 4 doses of Sildenafil the 
day before surgery, after surgery Sildenafil could be given to any child if that is 
deemed necessary by the consultant cardiac surgeon and the medical team responsible 
for their care. All clinically significant side effects thought to be related to Sildenafil 
administration in this study will be recorded and reported to the relevant authorities. 
 
Q8. What are the possible disadvantages and risks of taking part? 
 
Ans: The mainstay of your child’s surgical and medical care before, during and after 
surgery will follow the normal clinical practice of their consultant cardiac surgeon. 
Possible disadvantages and risks would therefore be related to taking 4 oral doses of 
Sildenafil liquid (0.5mg/kg) the day before surgery. Side effects including headache, 
flushing, diarrhoea, rash and heartburn have been reported in the literature but we do 
not foresee any clinical disadvantages or side effects associated with the dosage being 
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used in this study. Oral Sildenafil (0.5-2mg/kg/4-6hrs) is routinely used after heart 
surgery in our pediatric intensive care unit without clinically significant side effects. 
 
Q9. What are the possible benefits of taking part? 
 
Ans: We hope that giving 4 doses of the drug Sildenafil before surgery will protect the 
lungs during surgery to improve lung function and reduce related complications after 
surgery. If this is the case it would reduce the overall recovery time and intensive care 
stay after surgery. All children undergoing corrective heart surgery are closely 
monitored throughout their admission. Although this will also be the case for all 
research participants they will undergo a more detailed echocardiographic assessment 
both before and after surgery, providing additional clinical information that may be 
beneficial to the caring medical team. 
 
Q10. What if new information becomes available? 
 
Ans: All relevant additional information on the function of the heart and lungs found 
during the trial will be made available to the clinical team caring for your child to 
allow them to make the appropriate clinical decisions early. 
 
Q11. What happens when the research study stops? 
 
Ans: The research study stops when your child is discharged from hospital. There is no 
further participation or responsibility.  
 
Q12. What if something goes wrong? 
 
Ans: If taking part in this research project harms your child, there are no special 
compensation arrangements.  If you are harmed due to someone’s negligence, then you 
may have grounds for a legal action but you may have to pay for it.  Regardless of this, 
if you wish to complain, or have any concerns about any aspect of the way you have 
been approached or treated during the course of this study, the normal National Health 
Service complaints mechanisms should be available to you. 
 
Q13. Will my taking part in this study be kept confidential? 
 
Ans: All information that is collected about your child during the course of the 
research will be kept strictly confidential. Any information about your child, which 
leaves the hospital/surgery, will have his/her name and address removed so that he/she 
cannot be recognised from it. 
 
Q14. What will happen to the results of the research study? 
 
Ans: The principal aim of this study is to improve the management and care of 
children with inborn heart defects that make them prone to developing severe 
pulmonary hypertension after corrective heart surgery. We also plan to publish our 
results in peer reviewed medical journals. Any publications that arise should be 
available to everyone on-line. The information may also be used in presentations to 
local and international congenital heart disease forums as well as local charities and 
parent groups. You will not be specifically identified in any report or publication. 
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Q15. Who is organising and funding the research? 
 
Ans: This study is being funded by successful research grant application to the 
Yorkhill Children’s Foundation. It has been organised by Mr Tony Vassalos (Research 
Fellow, Cardiac Surgery) under the supervision of Mr Mark Danton (Consultant 
Cardiac Surgeon), Professor Fiona Lyall (Professor of Maternal and Fetal Health) and 
key Cardiac Surgery, Cardiology, Intensive Care and Pharmacy collaborators. 
 
Q16. Who has reviewed the study? 
 
Ans: As mentioned above the study is being funded by a successful research grant 
application to the Yorkhill Children’s Foundation. This involved a stringent, 2 phase, 
internal and external review process of the proposed study. The study has also been 
reviewed and approved by the Research Ethics Committee based in the Western 
Infirmary, Glasgow.  
 
Q17. Who can I contact for further information? 
 
Ans: If there is anything you do not understand or feel you would like further 
information on please do not hesitate to contact either of the persons named below 
through the Cardiac Surgery secretaries at Yorkhill Hospital (0141 201 0251) or the 
Cardiac Liaison Sisters who will introduce themselves during your child’s admission: 
- Mr Mark Danton, Consultant Paediatric Cardiac Surgeon, Yorkhill 
- Mr Tony Vassalos, Research Fellow, Department of Cardiac Surgery, Yorkhill 
- Cardiac Liaison Sisters (0141 201 9291) 
 
Q18. With whom can I register any complaints? 
 
- Ans: The standard NHS complaints procedure will be open to you.  
 
 
 
 
Parents of children participating in this trial will be given a copy of the information 
sheet and a signed consent form to keep.  
 
 
Thank you for your co-operation and patience. 
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6.2.6 Appendix 6: Parent Consent Form 
Centre Number: 
Study Number:  
Patient Identification Number for this trial: 
 
CONSENT FORM 
 
 
Title of Project: Does pre-operative Sildenafil protect against pulmonary related complications following 
cardiopulmonary bypass? A randomised trial in children undergoing cardiac surgical repair. 
 
 
 
 
Name of Researcher: Mr Tony Vassalos 
 
 
 
 
       Please initial box 
 
1. I confirm that I have read and understand the information sheet dated 18 January 2006   
 (version 2) for the above trial and have had the opportunity to ask questions. 
 
2. I understand that my child’s participation is voluntary and that I am free to withdraw at    
 any time, without giving any reason, without my child’s medical care or legal rights being affected. 
 
3. I understand that sections of my child’s medical notes may be looked at by responsible  
 individuals from the Yorkhill Division or from regulatory authorities where it is relevant to my 
child taking part in research.  I give permission for these individuals to have access to   
 my child’s records. 
 
4. I give permission for my child to take part in the above trial.    
 
 
 
 
 
 
_________________________ ________________ ____________________ 
Name of Parent or Guardian Date Signature 
 
 
 
_________________________ ________________ ____________________ 
Researcher Date Signature 
 
 
 
 
 1 for parent/guardian;  1 for researcher;  1 to be kept with hospital notes 
 
 
 
End Organ Effects of Paediatric Cardiopulmonary Bypass         Page 183 of 192 
 
Tony Vassalos  2010 
 
6.2.7 Appendix 7: Data Entry Proforma 
 
 
  
 
 
 
PATIENT FACTORS 
1. Age (Months)  5. BSA (m
2)  
2. Weight (Kg)  6. WCC (Preop)  …./….  
3. Height (cm)  7. Admitted         /         / 
4. Sex (M/F)  8. Discharged        /         / 
 
 
 
PREOPERATIVE FACTORS 
 1. Cardiac Diagnosis 
 
 2. Non-Cardiac 
Diagnosis 
 
 3. Cardiac Catheter 
(PAP/AO/PVR 
 PCWP/Qp:Qs)  
 4. Signs / Symptoms 
(L > R Shunt) 
 
 5. Medication 
 
6. Aspirin / Warfarin / 
Sildenafil  
 
 
 
 
 
 
 
 
Patient ID: 
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OPERATIVE FACTORS  
1. DATE ….. / ….. / ….. 7. CPB Temp (minimum rectal)  
2. XC time (mins)  8. UF volume (mls)  
3. BP time (mins)  
4. Surgeon & Anaesthetist                                              / 
  5. 
Inotropes 
(coming off)   
6. 
Aprotinin Regimen L =  P = M = 
 
 
 
 
RENAL OUTCOMES 
                       Postop Day  PreOp 
Day…  
…/… 
Th 
1st 
12hrs 
Th 2nd 
12hrs 
1 
.../... 
2 
…/.. 
3 
…/.. 
4 
…/.. 
5 
…/.. 
6 
…/.. 
7 
…/.. 
1. SCr (µmol/l) (18-40)           
2. CrCl (54-86) (ml/min/1.73m2)           
(Normal values in 
parenthesis) 
 
1hr  
 
2hrs 
 
3hrs 
 
4hrs 
 
5hrs 
 
Total Urine 
1st 24hr 
Diuretics 
(Inf / 
Bolus) 
3. Urine (mls)      
 
 
4. Dopamine (µg/kg/min)         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Timing 
Test 
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Timing 
 
 
RESPIRATORY OUTCOMES 
 Post 
Intubation 
Post 
CPB 
2 hrs 
Postop 
4hrs 
Postop 
8am 
Day 1 
 
1. 
Oxygenation 
Index (OI)      
2. 
Dynamic Compliance  
(CL) (ml/cmH2O/kg)      
(Hrs) 3. Mech. Ventilation  
(Days) 
Sildenafil 
(dose/days) 
(Hrs) 
4. 
Period in PICU  
(Days) 
Hospital  
Stay 
(days) 
 
 
 
Oxygenation Index: Mean airway pressure (cmH2O x 100 x FiO2 / PaO2 (mmHg) 
 
 
                 1st 24Hrs Post-Op        Days Post-Op 
Test 
2hr 4hr 8hr 12 Hr 
16 
  Hr 
20 
Hr 
24 
Hr 2 
 
../.. 
 
../.. 
 
../.. 
1. PVRI  (WU/m2)            
       5. Lactate Base Excess            
6. Inotrope Score            
7. LA pressure            
8. PA pressure            
9. 
Transpulmonary 
Gradient            
1
0. 
PaO2            
1
1. 
PCO2            
 
 
 
 
 
 
 
 
 
 
Timing 
Test 
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ECHOCARDIOGRAPHIC OUTCOMES 
 
Pre-Op <1hr post return to PICU Day 1 Post-Op 
1. LVEDD (mm) [23 +/- 3]    
LVESD (mm) [14 +/- 2]    
RVEDD (mm) [9-13]    
LV % FC [38.9 +/- 4.1]    
LV EF % [52-65] (1-18yr olds)    
M
-m
ode [m
ean +/- SD
] VP (cm/sec) [54.6 +/- 14] (2mn – 6yrs)    
2. Peak AO (LVOT) (cm/sec)  median 107.0
* [73-141]    
Peak PA (RVOT) (cm/sec) median 84.4* [63.8-70.5]    
AO annular diameter [11-13mm]    
PA annular diameter [8.4 – 11.6mm] (up to 10kg)    
VTIPA (stroke distance cm) [heart rate] 
    
VTIAO (stroke distance cm) [heart rate] 
    
MV Peak E wave (cm/sec) [79.7 +/- 18.8]    
SPEC
TR
A
L 
MV Peak A wave (cm/sec) [65.3 +/- 13.3]    
3. MV E/A Ratio [1.24 +/- 0.3]    
4. Regurgitation (L + R AV) (Y/N)      
5. Sa: Lateral Mitral (5.7 +/- 1.6) [5.3 – 6.1]    
Sa: Lateral Tricuspid (10.2 +/- 5.5) [8.8 – 11.7]       
Sa: Septum (5.4 +/- 1.2) [5.1 – 5.7]    
IVA (cm/sec2) [248 +/- 35]    
Ea: Lateral Mitral (9.7 +/- 3.3) [8.8 – 10.5]    
Ea: Lateral Tricuspid (13.8 +/- 8.2) [11.7 – 15.9]    
Ea: Septum (8.1 +/- 2.5) [7.5-8.7]    
Aa: Lateral Mitral (5.7 +/- 1.8) [5.3 – 6.2]    
Aa: Lateral Tricuspid (9.8 +/- 2.4) [9.1 - 10.5]    
Aa: Septum (6.1 +/- 1.5) [5.7 – 6.4]    
TD
I cm
/sec  (m
ean +/- SD
)  [95%
 C
I] E/Ea Ratio (L AV valve) (8.8 +/- 2.7) [8.1 – 9.5]    
(Normal values in parenthesis) 
 
Test Timing 
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HAEMATOLOGY OUTCOMES 
 1hr  Post-op 
2hr 
Post-op 
3hr  
Post-op 
4hr 
Post-op 
5hr 
Post-op 
Total 1st  
24 hrs   
1. Chest Tube Drainage (ml)         
 Intra-operatively Post-operatively 
2. PRC (units/ml)   
3. FFP (units/ml)   
4. Platelets  (units/ml)   
5. 
Other: 
 
 
 
 
 
 
 
 
COMMENTS / COMPLICATIONS: 
- 
- 
- 
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6.2.8 Appendix 8: Adverse Events Record Sheet 
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6.2.9 Appendix 9: Sildenafil Trial Prescription Form 
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6.2.10 Appendix 10: Protocol Registration Receipt 
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6.2.11 Appendix 11: R&D Management Approval 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
